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ABSTRACT
Emphysema is a lung disease characterised by abnormally large airspaces in the
lungs resulting from airspace wall destruction. In centriacinar emphysema the
airspace enlargement involves the respiratory bronchioles, while in panacinar
emphysema airspace enlargement is uniform across the alveoli and respiratory
bronchioles. These 2 patterns of emphysema are thought to result from different
pathological mechanisms. Glutathione S-transferase Ml (GSTM1) detoxifies
components of cigarette smoke, but polymorphic gene deletion occurs in
approximately 50% of populations. Cytochrome P4501A1 (CYP1A1) mediates the
metabolic activation of compounds in cigarette smoke. A genetic polymorphism of
CYP1A1 is thought to increase the efficiency of the enzyme, increasing the amount
of reactive species generated through metabolism. Since the GSTM1 and CYP1A1
gene polymorphisms have been associated with lung cancer and both enzymes
metabolise components of cigarette smoke they represent ideal candidates for
investigation into genetic susceptibility to emphysema. Expression of GSTM1 in
lung tissue by immunohistochemistry could not be differentiated from other GSTM
enzymes, including the highly homologous enzyme GSTM4. Reverse transcription
PCR was therefore used to identify expression of GSTM1, where there was an intact
gene, and GSTM4 in lung tissue. Deletion of GSTM1 was associated with
emphysema in the presence of concomitant lung cancer, but not with lung cancer
alone. No association between the GSTM1 polymorphism and either centriacinar or
panacinar patterns of emphysema could be demonstrated, but a small association was
found in cases with both centriacinar and panacinar emphysema. The glutathione S-
transferase Ml deletion was not associated with chronic obstructive pulmonary
disease, the clinical manifestation of emphysema, nor with the severe emphysema
found in autopsy specimens. The cytochrome P4501A1 polymorphism was
associated with emphysema concomitant with lung cancer, but no association could
be demonstrated with a specific pattern of disease. Furthermore, the CYP1A1
polymorphism was found to be associated with very early emphysema, detectable
only by microscope. No association was found between cytochrome P4501A1 and
lung cancer, nor with chronic obstructive pulmonary disease. This study
demonstrates that the GSTM1 and CYP1A1 polymorphisms have a small, but
significant, association with emphysema, which cannot be explained by concomitant
lung cancer, since lung cancer alone was not associated with either polymorphism.
The association of the polymorphisms with mild emphysema, in particular that seen
between CYP1A1 and microscopic emphysema, and not with the severe emphysema
represented by chronic obstructive pulmonary disease, and in the case of GSTM1
with autopsy emphysemas, indicates that these enzymes have a general role in the
early protection of the lung against damage caused by xenobiotics such as cigarette
smoke. Sequencing of the CYP1A1 gene identified a novel polymorphism, a C to A
substitution, which results in an amino acid change from threonine to asparagine at
positon 461of the gene. This amino acid is adjacent to the previously characterised
exon 7 isoleucine to valine polymorphism, but is nearer to the cysteine residue
thought to be of importance for haem binding of the enzyme. Of 26 Scottish
individuals previously genotyped as heterozygotes for the Ile-Val462 polymorphism,
14 were subsequently shown to actually have the Thr-Asn461 polymorphism. These
preliminary data indicate that in the Scottish population there is a polymorphism
which may be more common than the Ile-Val462 polymorphism. Further studies will
identify whether or not this novel polymorphism has a functional effect on the
enzyme and hence on disease susceptibility.
ABBREVIATIONS
GST Glutathione S-transferase gene or enzyme, for example GSTM1
refers to glutathione S-transferase Ml
CYP Cytochrome P450 gene, for example CYP1A1 refers to cytochrome
P4501A1
P450 Cytochrome P450 enzyme
COPD Chronic obstructive pulmonary disease






lm Mean linear intercept









RFLP Restriction fragment length polymorphism
SSCP Single strand conformational polymorphism
GIT Gastrointestinal tract
NNK 4-(methylnitrosamino)-1 -(3 -pyridy1)-1 -butanone
EROD Ethoxyresorufin-O-deethylase
XRE xenobiotic responsive element
BTE basic transcription element
Ah aryl hydrocarbon
AHH Aryl hydrocarbon hydroxylase
PAH Polycyclic aromatic hydrocarbon
RT-PCR Reverse transcription polymerase chain reaction
BS Tris buffered saline





EDTA Ethylenediaminetetra acetic acid
FT Fisher's exact test
Ile462 Allele of the CYP1A1 gene coding for an isoleucine residue at amino
acid position 462
Val462 Allele of the CYP1A1 gene coding for an valine residue at amino
acid position 462
Thr461 Allele of the CYP1A1 gene coding for an threonine residue at amino
acid position 461
Asn461 Allele of the CYP1A1 gene coding for an asparagine residue at
amino acid position 461
INTRODUCTION
1.1 Emphysema
Emphysema is a common lung disease which is characterized by loss of alveolar tissue
leading to increased airspace size. It is present, with variable severity, in one third of
all adult males, and at least half of male smokers (Pratt, 1988). Although emphysema
is related to cigarette smoke exposure, this is by no means exclusive, and
approximately 11% of non smokers will have emphysema, although severity is
generally much less compared to the severity found in the lungs of smokers (Pratt,
1988).
1.1.1 Chronic obstructive pulmonary disease
Clinically, emphysema presents as chronic obstructive pulmonary disease.
Emphysema, by definition, involves destruction of airspace walls. The walls of the
airspaces are attached to each other and to the small airways which supply them. This
attachment of the airspace walls allows these airways to maintain a circular
circumference by elastic pull from the walls. If the airspace wall attachments are
destroyed, the bronchiole circumference cannot be maintained, the airway collapses
inwards, and the volume of air which can pass through the airway is reduced (Lamb,
1995), Figure 1.1. Chronic obstructive pulmonary disease is characterized by a fixed
airways resistance (Pride, 1995). Asthma also presents as increased airflow resistance,
which is characteristically reversible, and is therefore not generally included under the
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term COPD (Pride, 1995). This term refers to lung disease which results in reduced
lung function, as measured by the forced expiratory flow of the individual in one
second (FEV1). Symptoms of chronic obstructive pulmonary disease include
persistent cough, purulent sputum, and breathing difficulty, particularly during
exercise. The damage caused to the lungs by emphysema is irreversible (Lamb, 1995).
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Figure 1.1 Photomicrographs of the cross-section of two small airways.
Magnification X50. (A) shows a bronchiole from a non-smoking individual which
shows no sign of disease. The alveolar walls surrounding the bronchiole provide
support which maintains the airway in a circular circumference. (B) shows an airway
from a patient with mild panacinar emphysema. The reduction in alveolar walls and
their attachments to the bronchiole has resulted in a collapsed, eliptical
circumference.
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Published figures on COPD mortality are probably underestimates (Strachan, 1995),
since reduced levels of FEV1 have been shown to be risk factors for other diseases,
including coronary heart disease and stroke. Emphysema and COPD are not only
important diseases for study because of their high mortality rates, they also account
for a large proportion of sickness leave and are a heavy burden on the health services
(Strachan, 1995).
1.1.2 Morphology of emphysema
Emphysema is in essence a morphologically defined disease with a constellation of
recoginsed but nonspecific clinical symptons and signs. Therefore, while diagnosis
can be made using CT scanning (MacNee et al, 1991), accurate and precise
determination of pattern of disease and severity requires direct morphological
examination of lung tissue.
Emphysema is defined as "enlargement beyond normal of the airspaces of the lung,
accompanied by airspace wall destruction, with no obvious fibrosis" (Snider et al,
1985). Within the generic term of emphysema, four main patterns of lung damage are
generally recognized. These patterns are centriacinar, panacinar, paracicatricial and
paraseptal. It is believed that these different patterns may reflect as yet unknown
different pathological causes (Kim et al, 1995).
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The normal architecture of the lung is comprised of a series of branching airways,
which become progressively smaller, before ending in sacs called alveoli. From the
mouth or nose, air travels through the trachea, which divides to form two bronchi.
These bronchi undergo further sub divisions to create the bronchioles which,
following division, become respiratory airways. The respiratory bronchioles lead into
the alveolar ducts, and these final structures of alveoli and respiratory bronchioles
form the acinus (Dunnill, 1962), the unit of gas exchange of the lung (Figure 1.2).
The type of emphysema seen is determined by the area of the lung, or the area
within the acinus, which is damaged.
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Figure 1.2 Normal architecture of the lung showing the series of branching
airways ending in the respiratory airways (respiratory bronchioles (RB), alveolar ducts
(AD) and alveolar sacs (AS)) which comprise the acinus. TB refers to the terminal
bronchiole.
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1.1.3 Morphological variants of emphysema
1.1.3.1 Centriacinar emphysema
Centriacinar emphysema is the most common form of emphysema, and is more
closely associated with cigarette smoking than panacinar emphysema (Gillooly &
Lamb, 1993b). The lesions of centriacinar emphysema are found centred around the
respiratory bronchioles, while the remainder of the acinus, the alveolar sacs and
alveolar ducts, are normal, Figure 1.3. This form of emphysema appears on the cut
surface of the lung as focal lesions of damage surrounded by normal lung
parenchyma (Lamb, 1995). It tends to be more common, and more severe, in the
upper lobes of the lungs, and towards the apex of the lobe (Thurlbeck, 1963). In very
severe centriacinar emphysema, the destruction of lung tissue may become confluent,
involving the periphery of the acinus, making it difficult to distinguish from
panacinar emphysema (Lamb, 1995).
1.1.3.2 Panacinar emphysema
Panacinar emphysema is diagnosed where enlarged airspaces are evenly distributed
across the acinus (Lamb, 1995), Figure 1.3. Generally, panacinar emphysema does not
affect the lung in focal lesions as does centriacinar emphysema, rather panacinar damage
occurs throughout the affected region, with the same degree of severity. In panacinar
emphysema, the destruction of airspace walls results in simplification of the architecture
of the lung, with the distinction between respiratory bronchioles and alveolar sacs and
ducts being lost (Dunnill, 1987). The lower lobes of the lung are preferentially involved
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in panacinar emphysema (Thurlbeck, 1963), and severity tends to increase towards the
base of the lobes. Panacinar emphysema is the form of emphysema associated with
alpha-1 antiprotease deficiency (Guenter et al, 1968), indicating the likely importance of
systemic rather than just local factors in the pathogenesis of this disease.
1.1.3.3 Paracicatricial emphysema
As its name implies, paracicatricial emphysema is invariably seen in association with
scarring. It does not involve any particular part of the acinus or the lung, but is focal
to the region of scarring (Dunnill, 1987). Generally, this type of emphysema is
asymptomatic since it does not involve large areas of lung tissue (Lamb, 1995). The
pathogenesis of this form of emphysema is thought to be increased elastic pull on
surrounding alveoli from scarring, and the inflammation and fibrosis around the scar
narrow the bronchioles such that air is trapped in the alveoli, further distending and
breaking the alveolar walls (Dunnill, 1987).
1.1.3.4 Paraseptal emphysema
Paraseptal emphysema is the form of emphysema in which the alveolar sacs and ducts
of the acinus are preferentially involved, while the respiratory bronchioles remain
uninvolved (Lamb, 1995), Figure 1.3. It is most apparent at the periphery of the
lobules, proximal to the lobular septa and adjacent to the pleura, and is generally more
severe in the upper lobes of the lung. In common with paracicatricial emphysema,
paraseptal emphysema is often found adjacent to areas of scarring and fibrosis.
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The different morphological forms of emphysema often coexist in the same lung sample
(Saetta et al, 1994b). This can make pathological diagnosis difficult, particularly where
severe damage is present.
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Normal lunc Centriacinar emphysema Panacinar emphysema Paraseptal emphysema
Figure 1.3 Diagrammatic representation of emphysema patterns in human lung.
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1.1.4 Morphological assessment of emphysema
There are a number of methods by which emphysema can be measured in lung
samples. These can be divided into either macroscopic assessment or microscopic
assessment techniques, and both techniques have advantages and disadvantages.
1.1.4.1 Macroscopic assessment of emphysema
Macroscopic assessment involves the examination by eye of inflated lung tissue, with
abnormal airspaces being classified as those airspaces measuring 1mm diameter or
more. Several methods have been reported in the literature for the macroscopic
assessment of emphysema (Lamb, 1995). The macroscopic assessment techniques
described in the literature allow either severity or involvement to be assessed in a
manner which is more accurate than evaluation of the entire lung by eye. However, true
quantitative measurement is not possible using any of these techniques.
Automated techniques for macroscopic assessment have been developed which allow
unbiased quantitation. The automative methods described use light transmission
through lung sections to detect differences between normal lung and less dense
emphysematous lung (Kory, 1966; Longfield, 1966).
Although truly quantitative, these methods are still subject to disadvantages.
Differences in the thickness and pigmentation of lung sections measured will affect
both the density and hence the light transmission of the sample. Only large amounts
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of lung destruction may be detected using light transmission and mild disease may
remain undetected.
There are several disadvantages ofmacroscopic assessment techniques. Firstly, they do
not allow pattern of disease to be assessed. This must be done separately, and when
more than one form of emphysema is present, separate evaluation of severity and/or
involvement must be carried out. Secondly, macroscopic assessment only detects
airspaces of 1mm diameter or more. The size of a normal airspace is approximately 250
pm (Schreider & Raabe, 1981), hence macroscopic detection occurs at a late stage in the
disease process where 75% of normal tissue has been destroyed. The use of
macroscopic assessment precludes the study of early emphysema where little damage
has occured. Macroscopic detection will also not identify increased airspace size in the
cohort of cases with airspaces measuring between 250pm and 1mm, hence the number
of emphysema cases will be limited, and biased towards severe disease.
1.1.4.2 Microscopic measurement of emphysema.
In order to detect early damage occuring in lungs before the stage where it can be
visualized macroscopically, several techniques have been developed which can detect
emphysema using microscopes (Saetta et al, 1985; Saito et al, 1989; Nagai et al, 1989).
However, microscopic techniques are open to subjective interpretation and they may be
non-quantitative (Gillooly et al, 1991). The mean linear intercept (Lm) is often used as
a microscopic measure of the alveolar surface area. While the Lm is an objective
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measurement of the loss of alveolar tissue in microscopic emphysema, there is little
information available on baseline levels of Lm measurements in the general population.
Furthermore, unless automated techniques employing image analysis are used, the
production of Lm measurements is time-consuming and labour intensive (Gillooly et al,
1991). Development of the Fast Interval Processor, an automated image analysis system
which measures the airspace wall surface area per unit volume of lung tissue (AWUV)
by Gillooly and colleagues (1991) has enabled the limits of normality of AWUV to be
measured in the general population to establish a baseline for airspace size in relation to
age (Gillooly & Lamb, 1993a). This work has provided a basis for the microscopic
measurement of emphysema in smokers, and it has subsequently been shown that
cigarette smoking is not the major influencing factor governing susceptibility to
microscopic emphysema (Gillooly & Lamb, 1993c).
1.1.5 Aetiology and pathogenesis of emphysema
Emphysema is associated with cigarette smoking, but the reason why cigarette smoke
exposure results in destruction of lung tissue is unclear. There is little direct evidence to
causally link cigarette smoke exposure with emphysema. In attempting to elucidate the
manner by which cigarette smoke results in emphysema, 2 main theories, the
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protease/antiprotease imbalance theory and the oxidant/antioxidant theory, have been
proposed.
1.1,5.1 Protease/Antiprotease theory of emphysema
Much of the evidence to support the protease/antiprotease theory is based on the
finding that emphysema can be induced in the lungs of animals by installation of
proteases, coupled with evidence that deficiency in al-antiprotease results in
increased susceptibility to emphysema. This evidence led Janoff & Carp to propose
the protease/antiprotease theory in 1977 (Janoff& Carp, 1977a), and to this date, this
hypothesis remains the major focus of investigation into the aetiology of emphysema.
1.1.5.2 al Antiprotease deficiency
Deficiency of al-antiprotease (al anti-trypsin, alPi) was first recognized to be
associated with susceptibility to emphysema by Laurell and Eriksson in 1963. Deficiency
of alPi results as a consequence of polymorphism of the gene encoding the enzyme, a
lPi is the major antiprotease circulating the body in the serum. Production of alPi
occurs primarily in the liver. The function of alPi is the inhibition of the proteases
elastase, collagenase, trypsin and thrombin (Kueppers & Beam, 1966), however, elastase
is thought to be the major physiologic substrate of alPi since it inactivates elastase faster
than any other protease (Weissler, 1987). alPi inactivates proteases by acting as a false
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substrate. Proteases recognize the active site of alPi, a Methionine-Serine peptide bond
at amino acid postion 358, and covalently bind the antiprotease. It has been shown that
the integrity of the Methionine site is essential for function of alPi (Johnson & Travis,
1979).
Deficiency of alPi can result from a variety of genetic defects, including gene deletion
(Takahashi & Crystal, 1990), point mutations resulting in premature termination of
transcription, and production of unstable mRNA (Satoh et al, 1988; Garver et al, 1986).
The major alleles of the alPi gene are the M, S, Z and null alleles. Individuals with
normal alPi levels are homozygous for the M allele, and the frequency of this
genotype in populations of Northern European extraction is 95% (Gadek & Crystal,
1982). Homozyotes for the ZZ allele show 12% of the normal alPi levels (Gadek &
Crystal, 1982) and are present at an estimated frequency of 1 per 2500 in the US
population (Weissler, 1987). Heterozygotes of the M, Z and S alleles, and
homozygotes for the S allele show reduced alPi levels. MZ heterozygotes show a
frequency of 4% in the US population (Weissler, 1987).
Deficiency of alPi predisposes individuals to develop emphysema, and this is
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specific to emphysema of panacinar pattern (Guenter et al, 1968). The exact
frequency of the ZZ genotype in the general population is unknown since these
individuals will only come to light if they experience symptoms of respiratory
disease (Weissler, 1987). As previously mentioned, emphysema only becomes
symptomatic when one third of the lung tissue has been destroyed (Pratt, 1988).
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Conceivably there is a proportion of non-smoking ZZ individuals with no symptoms
of emphysema which has never been included in studies of ZZ deficiency.
Smoking is very important in the induction of disease in alPi deficient individuals.
The average age of onset of symptomatic respiratory disease in ZZ homozygotes who
smoke is 40 years, as compared to 54 years in non-smoking ZZ individuals (Gadek &
Crystal, 1982). Homozygotes for the ZZ allele of alPi show an average rate of
decline in FEV1 which is approximately twice that of individuals with normal levels
of alPi (Weissler, 1987).
While deficiency of alPi may increase the susceptibility of an individual to
developing emphysema, ZZ individuals may only develop emphysema after smoking
(Gadek & Crystal, 1982). Therefore simply an imbalance of proteases and
antiproteases is insufficient to cause emphysema, and other crucial mechanisms must
be involved in the aetiology of this disease.
1.1.5.3 Animal models of emphysema
Animal models have contributed significantly to the understanding of how an
imbalance in proteases and antiproteases might produce tissue destruction which is
similar to emphysema. The first animal model for emphysema was described in
1964 when Gross and colleagues introduced papain into the lungs of rats. The tissue
destruction was shown to result from the elastolytic properties of the papain and
subsequently, several studies demonstrated that emphysema could be induced in
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animal lungs with the installation of pancreatic elastase. Whilst pancreatic elastase is
a very potent protease, it is unlikely to be important in the development of pulmonary
emphysema since it requires supra-physiological doses to produce emphysema by
intravenous injection of elastases (Ip et al, 1980).
Inflammatory cells are a source of elastase and other proteases which may be
relevant to the aetiology of emphysema. Proteases are used by these cells to facilitate
their migration through connective tissues to reach sites of inflammation. Neutrophil
elastase is a serine protease capable of degrading fibronectin, elastin, collagen types
III and IV, and proteoglycans. The elastase is produced by promyelocytes and stored
in the azurophilic granules of mature neutrophils. Studies by Fonzi & Lungarella
(1979) and Tarjan and colleagues (1980) have shown that intratracheal instillation of
homogenates of leukocytes causes emphysema in animal lungs. Subsequently,
studies using purified human neutrophil elastase have produced emphysema when
instilled intratracheally into the lungs of animals (Janoff et al, 1977b; Senior et al,
1977; Snider et al, 1984), and purified dog neutrophil elastase has produced
emphysema upon intratracheal instillation to dogs (Sloan et al, 1981).
Upon intratracheal installation of elastase to hamster lungs, within one hour oedema,
haemorrhage and infiltration of inflammatory cells is seen (Lucey & Clark, 1982).
Air space enlargement occurs over the next few hours, and 24 hours following
elastase introduction both elastin and collagen levels in the lung will have been
reduced. Elastin may be depleted by as much as two thirds of its original content
(Karlinsky & Snider, 1978).
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Elastase has been shown to be cleared from the lungs to the pulmonary circulation 24
hours after instillation (Stone et al, 1977), however damage continues to occur, with
the production of stable emphysematous lesions occurring at approximately 21 days
post insult (Weissler, 1987). Studies of the breakdown products of elastin indicate
that destruction is maintained for 2 weeks following elastase instillation (Kuchich et
al, 1980; Janoff et al, 1983). It is possible that some of this destruction is mediated
by neutrophil elastase which has been ingested by macrophages and released more
slowly as the macrophages die or undergo phagocytosis (Weissler, 1987).
1.1.5.4 Relevance of emphysema induced by intratracheal instillation of
proteases in animals
Although intratracheal instillation of proteases to animal lungs can produce
emphysema, attempting to apply this information to produce a theory of the aetiology
of human emphysema is problematic. Firstly, a single dose of elastin is enough to
produce emphysema in an animal lung, whereas in humans, it takes on average 30
years to develop symptomatic emphysema (Weissler, 1987). Secondly, intratracheal
instillation of proteases is not an ideal model of a disease thought to evolve from
cigarette smoke induced damage and recruitment of leukocytes, and the subsequent
local release of proteases.
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Several studies have attempted to produce more physiological models of human
emphysema by firstly exposing animals to cigarette smoke, secondly, by the
introduction of compounds to increase the sequestration of leukocytes in the lungs,
and finally, by the utilisation of agents which damage or reduce the activity of al-
antiprotease.
1.1.5.5 Animal models of emphysema produced by cigarette smoke exposure
Exposing animal lungs to cigarette smoke in order to produce emphysema is inherent
with difficulty, and while many smoking studies have been carried out, they have for
the most part failed to produce emphysema (Snider et al, 1986). Species differences
provide a major problem. Because human emphysema takes, on average, decades of
smoking to develop, precise dosage reproduction is difficult. Moreover, many
experimental variables exist, such as differences in experimental technique in
delivering cigarette smoke, in strength of cigarettes used, and in length of exposure
times, perhaps explaining why much of the research carried out using animals has
yielded conflicting results. Where morphologic changes are generated, often
insufficient study of the qualitative and quantitative evidence of emphysema is
undertaken to conclude whether the lungs manifest all the changes seen in human
emphysema (Huber et al, 1981).
Often, studies which have exposed animal lungs to chronic cigarette smoke in order
to produce models of emphysema have yielded histopathology which resembles other
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human lung diseases. For example, beagle dogs have been exposed to 2-7 cigarettes
daily over 2-4 months, which resulted in airspace enlargement. This airspace
enlargement was not comparable to human emphysema however, since the
enlargement appeared to result from the deletion of interalveolar septa, and
expansion of interalveolar pores, rather than from destruction of the parenchyma
(Frasca et al, 1983). In rats and hamsters, cigarette smoke exposure has been shown
not to cause emphysema, but rather to generate pathology similar to that seen in
human respiratory bronchiolitis, that is, epithelial hyperplasia, macrophage
accumulation, and alveolar wall fibrosis (Bernfield et al, 1979; Dalbey et al, 1980;
Wehner et al, 1981). These findings suggest that cigarette smoke exposure induces
different functional changes in the lungs of dogs, rats and hamsters as compared to
the damage seen in human emphysema, and these differences may represent a
different underlying pathogenetic mechanism.
In perhaps the most comprehensive study of an animal model of emphysema induced
by chronic cigarette smoke exposure, Fluber and colleagues (1981) exposed
approximately 300 rats thrice daily to cigarette smoke over a 6 month period.
Reduction of parenchyma in the region distal to the terminal bronchioles of the lung
was demonstrated. Changes in the physiological function of the lungs indicating a
reduction in lung elastic recoil were also observed, adding support to the possibility
that this study provides an animal model of emphysema. Flowever, as the authors
point out, their study did not indicate whether or not the increased airspace size
demonstrable was permanent, nor could they ascertain whether the airspace
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enlargement was the result of destruction, or was a reflection of differences in lung
growth of the smoke exposed rats.
In conclusion, research to produce a convincing animal model to study the
pathogenesis of human emphysema using chronic cigarette smoke exposure has
failed.
1.1.5.6 Animal models investigating the effect of protease/antiprotease
imbalance
Several studies investigating imbalances in proteases and antiproteases in animal
lungs have been carried out. By exposing rats to puffs of cigarette smoke, Janoff and
colleagues (1979) were able to show a reduced ability of lavage fluid alPi to inhibit
elastase. Activity of a 1 Pi in lavage fluid has also been reduced significantly by the
addition of human neutrophil myeloperoxidase and either hydrogen peroxide or
glucose oxidase and glucose to hamster lungs (Zaslow et al, 1985).
To produce sequestration of leukocytes in the lungs of animals, several investigators
have injected endotoxin intravenously in rhesus monkeys (Wittels et al, 1974), and
dogs (Guenter et al, 1981), and this has been shown to result in mild emphysema. D-
galactosamine is a compound which reduces al-antiprotease levels in the serum of
rats by damaging the liver, and hence reducing alPi synthesis by hepatocytes
(Blackwood et al, 1979). Combination of D-galactosamine with endotoxin injection
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has been shown to decrease lung elastin content, and causes some physiological
effects on lung function (Blackwood et al, 1984).
Chloramine T is an oxidizing agent which has been shown to cause reduction in the
activity of serum oclPi in dogs, and which has been used to generate lesions similar
to emphysema in the lungs of dogs (Abrams et al, 1981).
1.1.5.7 Genetic models of emphysema
Genetic models of emphysema have been reported in the literature. The blotchy
mouse is a model of deficient copper transport, which progressively develops lesions
similar to panacinar emphysema. Production of mature elastin and collagen requires
cross-linking of precursors by a copper-dependant enzyme lysyl oxidase (Weissler,
1987). The deficiency in copper transport demonstrable in the blotchy mouse affects
lysyl oxidase activity such that elastin and collagen synthesis is decreased (Snider et
al, 1986). The tight-skinned mouse is another genetic model of emphysema (Szapiel
et al, 1981; Rossi et al, 1984) which demonstrates deficiency of alPi in the serum,
although liver mRNA levels are normal (Martorana et al, 1993). The tight-skin
mouse develops alveolar septal destruction with lesions becoming apparent at 8
months of age, and air space enlargement developing from the age of 12 months
(Martorana et al, 1993). Tight-skin mice have also been reported to have abnormally
high elastase and cathepsin G levels in the lysosomal secretions of their neutrophils
(Gardi et al, 1994). The tight-skin mouse lung has been shown to contain increased
levels of inflammatory cells in the absence of infection (Snider et al, 1986).
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1.1.6 Mechanism of lung tissue destruction in emphysema
Studies carried out on animals have provided important information concerning how
tissue destruction may occur. However, even the more physiological studies which
mimic the long onset, genetic susceptibility, and possible involvement of
polymorphonucleocytes, do not provide any direct evidence for a link between cigarette
smoke exposure and emphysema. How then can the information gained from animal
model research be used to speculate on the manner in which cigarette smoking causes
the tissue destruction resulting in emphysema?
1.1.6.1 Neutrophil elastase
Neutrophil elastase is a serine protease which is stored in the azurophilic granules of
the neutrophil. It attacks almost all of the structural proteins of the lung, including
elastin, fibronectin, proteoglycans, and collagen types III (Mainardi et al, 1980) and
IV (Agar et al, 1986; Aruoma & Halliwell, 1989). The release of neutrophil elastase
in healthy lung tissue is normally kept to a minimum because few neutrophils are
found in lung tissue unless inflammatory cell recruitment occurs to increase their
numbers. Hunninghake and colleagues (1979) reported that neutrophils, eosinophils
and basophils make up less than 1% of the cells found in bronchoalveolar lavage, and
this reflects the numbers of polymorphonuclear leukocytes in healthy alveoli.
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Smokers lungs however, have much higher proportions of inflammatory cells in both
bronchoalveolar lavage fluid (Reynolds & Newball, 1974; Warr & Martin, 1976) and in
their respiratory bronchioles and alveoli (Niewoehner et al, 1974; Kuhn & Senior,
1978). These cells are thought to be recruited to the lung by chemotaxis in a number of
ways. Nicotine has been shown to be chemotactic for neutrophils, and to increase the
responsiveness of neutrophils to the chemotactic C5a complement peptide (Totti et al,
1984). The inflammatory response to tissue injury from cigarette smoke components is
also thought to result in chemotaxis. Stimulated alveolar macrophages have been shown
to release chemotactic factors for neutrophils in vitro following activation by
immunoreactive particles (Merrill et al, 1980; Hunninghake et al, 1980). An aqueous
suspension of whole cigarette smoke has been shown to modify the C3 component of
complement such that the alternative complement pathway is activated in vitro (Kew et
al, 1985), which may contribute to the recruitment of inflammatory cells to the lung.
1.1.6.2 Involvement of other proteases in emphysema
Neutrophils are not the only cells implicated in the release of proteases which may cause
lung tissue damage. Monocytes contain an elastase which, although only 3% as much as
present in neutrophils, may be expressed on the cell surface (Weissler, 1987), and may
therefore be more accessible to mediate damage (Senior, 1982). Mouse macrophages
secrete a metalloproteinase (Werb & Gordon, 1975) which can degrade elastin, and which
has been shown to be capable of proteolysis of alPi (Banda et al, 1980). Furthermore,
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metalloelastases are not susceptible to inactivation by alPi (Weissler, 1987). In humans,
bronchoalveolar lavage (BAL) fluid of smokers contains a metalloprotease, the amount of
which is correlated negatively with decreased activity of alPi (Niederman et al, 1984).
Macrophages contain other proteases which may have roles in protease/antiprotease
imbalances. Cathepsin B has elastolytic properties, and is expressed on the macrophage
cell surface (Orlowski et al, 1981). The macrophage cell surface also expresses
plasminogen activator, which can activate plasminogen to plasmin, a very effective
degrader of fibrin and proteoglycans (Chapman et al, 1984). Mass and colleagues
introduced homogenates of alveolar macrophages to the lungs of dogs by aerosol, and
observed that this treatment produced mild emphysema (1972). As well as containing
proteases which can be released and contribute to tissue damage, macrophages can be
primed to enhance their release of oxygen radicals by proteases (Speer et al, 1984).
Neutrophils contain proteases other than elastase which can be destructive to lung tissues.
Neutrophil collagenase causes little damage (Karlinsky & Snider, 1978), presumably
because it is specific only for Type I collagen. Cathepsin G is capable of degrading elastin,
but at 12% of the rate of digestion mediated by elastase. Proteoglycans, fibronectin and
laminin are also potential substrates of Cathepsin G (Kao et al, 1988). However, Lucey
and colleagues (1985) were unable to produce emphysema by intratracheal instillation of
Cathepsin G to the lungs of hamsters. Some evidence has been presented which suggests
that Cathepsin G may have a role in the solubilization of lung elastin by neutrophil elastase
in humans (Boudier et al, 1981; Reilly et al, 1984; Lucey et al, 1985). Proteinase 3 has
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elastolytic properties, and is the only protease besides neutrophil elastase to induce
emphysema-like changes in animals (Kao et al, 1988). However, this finding has not been
confirmed. Neutrophil myeloperoxidase has been shown to produce lesions similar to
pulmonary fibrosis when instilled into the lungs of animals (Johnson & Ward, 1981).
The research which has been carried out on the possible involvement of inflammatory
cells in the aetiology of emphysema is interesting but inconclusive. Inflammatory cells
do contain proteases which are capable of lung tissue degradation, and there is some
evidence to support the recruitment of inflammatory cells to the lung following cigarette
smoke exposure. However, there is, as yet, no conclusive proof that emphysema results
from an imbalance in the levels of proteases and antiproteases which is triggered by
cigarette smoking.
1.1.6.3 Cigarette smoke involvement in emphysema
Emphysema may develop following cigarette smoke exposure as a direct result of
toxicity from components in the smoke, either directly causing cytotoxicity, or
indirectly by affecting the protease/antiprotease levels in the lungs. Research into the
mechanisms by which reactive species in cigarette smoke might cause tissue destruction
can be referred to as the oxidant/antioxidant theory of emphysema aetiology.
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Cigarette smoke contains 1016 oxidants per puff, (Pryor et al, 1986). These reactive
species are capable of damaging tissue directly, and may contribute to the protease
burden of lungs by inactivating a 1 Pi in a number ofways.
The gas phase of cigarette smoke contains alkoxyl radicals, peroxyl radicals and
alkyl radicals (Evans & Pryor, 1994), Figure 1.4. Reaction between these radicals
and nitric oxide and nitrogen dioxide also contained in cigarette smoke (Church &
Pryor, 1985) can produce further harmful species, including peroxynitrates (Evans &
Pryor, 1994) and peroxynitrites (Beckman et al, 1994; Koppenol et al, 1992). Nitric
oxide can react with peroxyl radicals and produce alkyl peroxynitrites (Padmaja &
Huie, 1993), which are cytotoxic. It is thought that a steady state production and
destruction of radicals occurs in cigarette smoke, since the half-life of the radicals
present in smoke is long (Church & Stone, 1985). The gaseous phase of cigarette
smoke is capable of causing nitration of tyrosine, probably through reactions of
nitrogen oxides (Eiserich et al, 1994).
The particulate phase, or tar, of cigarette smoke contains 4 radicals, and phenolics,
which can autoxidize and polymerize to form semiquinone radicals (Evans & Pryor,
1994). The major tar radical is a quinone/hydroquinone complex which may reduce
molecular oxygen to produce the superoxide radical, capable of generating hydrogen
peroxide and the hydroxyl radical (Church & Pryor, 1985), Figure 1.4. Aqueous
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extracts of tar produce solutions that consume oxygen and contain hydrogen
peroxide, superoxide radicals and hydroxyl radicals (Evans & Pryor, 1994).
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The major organic-free radicals in gas-phase cigarette smoke are the alkyl radicals
(' R) and the alkoxyl (RO) and peroxyl (ROO) radicals. A steady state production of
radicals in cigarette smoke was suggeted by Church and Pryor (1985). In this model
nitric oxide is slowly oxidised to nitrogen dioxide:
N02 + 1/2 02 -> N02
Nitrogen dioxide may then react with reactive species, for example olefins, aldehydes
and dienes, to produce a carbon centered radical, R :
■
no2 + c==c -> o2n—c—C •
(R)
In the presence of dioxygen, the R radical can rapidly form peroxyl radicals:
R' + 02 —> ROO
The peroxyl radical can react with nitric oxide to produce peroxynitrites:
ROO + NO -» ROO—NO
Alternatively, the peroxyl radical can react with N02 to produce peroxynitrates:
ROO + N02 -> ROO—N02
Figure 1.4 Figure showing some of the major free radicals present in cigarette
smoke and their reaction products which may result from a steady state production of
radicals (Evans & Pryor, 1994).
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1.1.6.4 Tissue damage from reactive oxygen species
Reactive oxygen species are directly damaging to tissues in a number of ways.
Cigarette smoke can oxidise thiols (Fenner & Braven, 1968), and Church & Pryor
(1985) suggest that nitric oxide and nitrogen dioxide in cigarette smoke can oxidise
sulfhydryl groups, and thus impair enzyme function. Glutathione, an important
antioxidant, has also been shown to be oxidised by nitric oxide and nitrogen dioxide
(Church & Pryor, 1985). Alkyl peroxynitrates and peroxyl radicals are cytotoxic
species (Padmaja & Huie, 1993; Pryor & Stone, 1993), as are nitrogen dioxide,
peroxynitrites and peroxynitrates (Eiserich et al, 1994). Peroxynitrites are very
powerful oxidizing agents to -SH groups (Radi et al, 1991). Nitrogen oxides also can
cause the nitration of tyrosine (Eiserich et al, 1994) and of lysine s-amino groups
(Hood, 1993) and can produce peptide bond cleavage. In the lung, protein damage
may impair the function of membrane transport and receptor proteins, antioxidants
and surfactant proteins, and cause inactivation of important enyzmes, including alPi.
Nitration of tyrosine might also affect tyrosine phosphorylation pathways of cell
signalling (Eiserich et al, 1994).
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Free radicals can oxidize lipids and proteins in biomembranes (Niki et al, 1993), and
cigarette smoke can cause lipid peroxidation in plasma (Frei et al, 1991). Large
amounts of lipid peroxidation can alter the fluidity, potential and permeability of
membranes, which may lead to the eventual rupture of the cell membrane (Halliwell
& Gutteridge, 1990). Moreover, some of the end-products of lipid peroxidation can
be cytotoxic, affecting macrophage action, protein synthesis, and enzyme function,
and mediating protein cross-linking, thrombin release, and chemotaxis of
inflammatory cells (Halliwell & Gutteridge, 1990).
Lannan, and colleagues (1994) have shown that whole and gas phase cigarette smoke
can cause increased cell detachment and lysis and decreased cell attachment and
proliferation. When type I epithelial cells are damaged, type II cells replace them by
proliferation and differentiation. Decreased proliferation and attachment of type II
alveolar cells may contribute to the alveolar destruction seen in emphysema.
Superoxide produced by cigarette smoke has been shown to cause decreased
membrane fluidity of inflammatory cells (Tsuchiya et al, 1993). Biologically, this
may reduce the deformability of the inflammatory cells as they enter the lung, either
in the pulmonary circulation or in the alveoli (Dye & Adler, 1994). Exposure of
neutrophils to whole and gas-phase cigarette smoke has been shown to reduce
deformability via disruption of F-actin turnover (Drost et al, 1992). This will slow
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the passage of these cells out of the lung, hence any destructive effects mediated by
inflammatory cells may be prolonged. In cells of the lung, decreased fluidity of the
membranes will reduce cell spreading, which is necessary for cell attachment. Since
cell attachment is required for proliferation, this will affect the ability of the lung to
repair damage (Lannan et al, 1994).
Lung epithelial and endothelial permeability is increased in smokers as compared to
the lung permeability of non-smokers (Dye & Adler, 1994). This is thought to be
due to effects of cigarette smoke on the cell cytoskeleton. Cigarette smoke also has
deleterious effects on the number of gap junctions (van der Zandt et al, 1990) and
intercellular communication between gap junctions (Rutten et al, 1988).
Smokers have increased levels of ferritin in their lavage fluid (McGowan & Henley,
1988), and in alveolar macrophages (Quan & Golde, 1981). The binding of iron to
ferritin can prevent free iron from participating in hydroxyl radical production and
lipid peroxidation (Heffner & Repine, 1989). However, cells which are damaged
following inflammation can release their ferritin-bound iron (Halliwell & Gutteridge,
1984), and following interaction with superoxide, organic radicals, and ascorbate, the
iron can be freed to contribute to toxicity (Gutteridge et al, 1980; Bannister et al,
1982; Biemond et al, 1984; O'Connell et al, 1986). Lung tissue from patients with
suspected pathogenetic excess of reactive oxygen species demonstrates sequestration
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of erythrocytes and platelets in the microvasculature of the lung. Erythrocytes and
platelets can contribute to oxidative damage. Erythrocytes release iron bound to
hemoglobin which can then participate in iron-catalysed free radical reactions (Cross
et al, 1987). Platelets are capable of releasing chemotactic factors for neutrophils
(Boogaerts et al, 1982), and can stimulate increased neutrophil aggregation, granule
release (Boogaerts et al, 1982) and adherence (Tzeng et al, 1984). Furthermore,
platelets which have been stimulated with thrombin can directly damage endothelial
cell cultures (J0rgenson et al, 1986). Platelets can also release endoperoxides which
neutrophils can ingest and metabolize to produce inflammatory products (Marcus et
al, 1984).
As well as being directly damaging to lung tissues, oxidants derived from cigarette
smoking can cause tissue destruction indirectly. Many components of cigarette
smoke can inactivate alPi and it is generally believed that this occurs primarily by
oxidation of the protein (Evans & Pryor, 1994). Besides the methionine residue in
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the active site (Met ), alPi has several other methionine residues which can be
oxidized thereby affecting protein function (Evans & Pryor, 1994). Hydrogen
peroxide in either the gas phase or tar components of cigarette smoke can inactivate
alPi. Hydroxyl radicals and superoxide may inactivate alPi by direct oxidation.
Alkyl radicals do not inactivate alPi, which may be due to their high reactivity -
they may be so reactive that they interact with other substrates before reaching alPi.
Transition metals in cigarette smoke can participate in the production of hydrogen
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peroxide. alPi is known to have at least 1 copper binding site, and ferric ions can
bind alPi and produce reactive, peroxide derived species which can damage the
protein. Cigarette smoke contains high levels of both iron and copper. In lower
concentrations, nitrogen dioxide and hydrogen peroxide may cause slow damage to a
lPi. Peroxynitrous acid, formed from reaction of nitric oxide with superoxide may
also have damaging affects on alPi. Inactivation of alPi can occur by protein
damage, through nitration of tyrosine residues and s-amino groups of lysine, and
through peptide bond cleavage, all of which can be produced by nitrogen oxides
(Evans & Pryor, 1994; Eiserich et al, 1994).
Exposure of the lungs to oxidants in cigarette smoke not only affects the balance of
proteases and antiproteases through the inactivation of alPi. Fligiel and colleagues
(1984) showed that the exposure of proteins to hydrogen peroxide increased their
susceptibility to proteolytic attack.
Cigarette smoke may also be involved in the pathogenesis of emphysema through the
inhibition of the repair of damaged elastin. Elastin is formed by the cross-linking of
tropoelastin by desmosine. Before this cross-linking can occur, lysine residues of
elastin must be oxidised. This oxidation is mediated by the copper-dependant
enzyme lysyl oxidase (Weissler, 1987). If this enzyme is inhibited, damage to the
lung by elastase is greatly increased (Weissler, 1987). Cigarette smoke is known to
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inhibit elastin synthesis by blocking the cross-linking of tropoelastin (Janoff, 1985).
Basic cigarette smoke components can inhibit elastin synthesis which may occur by
the addition of polyanions to elastin. Lysyl oxidase is a negatively charged molecule
(Kagan et al, 1981), hence enzyme binding of elastin will be reduced if the elastin
becomes more positively charged. Another effect of the addition of polyanions to
elastin is increased attraction of elastase, which is positively charged (Kagan et al,
1981). Furthermore, lysyl oxidase function can be affected by reduced availability of
copper, on which it is dependant. Copper malnutrition, for example, can increase the
severity of damage induced by elastase (O'Dell et al, 1978). Cigarette smoke is
known to contain copper chelators, which may remove copper required for lysyl
oxidase mediated elastin cross-linking, and hence hinder repair (Weissler, 1987).
1.1.6.5 Environmental damage to lung tissue
Nitrogen oxides are environmental pollutants and are present in smog. Nitrogen dioxide
can cause emphysema-like changes in animal lungs following long-term exposure
(Snider et al, 1986). In hamsters nitrogen dioxide decreases lung elastin content and
causes emphysema-like change, although in adults this requires very great levels of
exposure (Snider et al, 1986).
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1.1.6.6 Lung protection against oxidative attack
While oxidative attack on tissue exposed to cigarette smoke can produce damage
which may result in emphysema, the lung is not unprotected against this form of
destruction. The lung has a series of antioxidant mechanisms which serve to protect
against oxidative attack. These mechanisms were defined by Sies (1987) as being
any cell process which 1. blocks the formation of free radicals; 2. metabolizes
oxidants to less harmful products; 3. compartmentalizes free radicals to prevent cell
destruction; and 4. repairs damage caused by free radicals.
Major airways contain mucopolypeptide glycoproteins which can act as sacrificial
scavengers of reactive species (Cross et al, 1984). The alveoli acquire many of their
complement of antioxidants from the epithelial lining fluid. Alveoli have been
shown to contain ceruloplasmin, transferrin, ascorbate, vitamin E, ferritin, bilirubin
and methionine (Heffner & Repine, 1989). High levels of reduced GSH are also
present in the alveoli (Cantin et al, 1987), and these levels are increased in smokers
lungs. Bronchoalveolar lavage fluid recovered from normal individuals contains
antioxidants which are capable of blocking lipid peroxidation in vitro (Pacht &
Davis, 1988).
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Superoxide dismutases catalyze the dismutation of superoxide to produce hydrogen
peroxide and oxygen. The different superoxide dismutases are found primarily in the
cytosol and nucleus, the mitochondria, or the plasma (Heffner & Repine, 1989).
Catalase catalyzes the dismutation of hydrogen peroxide to water and oxygen, and
can remove both hydrogen peroxide and superoxide from the intracellular
environment (Heffner & Repine, 1989). In mammalian cells, catalase is highly
compartmentalized, primarily to the peroxisome (Chance et al, 1979).
The glutathione redox cycle is capable of reducing hydrogen peroxide, eliminating
hydroperoxides (Ross et al, 1985) and lipid peroxides formed during free radical
attack of membranes (Moldeus et al, 1986).
Compartmentalization to keep oxidants away from vulnerable cell structures is very
important since oxidants are formed continuously in the cell during respiration. By
compartmentalization to the mitochondria, any toxic species are kept from damaging
the cell. Other examples of cell compartments which hold free radicals preventing
damage are peroxisomes and microsomes (Heffner & Repine, 1989).
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As has previously been mentioned, transitional metal ions are important in the
production of oxidants, since they can enhance lipid peroxidation and participate in
the production of the hydroxyl radical from superoxide and hydrogen peroxide. The
hydroxyl radical is so very reactive and toxic to cells, in comparison to superoxide
and hydrogen peroxide, that it is thought to be one of the most damaging species. By
reducing the availability of free transitional metals, production of hydroxyl radicals
can be limited (Heffner & Repine, 1987).
Free iron can be bound by the glycoproteins transferrin and lactoferrin, which
transport iron in the circulation (Gutteridge, 1986a). Flaemoglobin will readily
release bound iron (Gutteridge, 1986b), but compartmentalization in the erythrocyte
of haemoglobin prevents the iron from participating in free radical formation.
Caeruloplasmin is a plasma glycoprotein which catalyses the formation of ferric iron
from ferrous iron which can help produce free radicals (Heffner & Repine, 1989).
Ferric iron can then be bound by transferrin. Caeruloplasmin can also scavenge
superoxide and the hydroxyl radical, inhibit the oxidative inactivation of proteases by
products of the leukocyte myeloperoxidase system, and bind copper, which can also
participate in hydroxyl radical formation.
Vitamin E (a-tocopherol) is thought to be the primary defense against membrane
damage by oxidants. Vitamin E converts superoxide, hydroxyl radicals and lipid
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peroxyl radicals to less toxic forms, and can break the chain reaction of lipid
peroxidation. It is lipid soluble and can integrate into lipid membranes where it can
carry out antioxidant reactions (Heffner & Repine, 1989). P-carotene is a second
lipid soluble antioxidant which is present in lipid membranes. P-carotene can
scavenge superoxide, and can react with peroxyl-free radicals (Foote & Denny,
1968).
Vitamin C is a water-soluble antioxidant which is found in both intracellular and
extracellular spaces. Scavenging of superoxide and hydrogen peroxide can be carried
out by vitamin C (Heffner & Repine, 1989). Vitamin C can also inhibit the
inactivation of antiproteases mediated by the neutrophil myeloperoxidase-halide
system (Theron & Anderson, 1985), and inactivate oxidants released from
neutrophils (Anderson et al, 1988).
Both vitamin C and P-carotene have pro-oxidative capabilities (Heffner & Repine,
1989). Vitamin C can convert ferric iron to ferrous iron, which can then participate
in the generation of hydroxyl radicals (Halliwell & Gutteridge, 1984).
Uric acid is a potent antioxidant. It scavenges hydroxyl radicals, singlet oxygen,
oxoheme oxidants, and peroxyl radicals (Heffner & Repine, 1989). Vitamin C
oxidation can be prevented by uric acid (Sevanian et al, 1985), and transition metals
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can be bound by uric acid (Davies et al, 1986), thereby removing them from
availability to produce hydroxyl radicals.
ADP ribosyl transferase is a nuclear enzyme which mediates excision repair after
minor or moderate damage to DNA (Schraufstatter et al, 1986), for example, single
strand breaks. Following severe damage, the enzyme depletes cellular NAD+ and
initiates cytotoxicity (Berger, 1985).
Phospholipase A2 and the seleno-enzyme phospholipid hydroperoxide glutathione
peroxidase both degrade peroxidized membrane phospholipids therefore removing
damaged membrane before chain peroxidation can be initiated (van Kuijk et al,
1987).
1.1.6.7 Other mechanisms of lung protection
Cellular proliferation to replace damaged tissue is another major mechanism of repair
available to the lung. Rats exposed to hyperoxia show lung cell proliferation and
changes in cell morphology which may be indicative of the production of cells which
are more resistant to subsequent oxidant attack (Heffner & Repine, 1989).
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As previously mentioned, Lannan and colleagues, 1994, found that decreased cell
membrane fluidity, which can be induced by cigarette smoke exposure, affects the
ability of cells to spread, attach and proliferate. Cigarette smoke exposure also
caused increased cell detachment and lysis.
Lung protection can also be provided by recruitment of cells rich in antioxidants
from the circulation. Erythrocytes, for example, contain high levels of superoxide
dismutase (SOD), catalase, and GSH redox cycle components (Toth et al, 1984).
Moreover, superoxide can cross the erythrocyte membrane and be dismutased by
erythrocyte SOD (Lynch & Fridovich, 1978). Oxidant exposure causes erythrocytes
to bind preferentially to endothelial cells (Wali et al, 1987), which may provide a
sink for hydrogen peroxide and superoxide and prevent further reactive species
formation (Winterbourn & Stern, 1987). Toth and colleagues, 1986, demonstrated
that levels of GSH and catalase were higher in erythrocytes of smokers than in non-
smokers. Smokers' erythrocytes were also more effective at protecting endothelial
cell cultures against H2O2 damage when compared to the erythrocytes of non-
smokers.
Platelets contain components of the glutathione redox cycle and catalase (Ramos
Martinez et al, 1979; Del Principe et al, 1985). By virtue of their small size, platelets
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can form close associations with activated neutrophils, allowing reduction of
neutrophil-derived oxidants (Pietra et al, 1981).
Phagocytes also contain antioxidants, and can lower H2O2 levels in vitro (Berger et al,
1987). Phagocytes may be protective in the lung when unstimulated, or following cell
lysis, since they may be sources of antioxidants (Heffner & Rapine, 1989).
1.1.7 Mechanisms of tissue destruction and pattern of disease
The mechanisms by which cigarette smoke may cause tissue damage have been
discussed, but how might these mechanims contribute to destruction in such a
manner that different patterns of damage result, for example producing centriacinar
rather than panacinar emphysema in a lung sample?
-9
The halt-life of the hydroxyl radical has been estimated to be 10 seconds (Pryor,
1986), therefore hydroxyl radical mediated damage will occur close to the source of
the hydroxyl radical (Leanderson, 1993). Following cigarette smoke exposure, the
damage caused by the hydroxyl radical would be expected to occur around the region
of the respiratory bronchioles. When cigarette smoke enters the lung, it enters
progressively more numerous, smaller airways, which decreases flow of the smoke,
until flow stops altogether in the region of the respiratory bronchioles. As the
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particles contained in the smoke bounce around, they are deposited, and can be
adsorbed onto the epithelium (Harley, 1988). Cigarette smoke components reach the
alveolar ducts and sacs primarily by diffusion from the respiratory bronchioles
(Saetta et al, 1994a). Consequently, the area of the lung most likely to be damaged
as a direct result of cigarette smoking is the region of the respiratory bronchioles.
Centriacinar emphysema is the form of emphysema where damage is centred around
the respiratory bronchioles. It is almost exclusively associated with cigarette
smoking, and severity of disease is directly related to the dose of smoke exposure
(Lamb, 1995). Panacinar emphysema, however, is found throughout the acinus, and
is not as clearly related to cigarette smoke exposure as is centriacinar emphysema
(Gillooly & Lamb, 1993b). Furthermore, panacinar emphysema is the form of
disease seen in individuals with al-antiprotease deficiency (Guenter et al, 1968).
Alpha 1-antiprotease is a systemic enzyme, therefore it is possible that panacinar
emphysema may be related to both the direct effects and the systemic effects of
cigarette smoke exposure (Saetta et al, 1994a). In a recent article, Saetta and
colleagues presented evidence that panacinar and centriacinar emphysema are
different diseases, and that these 2 diseases give rise to the airflow limitation of
































Figure 1.5 Diagram of the different mechanisms by which centriacinar and
panacinar emphysema might give rise to chronic obstructive airways disease
(adapted from Saetta et al, 1994a)
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1.1.8 Emphysema and lung cancer
Emphysema and lung cancer are both cigarette smoking associated diseases. It is
therefore probable that some components of cigarette smoke cause the damage which
may result in emphysema or the genotoxic injury which eventually leads to lung
cancer.
In the discussion of the possible role of oxidants in the pathogenesis of emphysema,
it has been shown that oxidative species are cytotoxic. Oxidants have also been
shown to be genotoxic. Cigarette smoke condensate can induce DNA single-strand
breakage in vitro via the production of reactive oxygen species (Nakayama et al,
1985). The tar fraction of cigarette smoke has also been shown to induce DNA
damage (Borish et al, 1985). Birnboim & Kanabus-Kaminska (1985) demonstrated
that superoxide can cause DNA strand breakage, as can the hydroxyl radical (Bradely
& Erickson, 1981). The hydroxyl radical can also cause the hydroxylation of DNA
bases (Aruoma & Elalliwell, 1989). Radical species may also demonstrate promoter
activity (Church & Pryor, 1985).
Research into the aetiology of emphysema has generated more questions concerning
the cause of emphysema instead of elucidating the basic mechanisms by which
cigarette smoke can induce tissue destruction. Perhaps the most interesting question
which arises from any discussion of the aetiology of emphysema is why do only
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some smokers develop emphysema? Discounting genetic disorders such as al-
antiprotease deficiency and defects in copper metabolism, which would be expected
to have a major impact on susceptibility to emphysema, some mechanism must exist
which can vary interindividual susceptibility such that only a proportion of smokers
develop emphysema. From discussion of the aetiology of emphysema, it is clear that
this disease is polygenic, but even so, there must be some factor, or factors, with a
great deal of influence on an individual's susceptibility. In cases of heavy smokers
who do not develop emphysema one would predict a strong protective mechanism is
present which can counteract the large quantities of toxic chemicals flooding the
lungs. Equally, light smokers who are exposed to relatively small doses of cigarette
smoke, and non-smokers, can develop emphysema, which suggests that these
individuals have some fundamental defect in the protective capacity of their lungs
which increases their risk of developing tissue destruction.
Gillooly & Lamb (1993b) measured the alveolar wall surface area per unit volume of
lung tissue (AWUV) among smokers in order to study microscopic emphysema.
When the smokers' mean AWUV values were plotted against the distribution of
AWUV in a non-smoking population (Figure 1.5) (Gillooly & Lamb, 1993a), only
26% of smokers' AWUV values fell below the normal distribution, indicating the
presence of microscopic emphysema. Figure 1.7. Furthermore, there was no
correlation between daily cigarette consumption and low AWUV values. Of the
heavy smokers, 69% had mean AWUV values within the normal distribution. The
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finding that microscopic emphysema is present in only some smokers, and is not
directly related to cigarette smoking in a dose-dependant manner, suggests that a





Figure 1.6 Graph showing the decline of alveolar wall surface area per unit
volume of lung tissue (AWUV) with age. This data can be used to define the normal
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Figure 1.7 Graph showing alveolar wall surface area per unit volume of lung
tissue (AWUV) of smokers and non-smokers plotted against age. A proportion of
smokers have abnormally low AWUV values which do not show a dose dependant
relationship.
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Since oxidants can cause both cytotoxicity and genotoxicity, cigarette smoke
exposure may lead to the development of lung cancer or emphysema, or both
diseases in the same lung. Many studies have linked xenobiotic metabolising
enzyme polymorphisms with susceptibility to lung cancer. Consequently, these
enzymes may have a role in conferring susceptibility to emphysema, a disease also
associated with cigarette smoke exposure. Many of the enzymes in the xenobiotic
metabolising system are polymorphic, and disadvantageous polymorphisms can
occur in relatively high levels in the general population. The xenobiotic
metabolising system represents a very important first defence against tissue
destruction. Deficiency in aspects of this defence resulting from polymorphism might
therefore explain why there is not always a clear cut relationship between levels of
cigarette smoke exposure and the subsequent presence and amount of disease.
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1.2 Xenobiotic Metabolising Enzymes
Metabolism of compounds in the body can be divided into 2 different components,
called Phase I and Phase II metabolism. Their function is the detoxification of both
xenobiotics and internal compounds to make them more easily excreted from the
body in the urine or bile (Gibson & Skett, 1986).
Although the majority of reactions carried out by the drug metabolising enzymes
produce less reactive compounds, a minority of the products will be more reactive,
resulting in a potential for toxicity in tissues (Gibson & Skett, 1986). The Phase I
enzymes generally produce compounds which are suitable substrates for the Phase II
enzymes. Phase II enzymes detoxify these substrates to produce non-toxic,
excretable metabolites. As a result of this metabolism, particularly that of the Phase I
enzymes, reactive, electrophilic molecules can be produced, which may attack
membranes and DNA in peroxidation reactions. Procarcinogens can also be
activated to their full carcinogenic forms by the Phase I enzymes in this way. Thus,
although the drug metabolising enzymes function to protect the body from harmful
chemicals, they can also act to produce metabolites which are more toxic than the
original substrates.
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1.2.1 Polymorphisms of xenobiotic metabolising enzymes
Polymorphisms exist in the genes of many of the major xenobiotic metabolising
enzymes. From the above discussion of metabolism, it can be seen that where a
polymorphism of one of these enzymes exists, it may have effects on the balance of
reactive species and non-toxic metabolites circulating the body. Whether metabolism
produces more reactive species, or more non-toxic metabolites depends on the
enzyme involved, the site of action of the enzyme, and the substrate encountered by
the enzyme.
An enzyme polymorphism is not necessarily significant in terms of disease
pathogenesis because of the large degree of redundancy within the xenobiotic
metabolising system. For example, a polymorphism which increased the activity of a
Phase I metabolizing enyzme might produce an excess of highly reactive metabolites.
Because of redundancy in Phase II metabolism, the excess of reactive species
produced by the polymorphic Phase I enzyme may easily be detoxified before
damage can occur. However, if there are coincident polymorphisms within Phase II
enzymes, there may be a decrease in the protective capacity afforded by
detoxification. The effects of the original polymorphism of Phase I metabolism
might then result in toxicity.
1.2.2 Mechanisms of polymorphism production
There are many mechanisms by which polymorphisms of the drug metabolising
enzymes can arise. These result in the production of altered protein, or no protein at
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all, giving rise to the phenotypic changes seen. The mechanisms by which these
arise include direct DNA mutations in the genes of the enzymes produced from
deletion, insertion or rearrangement. Messenger RNA splicing may be affected to
produce defective protein, and the stability ofmRNA can also be altered, which will
affect the amount of protein produced. At the protein level, a polymorphism may be
seen where there is an alteration in the rate of synthesis of the protein or increased
degradation of the protein. At the functional level, the enzyme may have an altered
<
substrate affinity or substrate specificity and the rate of enzyme catalysis may also be
affected.
Recently, gene amplification has been reported to occur in the gene of one
polymorphic xenobiotic metabolising enzyme, cytochrome P4502D6 (Johanssen et
al, 1993). Whether this phenomenon is specific to this single gene or not remains to
be seen.
Examples of the above mechanisms include cytochrome P450 2D6, where mRNA
splicing defects can result in at least 3 alternate mRNA transcripts (Meyer, 1990).
Gene deletion, resulting in a lack of protein expression, is the mechanism whereby
GSTM1 is polymorphic. Promoters and enhancers can affect metabolizing enzymes.
An example of this is one of the polymorphic alleles of the cytochrome P4501A1
gene, which is thought to increase the induction of protein expression (Petersen et al,
1991).
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1.2.3 Detection of xenobiotic metabolising enzyme polymorphisms
Many xenobiotic metabolizing enzymes are polymorphic. Historically, these
polymorphisms have come to light because of phenotypic effects on metabolism of
therapeutic drugs, for example the debrisoquine/sparteine polymorphism of
cytochrome P4502D6. Polymorphisms were demonstrated to occur using
biochemical methods which detected changes in protein conformation, for example
gel-shift assays. With the advent of molecular biological techniques, many more
polymorphisms are being identified through changes in DNA or RNA using
restriction enzyme fragment length polymorphism (RFLP) analysis, single strand
conformational polymorphism (SSCP) analysis, and direct cloning and sequencing of
genes. Novel xenobiotic metabolizing enzymes are still being discovered, many of
which may prove to have polymorphisms, once they have been characterized.
1,3 Xenobiotic metabolising envzmes and susceptibility to disease
This study is concerned with polymorphic xenobiotic metabolizing enzymes and
susceptibility to emphsema. In discussing which enzymes may be involved in the
development of emphysema, emphasis will be made on enzymes which have been
shown to be involved in other forms of disease. Several forms of xenobiotic
metabolizing enzymes have been shown to be involved in susceptibility to cancer,
and this has become the major focus of research into polymorphic xenobiotic
metabolizing enzymes. Of importance in the development of tumours are the
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enzyme families of the cytochrome P450s, the N-acetyl-transferases, and the
glutathione S-transferases.
1.3.1 Cytochrome P450s
The cytochrome P450s are a gene superfamily of Phase I metabolizing enzymes
whose function is the oxidative degradation of xenobiotics and the synthesis of
steroids and bile acids. Many xenobiotics require metabolism to more hydrophilic
forms before they can be excreted from the body in the urine or the bile (Gonzalez,
1992). It is thought that the high degree of polymorphism found in the cytochrome
P450 superfamily may be due to the evolutionary development of new P450s through
genetic change. Some changes may confer selective advantage on individuals, which
results in the polymorphism becoming fixed in the population (Gonzalez, 1992).
The cellular location of the P450s is the endoplasmic reticulum or the mitochondrial
membrane, where they function as the terminal oxidase in the electron transport
chain (Gibson & Skett, 1986). P450s are divided into families by similarity of amino
acid sequence. Mammals have 10 families of P450, which are then subdivided into
various subfamilies and subsequent forms. The human genome is estimated to
contain a minimum of 50 different P450 genes (Nebert et al, 1993). P450s from
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different families share high sequence and amino acid homology (up to 40%)
(Gonzalez, 1992). P450 genes demonstrate high degrees of conservation in the
cytochrome P450 reductase binding site, the N-terminal membrane-bound domain,
and the C-terminal haem-binding region (Smith et al, 1994).
Of the cytochrome P450s, the CYP1, CYP2 and CYP3 families are involved in
xenobiotic metabolism (Gonzalez, 1992). A summary of the properties and

















2A 2 known Aflatoxin B,, Nitrosamines Liver Xenobiotic
metabolism
2B 2 known Aflatoxin Bb
Cyclophosphamides
Liver, lung, GIT Xenobiotic
metabolism
2C 5 known Benzo[a]pyrenes Liver, GIT Xenobiotic
metabolism
2D 3/4 NNK Liver, brain Xenobiotic
metabolism
Table 1 Table summarizing the function, expression and substrates of the
cytochrome P450 families of enzymes involved in xenobiotic metabolism (continued




















Liver, GIT, lung Xenobiotic
metabolism
4A 2-4 Fatty acids,
Prostaglandins,
Leukotrienes
Pancreas, liver Xenobiotic and
Endogenous
metabolism




Table 1 (continued) Table summarizing the function, expression and substrates of
the cytochrome P450 families of enzymes involved in xenobiotic metabolism.
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As indicated in Table 1, of the xenobiotic metabolising P450s, only enzymes from
the 1A, 2B, 2F, and 4B families have been shown to be expressed in lung tissue. The
CYP1A family comprises 2 genes, termed CYP1A1 and CYP1A2. Of the CYP1
enzymes, CYP1A1 metabolises polycyclic aromatic hydrocarbons, and is expressed
in lung tissue, whereas CYP1A2 is primarily a hepatic enzyme, involved in
nitrosamine and arylamine metabolism. The CYP2B subfamily contains one gene,
CYP2B6, and an inactive pseudogene, CYP2B7P. The metabolic activation of
cyclophosphamides and aflatoxin B) is mediated by CYP2B6. Cytochrome P4502F1
is expressed in lung at low levels, and has been shown to metabolise 3-Methylindole,
an aromatic amine. CYP4B1 expression has been detected in lung tissue, and this
enzyme metabolises aflatoxin B, and aromatic amines.
1.3.1.2 Cytochrome P450s important in lung disease
Of the cytochrome P450 enzymes expressed in lung tissue, CYP1A1, CYP2F1, and
CYP4B1 all metabolise components of cigarette smoke (see Figure 1.8 for an
example of this metabolism in the case of benzo[a]pyrene), and might therefore be
involved in the mechanism of tissue damage which causes emphysema.
Polymorphisms in the genes of these cytochrome P450s might alter their activity,
thereby affecting the balance of cigarette smoke metabolites in the lung, and hence
influencing susceptibility of the tissue to the development of damage resulting in







Glutathione conjugate Cys S
Glutathione S-transferase
Glu
Figure 1.8 Diagram showing the detoxification pathway of benzo[a]pyrene by
cytochrome P450s and Glutathione S-transferases. In an initial reaction, the
cytochrome P450 activates the precarcinogenic benzo[a]pyrene to a derivative,
benzo[a]pyrene-7,8-epoxide. The glutatione S-transferase then detoxifies the
harmful derivative through its conjugation with glutathione. The glutathione
conjugate undergoes further metabolism before being excreted in the urine or bile.
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1.3.1.3 Cytochrome P4502F1
CYP2F1 has been shown to contain RFLPs in the 3' flanking region of the gene
(Nhambuto et al, 1989), which were subject to Mendelian inheritance. A variant of
CYP2F1, CYP2Flv, has been described, which contains 2 deletions (161 bp at
putative exon 4, 388bp at putative exons 8 and 9), and is thought to be non-functional
due to the lack of a cysteine residue, which serves as the fifth thiolate ligand to the
haem iron at the P450 site. CYP2F1 may be induced by cigarette smoke, since it has
so far only been detected in the lungs of smokers, and in one liver sample from a
smoker (Nhambuto et al, 1989). While this data suggests the possibility of
polymorphism in the CYP2F1 gene, which may be of revelance to the metabolism of
cigarette smoke, this preliminary work has not initiated further study into evidence of
a role for this protein in disease susceptibility.
1.3.1.4 Cytochrome P4501A1
CYP1A1 has been localized to the chromosomal location 15q22-24 (Hildebrand et
al, 1985). Several polymorphisms of CYP1A1 have been demonstrated (Bale et al,
1987; Spurr et al, 1987; Haugen et al, 1990; Flayashi et al, 1991a; Crofts et al, 1993).
Of these polymorphisms, 2 have been shown to be involved in susceptibility to lung
cancer. The first polymorphism is a Mspl restriction enzyme fragment length
polymorphism which is produced by a C-T mutation in the 3' non-coding region of
the gene, 250bp downstream of the polyadenylation signal (Kawajiri et al, 1990).
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The CYP1A1 Mspl polymorphism has been shown to be related to ethoxyresorufin-
O-deethylase (EROD) activity in peripheral lymphocytes (Landi et al, 1994).
Individuals heterozygous or homozygous for the Mspl polymorphism showed
increased basal and inducible EROD activity. The CYP1A1 Mspl RFLP has been
shown to be associated with aryl hydrocarbon hydroxylase (AHH) activity (Petersen
et al, 1991). High AHH inducibility has been shown to be associated with
susceptibility to lung cancer (Kellermann et al, 1973a, 1973b; Kouri et al, 1982;
Trell et al, 1985).
The Mspl polymorphism is linked to a second polymorphism, an A to G transition in
exon 7 of the gene, which results in an isoleucine to valine amino-acid substitution
(Hayashi et al, 1991a; Hirvonen et al, 1992; Sivaraman et al, 1994). It has been
demonstrated (Hayashi et al, 1991b, quoted in Kawajiri, et al, 1993) that when
produced in yeast, the polymorphic valine allele of this gene results in an enzyme
which exhibits a higher aryl hydrocarbon hydroxylase activity, and an increased
mutagenic activity with benzo(a)pyrene in comparison with the isoleucine allele. It
has been proposed that the cytochrome P450 1A1 exon 7 polymorphism produces a
more highly inducible enzyme as a result of the valine amino acid substitution, and
thus induction of gene expression by xenobiotics will be increased. If cytochrome
P4501A1 metabolism functions to activate procarcinogens and produce more
electrophilic and toxic metabolites, having an increased inducibility of the gene could
be detrimental.
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1.3.1.4.1 CYP1A1 is expressed in lung tissue
Antilla and colleagues, 1991, studied expression of CYP1 enzymes in lung using
antibodies which detected both CYP1A1 and CYP1A2. Since CYP1A2 is expressed
in the liver, lung detection of CYP1 enzymes should reflect CYP1A1 enzyme
expression only. CYP1A enzyme expression was localized to the peripheral airways,
in type I and type II alveolar epithelial cells, in ciliated columnar and cuboidal
bronchiolar epithelium. CYP1A was present in the bronchial wall in minimal
amounts, and where present, was localized in the epithelium of bronchial glands and
the endothelium of capillaries. In 1994, in a study of smokers with lung cancer,
Antilla and colleagues found an association between expression of CYP1A1 and
susceptibility to bronchial tumours, which mainly consisted of squamous carcinomas.
1.3.1.4.2 CYP1A1 expression is induced by cigarette smoking
Cytochrome P450 1A1 expression can be induced by some of the xenobiotics which
it functions to metabolize. In rodents, the CYP1A1 gene is regulated by an inducible
enhancer termed the XRE (xenobiotic-responsive element) (Fujisawa-Sehara et al,
1986), and a promoter element which regulates the basic transcriptional activity
(Yanagida et al, 1990), termed the BTE (basic transcription element). The XRE is
situated upstream of the gene, while the BTE is adjacent to the TATA gene sequence.
Both the XRE and the BTE sequences are required to induce expression of CYP1A1
(Kawajiri & Fujii-Kuriyama, 1991). The human CYP1A1 gene was found to contain
homologous sequences to both the XRE and the BTE suggesting similar regulation
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of gene expression (Kubota et al, 1991; Hines et al, 1988). The induction of
CYP1A1 is mediated by the aryl hydrocarbon (Ah) receptor, a cytosolic receptor
which is activated by polycyclic aromatic hydrocarbons, certain nitrosamines and
some arylamines (Nebert & Jones, 1989).
CYP1A1 is thought to be one enzyme among several which mediates aryl
hydrocarbon hydroxylase (AHH) activity. Levels of AHH activity have been
correlated with the Mspl CYP1A1 polymorphism (Petersen et al, 1991).
CYP1A1 is primarily extrahepatic, and has been shown to be predominantly
expressed in lung and leukocytes. McLemore and colleagues showed by Northern
blotting that cytochrome P450 1 Al is expressed in the lungs of cigarette smokers but
not in the lungs of non-smokers (1990). Furthermore, a decrease in the amount of
cytochrome P450 1A1 mRNA was demonstrated to be time-dependent in lungs of
ex-smokers. This evidence strongly suggests that expression of this isoenzyme is
induced by components of cigarette smoke. In vitro induction of cytochrome P450
1A1 has been shown using (5-naphthoflavone, which induces CYP1A1 through the
same receptor mechanism as polycyclic aromatic hydrocarbons (Andersson et al,
1993). In cancer patients, activity of CYP1A1 is increased in peripheral leukocytes
as compared to leukocytes from healthy individuals (Rudiger et al, 1985; Bartsch et
al, 1990). CYP1A1 activity has also been correlated with sister chromatid exchanges
(van Poppel et al, 1992; Thompson et al, 1989). Two studies have found an
association between AHH activity and DNA adduct levels (Bartsch et al, 1991;
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Geneste et al, 1991). However, this result was disputed by Shields and colleagues in
1993, who could demonstrate no association between the CYP1A1 exon 7
polymorphism, which is thought to result in higher enzyme activity, and polycyclic
aromatic hydrocarbon-DNA adducts in human lungs. It is possible that the study by
Bartsch and colleagues measured non-PAH adducts, since the sensitivity of their
method was not sufficient to identify the chemical nature of the adducts. A further
study by Ichiba and colleagues (1994) found higher levels of aromatic DNA adducts
in leukocyte DNA from individuals homozygous for absence of the CYP1A1 Mspl
polymorphism, as opposed to heterozygotes for the polymorphism.
1.3.1.4.3 Polymorphism of the CYP1A1 gene and disease susceptibility
Homozygosity for the CYP1A1 gene Mspl RFLP has been shown to be more
common in Japanese lung cancer patients (20.2%) than in normal controls (10.6%)
(Kawajiri et al, 1990). No significant difference was seen between controls and
patient groups with stomach, colon or breast cancer. Of the 4 main histological types
of cancer, small and large cell carcinomas and squamous carcinoma are strongly
associated with cigarette smoking, while adenocarcinoma is less strongly implicated
(Kawajiri et al, 1993). When the lung cancer patient group was divided according to
histological type of cancer, individuals homozygous for the Mspl polymorphism
comprised 26% of the individuals with squamous, small and large cell carcinomas, a
highly significant difference from controls. The frequency of the CYP1A1 Mspl
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homozygous genotype was similar between controls and the group of
adenocarcinoma patients.
Nakachi and colleagues, 1991, extended the study of CYP1A1 Mspl polymorphism
and susceptibility to lung cancer by genotyping squamous carcinomas and analysing
the genotypes in terms of smoking history. Squamous carcinoma is the form of
carcinoma with the clearest association with cigarette smoking (Lubin & Blot, 1984).
Nakachi and colleagues demonstrated that individuals homozygous for the Mspl
polymorphism had a significantly increased risk for the development of squamous
carcinoma at low dose exposure to cigarette smoke. At the lowest dose level of
cigarette smoke exposure studied, which was 3x10^ cigarettes (~40 pack years), the
relative risk of developing squamous carcinoma in CYP1A1 Mspl homozygotes was
7.3 (with risk of heterozygotes and homozygous non-polymorphic individuals as a
base-line of 1.0). Heterozygotes and homozygous non-polymorphic individuals
demonstrated a clear dose-dependent relationship between cigarette smoke exposure
and relative risk of developing squamous carcinoma.
The results from Kawajiri and colleagues indicate that the CYP1A1 Mspl RFLP is
involved in susceptibility to lung cancer. Nakachi and colleagues (1991) have shown
that this susceptibility is not directly dose dependant. Individuals homozygous for
the Mspl polymorphism are more susceptible to squamous carcinoma at lower levels
of exposure.
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The very significant susceptibility to lung cancer demonstrated by genotyping
CYP1A1 in Japanese populations has not been found in Caucasian populations. This
discrepancy may have arisen because Japanese populations have much higher
frequencies of the CYP1A1 Mspl polymorphism than have been found in Caucasian
populations.
In 1991, Tefre and colleagues, failed to demonstrate an association between the Mspl
polymorphism and a population of Norwegian lung cancer patients. The proportion
of the Mspl rare CYP1A1 genotype was similar between 2 control groups from
Norway and a Caucasian population from North America. The frequency of the
CYP1A1 Mspl allele was only one third as common in the Norwegian and North
American populations as the polymorphism frequency in Japanese demonstrated by
Kawajiri and colleagues, 1990. Shields and colleagues (1992) investigated whether
or not there was association between the CYP1A1 Mspl polymorphism and
susceptibility to lung cancer in a US population. No statistically significant
difference was demonstrated between lung cancer patients and case-matched
controls. Hirvonen and colleagues, in 1992 and 1993, studied the CYP1A1 Mspl
polymorphism in the Finnish population, and found no association between the
polymorphism and susceptibility to lung cancer.
Recently, Alexandrie and colleagues, 1994, failed to identify a statistically
significant association between the CYP1A1 Mspl and exon 7 polymorphisms and
susceptibility to lung cancer. An increased frequency of the Mspl polymorphism and
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the valine substitution was observed in individuals with squamous cell carcinoma,
but the difference from controls was not statistically significant.
Polymorphism of the CYP1A1 gene is thought to be correlated to the aryl
hydrocarbon hydroxylase (AHH) inducibility phenotype (Petersen et al, 1991). AHH
inducibility demonstrates a trimodal distribution in the population, which may
indicate a genetic polymorphism in metabolism. Petersen and colleagues found that
heterozygotes for the Mspl polymorphism had higher AHH inducibility than
predominant homozygotes, indicating a possible correlation between the CYP1A1
genotype and AHH phenotype. High AHH inducibility has been shown to be
associated with susceptibility to lung cancer (Kellermann et al, 1973a, 1973b; Kouri
et al, 1982; Trell et al, 1985).
CYP1A1 Mspl polymorphism has also been shown to be associated with
susceptibility to colorectal cancer in Japanese and Hawaiian populations, but not in
Caucasian populations (Sivaraman et al, 1994). Although the Mspl polymorphism
was found to be in close linkage with the exon 7 polymorphism, no statistical




The glutathione S-transferases (GSTs) are a gene superfamily which detoxify
xenobiotics by their conjugation with glutathione. In this manner, electrophilic
compounds which might cause cytotoxic or carcinogenic damage may be removed
from the body in the urine or bile. Glutathione S-transferases mediate Phase II
metabolism, directly detoxifying xenobiotics and also detoxifying electrophilic
metabolites derived from Phase I metabolism. Substrates for GST metabolism
include aflatoxin Bl, benzo[a]pyrene derivatives (see Figure 1.8), halogenated
alkanes and alkenes, trans-stilbene oxide, and nitrosoureas (Smith et al, 1994).
GSTs also function to transport hormones and hydrophobic compounds (Listowsky
et al, 1988), and demonstrate glutathione peroxidase activity against lipids and DNA
(Jakoby, 1978).
The expression of many GSTs is induced by the xenobiotics they metabolize, and
GSTs are also regulated by hormones. Induction can be mediated by the binding of
xenobiotics, antioxidants or glucocorticoids to responsive elements in the 5' flanking
region of the GST genes (Rushmore & Pickett, 1993).
The GSTs have been classified into 7 classes, 6 of which are cytosolic, and at least 1
microsomal (Mannervik et al, 1992). The cytosolic classes are termed alpha, mu, pi,
sigma and theta, and the letters A, M, P, S and T denote the class to which an enzyme
belongs. Recently a novel GST class, termed kappa (GSTK) has been identified
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(Pemble et al, 1996)Enzymes are assigned to a class based on their amino acid
homology. GSTs have been shown to be expressed in most cells and tissues, but
cellular expression depends on hormonal and environmental factors.
The mu and alpha classes of GSTs both encode at least 6 enzymes, the pi class
encodes 2 enzymes, and the theta class has so far been shown to encode a single
enzyme (Awasthi et al, 1994). Cytosolic GSTs form dimers, and the very high
degree of sequence similarity between enzymes in each class of GST may result in
heterodimerization occurring between different monomers. The pattern of
expression of GSTs may therefore vary not only through cell and tissue specific
induction, but also through variable heterodimerization of the monomers induced
(Hussey et al, 1991).
Class alpha and pi GSTs have been implicated in resistance of tumours to
chemotherapeutic agents (Hayes & Wolf, 1990).
Several studies of GST distribution in rats (Coursin et al, 1992) and mice (McLellan
et al, 1992) have been published but there is little data on the distribution of GST
isoenzymes in adult human lung (Awasthi et al, 1987; Fryer et al, 1986).
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1.3.2.1 Polymorphic glutathione S-transferases
The mu class of GSTs contains a polymorphic enzyme, GSTM1. GSTM1 is known
to metabolise cytotoxic components of cigarette smoke, including benzo[a]pyrene
(Jernstrom et al, 1990). Substrates of GSTM1 include not only compounds of
cigarette smoke which are directly cytotoxic, but also breakdown products of Phase I
metabolism which may be cytotoxic (Gibson & Skett, 1986).
The GSTM1 polymorphism arises because of gene deletion and subsequent lack of
protein expression, and affects approximately 50% of Caucasian populations
(Seidegard & Pero, 1985; Seidegard et al, 1988). The exact nature of the deletion is
unknown. Originally, the deletion was thought to involve a 267bp region including
exons 4 and 5 of the gene. Recently, however, some evidence has been presented
which suggests that the deletion may encompass the entire gene (Board et al, 1990;
Seidegard et al, 1988). A number of studies have found that GSTM1 deletion is
associated with an increased incidence of tumours. Tumours associated with
GSTM1 deletion include adenocarcinoma of stomach and large bowel (Strange et al,
1991), pituitary adenomas (Fryer et al, 1993a), liver carcinoma (Harada et al, 1987),
bladder cancer (Daly et al, 1993; Bell et al, 1993), multiple skin cancers (Heagerty et
al, 1994), and colon cancer, particularly proximal colon cancer (Zhong et al, 1993a).
Several studies have also presented evidence contradicting some of the GSTM1
associations observed. Lin and colleagues, 1994, were unable to demonstrate
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association between GSTM1 polymorphism and susceptibility to bladder cancer.
Similarly, Zhong and colleagues (1993a) showed lack of association between the
GSTM1 deletion and development of bladder cancer, or of breast cancer.
1.3.2.2 GSTM1 deletion and susceptibility to lung cancer
The evidence for an association of GSTM1 deletion with lung cancer in cigarette
smokers is controversial. In 1986, Seidegard and colleagues presented the first
evidence for an association between GSTM1 deletion and susceptibility to lung
cancer, in a US population. Studies by Howie and colleagues (1990a) and Seidegard
and colleagues (1990) confirmed this association. Furthermore, the results of
Seidegard and colleagues (1990) indicated that in the US population,
adenocarcinoma of the lung was particularly associated with the GSTM1
polymorphism.
Subsequently, Zhong and colleagues (1991) studying a UK population found that
deletion of GSTM1 was not associated with lung cancer in total, but a significant
correlation between the polymorphism and squamous carcinoma was demonstrated.
Indeed, a negative correlation between GSTM1 deletion and adenocarcinoma was
demonstrated. Hirvonen and colleagues (1993) also demonstrated a statistically
significant association between GSTM1 deletion and susceptibility to squamous
carcinoma in a Finnish population. In 1993, Brockmoller and colleagues, were
unable to demonstrate any association between GSTM1 deletion and susceptibility to
lung cancer in a German study group.
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A study of Japanese individuals by Kihara and colleagues (1994) presented evidence
which supports the role of GSTM1 deletion in susceptibility to squamous and small
cell carcinomas of the lung. The association found by Kihara and colleagues was
also seen to be related to cigarette smoke exposure, with higher frequencies of
GSTM1 deletion seen in individuals with increased smoking history. Alexandrie and
colleagues (1994) were similarly able to demonstrate an association between GSTM1
deletion and susceptibility to small cell carcinoma which was age-related. In patients
under 61 years of age, the link between GSTM1 deletion and small cell carcinoma
had an odds ratio of 3.1 (95% confidence intervals of 1.1-9.1) in comparison to a
COPD group of controls, while patients aged less than 61 years had an odds ratio of
5.6 (95% confidence intervals of 1.4-22.5) compared to healthy controls. A very
significant difference was observed between frequencies of the GSTM1 deletion in
male and female sufferers of squamous cell carcinomas in the study by Alexandrie
and colleagues. GSTM1 deletion was significantly associated with squamous
carcinoma in women when compared to healthy controls (odds ratio 3.3, 95%
confidence intervals of 1.2-9.7). Antilla and colleagues (1994) studied both GSTM1
and the CYP1A1 polymorphism discusssed in section 1.3.4.3. Antilla and colleagues
demonstrated that in a smoking group of individuals with lung cancer, expression of
CYP1A1 is associated with susceptibility to bronchial tumours (p=0.001). However,
in individuals with CYP1A1 expression, presence of GSTM1 would seem to be
protective against development of bronchial tumours (p=0.037).
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1.3.2.3 GSTM1 deletion and susceptibility to non-neoplastic disease
The GSTM1 polymorphism has also been investigated in a number of non-neoplastic
diseases. Davies and colleagues (1993) showed that the GSTM1 deletion is not
involved in the development of primary biliary cirrhosis. Association between
GSTM1 deletion and susceptibility to alcohol cirrhosis was investigated by Groppi
and colleagues in 1991. No association was demonstrable between the GSTM1
polymorphism and development of alcohol cirrhosis. However, Harada and
colleagues (1987), showed that the GSTM1 deletion is associated with susceptibility
to chronic liver hepatitis and liver cancer.
1.3.2.4 GSTM1 involvement in specific cellular and biochemical processes
In 1991, Liu and colleagues, demonstrated a significant correlation between levels of
aflatoxin BrDNA adducts and activity of GST mu enzymes (representative of the
GSTM1 polymorphism, since individuals showed high or low conjugating activity).
The results of the study by Liu and colleagues, indicate that GSTM1 may have a role
in detoxification of aflatoxin Bb and hence deletion of GSTM1 may increase
susceptibility to liver cancer.
Deletion of GSTM1 has been shown to be associated with increased sister chromatid
exchanges in lymphocytes of healthy smokers (van Poppel et al, 1992). The GSTM1
polymorphism has also been linked to levels ofDNA adducts in lung tissue. Shields
and colleagues (1993) observed a positive correlation between GSTM1 deletion and
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DNA adduct levels. Ketterer and colleagues (1992) also presented preliminary
results suggesting a negative correlation between GSTM1 and DNA adduct
formation in lung tissue from smokers. In 1994, however, Ichiba and colleagues
were unable to demonstrate any correlation between GSTM1 deletion and aromatic
DNA-adduct levels.
Polymorphism of the GSTM1 and CYP1A1 genes have been shown to act
synergistically in determining susceptbility to lung cancer in the Japanese population
(Hayashi et al, 1992). Individuals with an intact GSTM1 gene and homozygosity for
the non-polymorphic exon 7 allele of CYP1A1 were taken as a base-line of 1.0 for
calculation of odds ratio. Individuals homozygous for the CYP1A1 exon 7
polymorphism and lacking GSTM1 were found to have odds ratios of 5.4 for lung
cancers in total, 7.9 for squamous cell carcinomas and 3.8 for adenocarcinomas. In a
Swedish population study, Alexandrie and colleagues, 1994, demonstrated no
association between polymorphism of CYP1A1 and susceptibility to lung cancer,
although a statistically significant age-related link between GSTM1 deletion and
increased risk for small cell carcinoma was identified. When the lung cancer group
was analysed for both genotypes, individuals polymorphic for CYP1A1 and the
GSTM1 deletion had a significantly increased risk for developing squamous cell
carcinoma (odds ratio of 3.0, 95% confidence intervals from 1.2-7.2). GSTM1
deletion has also been shown to be associated with increased risk for mutation in the
tumour suppressor gene p53 in Norwegian lung cancer patients (Ryberg et al, 1994).
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1.3.3 N-Acetyl Transferases
The N-acetyl transferases are Phase II metabolising enzymes which catalyse the
acetylation of oxygen or nitrogen atoms using acetyl CoA as a cofactor. Substrates
for N-acetyl transferases include aromatic amines, for example amino acid
pyrolysates which are important dietary carcinogens formed during the frying or
grilling of food, and drugs such as isoniazid, procainamide and hydralazine.
Polymorphism of the N-acetyl transferases was first recognized through inter-
individual variation in the metabolism of isoniazid, a drug used for treatment of
tuberculosis. On the basis of their metabolism of isoniazid, individuals can be
designated "fast" or "slow" acetylators. The slow acetylator trait is present in
Caucasian populations at a frequency of 40-70%, but the frequency of the
polymorphism is highly variable among different races (Smith, 1994). Genetic
studies have identified 2 genes, NAT1 and NAT2, and a pseudogene, NATP at the
chromosomal locus 8p 21.2-23.1. Both the NAT1 and NAT2 genes have been shown
to be polymorphic as a result of point mutations within the genes (Blum et al, 1991;
Hickman & Sim, 1991). Slow acetylation has been associated with increased risk for
bladder cancer, presumably as a result of the decreased ability to detoxify aromatic
amines, which are potent bladder carcinogens (Hein, 1988). The rapid acetylator
genotype has been shown to be associated with increased susceptibility to colon
cancer (Kadlubar, 1994). The mechanism by which this susceptibility results is
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thought to be increased metabolic activation of procarcinogens by O-acetylation in
the colon (Wolf, 1990).
While the N-acetyl transferases have been associated with susceptibility to both
bladder cancer and colon cancer, there have been no reports of association with lung
cancer. N-acetyl transferases are expressed in lung tissue, as well as in liver, colon,
and red and white blood cells (Smith, 1994), and cigarette smoke contains aromatic
amines, therefore, it may be speculated that polymorphisms of the NAT genes may
affect lung disease.
1.3.4 Candidate polymorphic xenobiotic metabolising enzymes for
investigating susceptibility to emphysema
While there may be a role for polymorphisms of N-acetyl-transferases and
cytochrome P4502F1 in influencing disease susceptibility in the lung, there is not a
great deal of evidence implicating these enzymes in lung disease. Other xenobiotic
metabolising enzymes may be discounted for study since they are either not
expressed in significant levels in lung or they do not metabolise components of
cigarette smoke.
Of the polymorphic xenobiotic metabolising enzymes which have been discussed,
the CYP1A1 and GSTM1 polymorphisms would seem to be most likely to be
involved in increasing susceptibility to emphysema. In summary, both the GSTM1
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and CYP1A1 gene polymorphisms have been linked to disease susceptibility, and in
particular to lung cancer susceptibility. Expression of CYP1A1 is induced by
cigarette smoke exposure (McLemore et al, 1990), and a functional difference in
activity of the polymorphic variant of CYP1A1 has been identified (Hayashi et al,
1991b, quoted in Kawajiri, et al, 1993). CYP1A1 can activate polycyclic aromatic
hydrocarbons (including benzo[a]pyrene and 3-methylcholanthrene), which are
present in cigarette smoke, to produce highly reactive compounds (Kimura et al,
1986; Kawajiri et al, 1984). CYP1A1 might therefore be considered as an ideal
candidate for investigation into the interindividual variation in susceptibility to
emphysema. GSTM1 is known to detoxify components of cigarette smoke,
including benzo[a]pyrene (Jernstrom et al, 1990). Expression of GSTM1 has not
been clearly demonstrated in human lung tissue, but the enzyme is expressed in high
levels in liver (Faulder et al, 1987). Even if GSTM1 is not expressed in lung tissue,
the enzyme might have an important role in the development of emphysema, since
panacinar emphysema may result from systemic damage (Saetta et al, 1994a).
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AIMS
The aims of this thesis were to characterise the pattern and severity of emphysema in
a series of biopsy and autopsy lung samples. This series of cases could then be used
for genotyping studies into susceptibility to emphysema and lung cancer conferred
by the polymorphic xenobiotic metabolising enzymes glutathione S-transferase Ml
(GSTM1) and cytochrome P4501A1 (CYP1A1). To establish frequencies of the 2
polymorphisms in the Scottish population, a large group of anonymous blood
samples was collected and genotyped, which comprised the control group for
comparison in disease association. To investigate into whether or not the GSTM1
and CYP1A1 polymorphisms influenced chronic obstructive pulmonary disease
(COPD), the clinical manifestation of emphysema, patients with COPD were also
genotyped.
Previous expression of glutathione S-transferases in lung tissue had ascertained the
expression of the classes mu, alpha, and pi by immunohistochemistry. However, the
presence of GSTM1 in lung tissue had not been clearly demonstrated, and since the
polymorphism may be involved in lung disease susceptibility, expression of this
enzyme was further investigated using Western blotting and RT-PCR.
From the above studies ofGST expression in human lung, and GSTM1 and CYP1A1
polymorphisms and susceptibility to lung disease, it was anticipated that information
might be generated on the mechanisms by which lung diseases develop. If a role for
polymorphic xenobiotic metabolising enzymes in influencing disease susceptibility




Twenty-one lungs, or lobes of lungs obtained at pneumonectomy were studied. For
histological preparation, lungs were fixed-inflated with buffered formalin for 24hr
before selection of blocks from macroscopically normal or mildly emphysematous
lung. Of the 21 lungs studied, all but 3 had peripheral tumours. These blocks were
then processed to paraffin wax and sectioned at 2p for immunohistochemical study.
Polyclonal rabbit antisera to human GST were the kind gift of Dr. JD Hayes
(Harrison et al, 1989). Anti-GSTP was raised against purified human lung GSTP
and the other antisera were raised against human liver preparations. Anti-GSTM was
raised against liver GSTM which is the product of the GSTM1 gene. However since
GSTM4 has greater than 90% sequence homology with GSTM1 (Zhong et al, 1993b)
it is possible that the polyclonal antibody could react with the product of both genes.
The immunostaining protocol used avidin-peroxidase and 3,3 diaminobenzidine
detection (Harrison et al, 1989). Sections were preincubated with 50% pooled
normal human serum in Tris buffered saline. This preincubation resulted in a marked
reduction of background staining in controls using normal rabbit serum instead of
polyclonal antibody. Antisera were used at a dilution of 1:200 in TBS containing 5%
normal swine serum. Sections were assessed by two independent observers.
2.2 Western Blot Analysis of Bronchoalveolar Lavage Fluid
Four Bronchoalveolar Lavage (BAL) samples were obtained from healthy
volunteers, and Western blotting of these BAL samples was carried out by Dr W
Wallace. Following centrifugation to remove cellular debris, 10 ml aliquots were
taken and placed in separate lengths of 14mm Viskose dialysis tubing (Medicell
International Ltd., London). Protein was concentrated by dialysis against glycol
methacrylate (BDH Chemicals, Poole) overnight at 4°C to give a final sample
volume of 200pl. This was mixed with an equal volume of sample buffer (3.6mls
distilled water, 1ml 0.5M Tris-HCl pH 6.8, 10% w/v SDS, 0.8ml 1M dithiothreitol,
0.8ml glycerol and 0.05ml 0.05% w/v bromophenol blue) and boiled for 5 minutes
prior to loading on a 7.5% polyacrylamide gel. Protein was transferred to
nitrocellulose and probed with GSTP antibody. Detection was by enhanced
chemiluminescence (Amersham, UK).
2,3 Detection of human GSTM1 by Western blotting
Western blotting using antibodies to mu class GSTs was carried out on proteins
derived from lymphocytes extracted from blood samples. If mu class GSTs were
detected using this technique, Western blotting could then be applied to human lung
tissue extracts to investigate mu class GST expression in the lung. If GSTM1
expression occurs at high levels in lung tissue, the difference in expression between
individuals null for GSTM1 and those individuals with the intact gene, would
provide evidence that where the gene is not deleted, GSTM1 expression occurs in
lung tissue.
2.4 Selection of samples for study of disease susceptibility and collection of
control population samples
2.4.1 Collection and assessment of lung samples with emphysema
The lungs studied in this thesis were selected from biopsy and autopsy cases which
entered the Pathology Department of Edinburgh University as part of the routine
biopsy service provided by the department.
The majority of lung biopsies received were suspect lung cancer cases as diagnosed
by chest x-ray, and biopsy tissue generally comprised the lung lobe, or lobes, in
which the abnormality arose. Lung samples received by the department were cut into
slices, and blocks of 2cm square were cut for processing in paraffin wax to enable the
production of microscopic slide specimens. Lung tissue selected for the production
of slides usually included several blocks from areas affected by disease, areas
unaffected by disease, and in lung where tumour was found, samples from the lymph
nodes, in particular the hilar lymph node. The remaining lung tissue was fixed and
stored in formaldehyde. Autopsy lung samples were stored in a similar fashion if the
tissue was shown to have lung disease following examination.
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Macroscopic emphysema is defined as airspaces measuring 1mm or greater in
diameter. All lung samples stored in formaldehyde were examined for the presence,
type and extent of macroscopic emphysema. This thesis concerns centriacinar and
panacinar emphysema only, and lung samples were assessed for the presence of these
2 types of emphysema alone. The extent of the lung affected by emphysema was
estimated in each case: for centriacinar emphysema, the approximate number of
lesions visible on the cut surface of the lung was recorded; for panacinar emphysema,
the percentage involvement of the lung was calculated. Often, although airspaces
were not as large as 1mm in diameter, emphysema was visible since the cut surface
of the lung appeared grainy, and less smooth than unaffected lung tissue. Areas of
the lung affected in this manner were described as Grade 1/2 panacinar emphysema,
and the percentage of the lung involved was recorded.
Assessment of the extent of emphysema was recorded as described above, but to give
some idea of the severity which was encountered, samples were classed as having
mild, moderate or severe emphysema. The lung biopsy and autopsy cases assessed
were subject to considerable variation, for example, the size of samples varies
depending on which side of the lung the lobe is removed from, and how far into the
middle of the lobe the tissue is cut. Although several lung slices were assessed for
each case, assigning severity is both inaccurate and arbitrary. However it is useful to
summarize the extent of disease severity found in the cases assessed.
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Mild emphysema was classified as a lung surface containing 20% or less
involvement of panacinar emphysema, or 20 or less lesions of centriacinar
emphysema. Between 21 and 50% involvement of the lung with panacinar
emphysema, and tissue containing 21-50 centriacinar lesions, was classed as having
moderate disease. Panacinar emphysema affecting over 50% of the surface of the
lung, and centriacinar lesions numbering over 50, were classed as severe emphysema.
Where both panacinar and centriacinar emphysema were present, severity was always
assessed with reference to the more severe pattern. While this classification of
severity is useful, it is purely based on assessment by eye, and will not correlate to
the extent of clinical symptoms of the patients. Furthermore, the percentage
involvement of the lung tissue by panacinar emphysema is variable since the severity
of damage will vary, and in centriacinar emphysema, lesions may vary in size. Age
must also be considered in the assessment of panacinar emphysema. As individuals
age, the airspaces in their lungs increase in size (Gillooly & Lamb, 1993a), therefore
what might be classified panacinar emphysema in a younger person's lung tissue
might represent normal tissue of an older individual.
Macroscopic emphysema is defined as airspaces in the lung of 1mm diameter or
greater. Since the average diameter of an airspace measures 250pm (Schreider et al,
1981), by the time sufficient damage has occurred for it to be visible
macroscopically, three quarters of the airspace wall must have been destroyed. It is
therefore important to be able to detect and measure damage which, although not
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macroscopically visible, is occurring in the lung. This early damage is termed
microscopic emphysema.
Microscopic emphysema was measured using histological specimens of lung tissue
by Dr Gillooly. Six blocks of lung tissue were cut from each lobe, and were analysed
using the fast interval processor, an automated photosensitive scanning device which
counts the number of intercepts of alveolar walls with a test line (Gillooly et al,
1991). From the total number of intercepts counted, the mean linear intercept (Lm)
can be calculated (Dunnill, 1987). The Lm value obtained may then be used to
calculate the alveolar wall surface area per unit volume of lung tissue (AWUV) with
the equation AWUV = 2/Lm (Gillooly et al, 1991).
With increasing age, the number of alveolar walls decreases (Gillooly & Lamb,
1993a), hence in order to determine the presence of microscopic emphysema,
AWUV values must be compared to the limits of normality of the general population.
The distribution of AWUV values in a non-smoking population were determined by
morphometry (Gillooly & Lamb, 1993b). The lower limits of AWUV normality
(95% limits) in non-smokers can be seen in Table 2. Where the AWUV value
obtained from a lung falls below the 95% limits of normality in the general
population, this individual can be classed as having microscopic emphysema.
Information on patients from whom the lung tissue had been obtained was collected
by Dr Gillooly and myself, and included details of disease, sex, age, smoking history,
and lung function test results. Since this data was obtained from biopsy reports and
clinical reports, the information collected was not always complete for each patient.
86



















- Table of the lower limits (95% limits) of alveolar wall surface area per unit
of lung tissue (AWUV) in the non-smoking population (Gillooly & Lamb,
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2.4.2 Selection of paraffin wax embedded lung samples for analysis
Selection of blocks of archival tissue for PCR analysis was carried out on the basis
that tissue yielding as much DNA as possible was required. It was anticipated that
poor DNA yield generated from blocks containing peripheral lung might represent a
problem for PCR of these samples. Hence, blocks containing bronchi and/or lymph
nodes were favoured over those with only peripheral lung. The expected yield from
these blocks would be far greater since the cell volume in peripheral lung will be
much lower than that seen in bronchial lung or lymph node tissue. Furthermore, lung
tissue, particularly that of individuals biopsied for lung cancer, is likely to contain tar
and other chemicals from cigarette smoke exposure which may inhibit either the
DNA extraction or PCR amplification from this tissue. The presence of tumour was
avoided, although selection was made on the basis of eye examination, therefore
tumour tissue presence cannot be completely ruled out. It is well characterised that
tumour cells may contain mutations of their DNA, hence genotyping of tumour tissue
may give results which do not reflect the genotype of genomic DNA. By avoiding
tumour in the blocks selected, it was expected that the prevailing DNA yieded for
PCR analysis would be that of normal tissue. If areas of tumour were present in the
only blocks available for analysis, wherever possible, these were removed from the
adjacent areas of normal tissue using a scalpel and discarded.
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2.4.3 Blood samples
Two sets of blood sample groups were collected for this project. The first, a control
group, comprised 400 blood samples collected by Dr P-L Yap of the Edinburgh and
South-East Lothian Blood Transfusion Service. These samples were completely
anonymous, thereby providing a control group for comparison with disease cases in a
cross-sectional study of disease susceptibility. The second set of blood samples were
collected from patients attending a chronic obstructive airways disease clinic run by
Dr W Macnee, Department of Respiratory Medicine, Royal Infirmary of Edinburgh.
Clinical details including age, sex, smoking history and measurements of disease
severity were collected for all cases.
2.4.4 Fresh lung tissue
Fresh lung tissue was only infrequently used in this study, to provide high quality
DNA for optomisation of the GSTM1 and CYP1A1 PCR protocols. The tissue was
obtained from normal tissue in lung resections for cancer.
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2.5 DNA extraction
Fresh tissue samples were dissected into cubes of approximately 0.5cm3, DNA was
extracted using the method of Jackson and colleagues (1990) , as described for
paraffin wax-embedded samples. The remaining fresh lung tissue was snap frozen in
liquid nitrogen and stored at -70°C. DNA was extracted from blood samples using
the method of Smith and colleagues (1992).
Two sections of 10pm thickness were cut from paraffin wax embedded tissue blocks
using a microtome. DNA was extracted from paraffin wax-embedded tissue by
incubating sections with 400 pi buffer A (50mM KC1, 2.5mM MgCl2, 20mM Tris-
HC1, pH 8.0, 0.45% Nonidet P-40, 0.45% Tween 20), containing 200 mg/ml
Proteinase K at 55°C for 2 hours. After boiling for 20 minutes, samples were stored
at -20°C (Smith et al, 1992). Following brief centrifugation, 15 pi of the supernatant
was used to amplify DNA fragments by PCR.
The amount of paraffin wax-embedded material was limited to 2 10pm sections for
extraction since it is well known that inhibitors of PCR are present in paraffin wax,
and in the fixation buffers used in tissue preservation and embedding. The amount of
paraffin embedded material must be sufficiently large for DNA to be extracted whilst
keeping inhibitory factors as limited as possible. The use ofmore numerous sections
was investigated, but no increase in PCR yield was observed.
The use of xylene in deparaffmisation of lung tissue sections was investigated, as
was phenol:chloroform washing and ethanol precipitation of the extracted DNA
following Proteinase K incubation, but PCR yield was not significantly increased
with the addition of these extra steps. The efficacy of the chelating agent ChelexR
100 (Biorad, Richmond CA) in increasing PCR yield was also investigated following
the report of Stein & Raoult (1992). However, no increased yield was demonstrable
using this reagent.
2,6 Polymerase Chain Reaction
2.6.1 Reverse Transcription Analysis
To determine the expression of GSTM1 and GSTM4 in lung, RNA was extracted
from 3 lung tissue samples. Of these samples, 2 were disease-free, while the third
sample was derived from lung tissue containing a pneumococcal infection. RNA was
extracted from fresh lung tissue using RNAzol B (Biogenesis, UK) as per
manufacturers instructions. cDNA was then amplified using oligodT (Gibco BRL,
UK), with a standard mix of PCR reagents, Superscript enzyme and dithiothreitol
(Gibco BRL, UK), and RNAsin (Promega, UK). Reverse transcription was carried
out at 37°C for 10 mins, 42°C for 1 hour, 50°C for 10 mins and 94°C for 10 mins.
Primers were chosen which amplified both GSTM1 and GSTM4 to produce cDNAs
of 657bp in length which were distinguished by digestion with Ncol restriction
enzyme (Gibco BRL, UK). GSTM1 gave expected fragments of 311, 221 and 125bp,
whereas GSTM4 produced fragments of 436 and 221 bp. Therefore four fragments of
436,311,221 and 125bp were expected if tissue expressed both genes. Digestion took
place overnight at 37°C, before analysis by agarose gel electrophoresis (FMC
Bioproducts, US). DNA was visualised by ethidium bromide staining and
examination under ultraviolet irradiation.
The primers (Oswell DNA Services, UK) used were:
P1: 5 '-ATGCCCATGATACTGGGGTACTGG-3'
P2: 5'-CTACTTGTTGCCCCATACATCCAT-3'
2.6.2 GSTM1 PCR assay
The PCR buffer was a standard mix of nucleotides and contained 3% DMSO (Sigma,
US). The amplification was achieved by adding 5U of Taq polymerase (Promega,
UK) in a hot start, and undergoing 35 amplifications of 59°C for 30 seconds, 72°C
for 90 seconds, and 94°C for 30 seconds. Amplified DNA was electrophoresed in 3%
agarose gels (FMC Bioproducts, US). DNA was visualised by ethidium bromide
staining and examination under ultraviolet irradiation.
The primer strategy used was a modification of that used by Zhong and colleagues
(1993b) and Shea and colleagues (1990) (Figure 2.1). This method allowed the
amplification of both GSTM1 and GSTM4 and hence provided a positive control for
each reaction, since GSTM4, which is not known to be polymorphic (Zhong et al,
1993b), was always amplified. This was particularly important as DNA extracted
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from archival paraffin blocks may be of poor yield. Hence a loss of GSTM1
identified in this way could be distinguished from a failed PCR reaction.





The primers 22y and 23y when used together in a PCR reaction amplify a DNA
fragment of 202bp in length, while the use of 22y and 24y together results in the




Primers: 22y 23y 24y
Figure 2.1 Schematic diagram of the GSTM1 gene. The upstream primer
(22y) is situated in exon 4, whereas both downstream primers (23y and 24y)
are located in exon 5. Both 22y and 23y anneal to GSTM4 in addition to
GSTM1, and thus serve as a positive control for the PCR assay. Primer 24y is
specific for GSTM1.
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2.6.3 CYP1A1 PCR Analysis
Genotyping was carried out by polymerase chain reaction analysis using buffer and
1.5mM MgCl2 (Promega, UK), 150pM deoxynucleotides (Pharmacia, UK), 5%
DMSO (Sigma, US), 25 pmoles of primer (Oswell DNA Services, UK) and 2.5 units
of Taq polymerase (Promega, UK). The primers used were from intron 6 and exon 7
and the sequences were:
upstream 5'-AAAGGCTGGGTCCACCCTCT-3';
downstream 5'-AAAGACCTCCCAGCGGGCCA-3'.
The downstream primer incorporates a mismatched base to engineer an Ncol
462
restriction enzyme site in the PCR products derived from the He allele of the
462
gene. In the Yal allele of the gene, this restriction site is lost. The primers
amplify both alleles, and the genotypes are distinguished by Ncol digestion of the
products. An Ncol restriction enzyme site located upstream of the mutation in either
genotype serves as a positive control for PCR product digestion (Figure 2.2). PCR
products were electrophoresed in 3% NuSeive and SeaKem agarose (FMC
Bioproducts, US), and restriction enzyme digestion fragments were electrophoresed
in 3% Metaphor agarose (FMC Bioproducts, US).
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CYP1A1 GENE
Exon 1 3 4 5 7
Position of primers in PCR
Gene sequence of exon 7
5' TGT ATC GGT GAG A CC ATT G CC CGC TGG GAG GTC TTT 3'
Isoleucine allele
Cys lie Gly Glu Thr lie Ala Arg Trp Glu Val Phe
f
5' TGT ATC GGT GAG ACC GTT GCC CGC TGG GAG GTC TTT 3'
Valine allele
Cys lie Gly Glu Thr Val Ala Arg Trp Glu Val Phe
Downstream primer: 3' AC CGG GCG ACC CTC CAG AAA 5'
Figure 2.2 Schematic diagram of the CYP1A1 gene structure showing the PCR
assay and restriction enzyme analysis used in genotyping. * indicates the position of
the base change (T to G) introduced by the downstream primer to create a Ncol
restriction enzyme recognition site (box). The substitution of a G for an A in the




Stastical analysis of the genotyping results for both the GSTM1 and CYP1A1
polymorphisms was carried out using the Minitab for Windows 6.0 Statistics
Package for yl analysis, and the Instat Statistics Package (GraphPad Software, Instat
V2.05a) for Fishers exact test calculations. All statistics were calculated from a null
hypothesis for an unmatched cross-sectional study of disease association (Campbell
& Machin, 1993).
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2.7 Sequencing of the CYP1A1 gene
The PCR fragment amplified from the CYP1A1 gene using the primers described
was sequenced to check that the mismatch introduced by the 3' primer did not affect
the remainder of the amplimer in any way. Initially, sequencing was carried out by
cycle sequencing the fragment using the 3' primer. When this method was
unsuccessful, cycle sequencing using the 5' primer was carried out, but this method
failed to provide readable sequence. The CYP1A1 PCR fragment was then cloned
and sequenced by direct sequencing.
2.7.1 Cycle sequencing of the CYP1A1 gene
Cycle sequencing was carried out using the Stratagene Cyclist DNA Sequencing Kit
(Stratagene, UK). A master mix containing 200 fmol template, 1 pmol primer,
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sequencing buffer, 10 pCi S radioactive label, 1 pi Exo'Pfu DNA polymerase, 4 pi
DMSO was made up to 30 pi volume with water, and 7 pi of the mix added to 3 pi
aliquots of the 4 dideoxyribonucleotides. Samples were mixed and overlaid with
30pl paraffin oil before cycling in a thermocycler. Cycling was carried out at an
initial 5 minute denaturation temperature of 95°C, followed by 30 cycles of 95°C for
30 seconds, 65°C for 30 seconds, and 72°C for 1 minute. To stop the cycling
reaction, 5 pi of stop solution was added to the samples, and the reactions were heat
denatured for 5 minutes at 80°C before loading onto a sequencing gel.
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2.7.2 Cloning of the CYP1A1 PCR Product
PCR products were purified using Glassmax columns (Gibco BRL, UK), before their
ligation into the PGEM-T vector (Promega, UK). Ligation reactions were
transformed into JM109 competent cells (Gibco BRL, UK), which were grown on L-
amp plates treated with lOOpl 2% X-Gal and lOOpl 40mM IPTG to allow blue/white
selection of transformed cells to occur. Transformed colonies containing vector were
selected and grown in L-broth containing ampicillin, and the vector was isolated
using the Wizard Miniprep System (Promega, UK). Miniprep isolated DNA was
digested with Ncol restriction enzyme (Gibco BRL, UK) at 37°C overnight to
identify vectors containing CYP1A1 DNA. Colonies with vectors containing
CYP1A1 inserts were then grown in 100ml L-broth containing Ampicillin for
preparation ofDNA by maxiprep using the Qiagen-tip system (Qiagen, UK). DNA
recovered by maxiprep was quantified on ethidium bromide agar plates, before the
application of chain termination sequencing.
2.7.3 Chain termination sequencing of cloned CYP1A1 PCR products
The double stranded vector containing the CYP1A1 PCR product (5pg
concentration) was denatured with 2M sodium hydroxide, 2mM EDTA, neutralized
with 2M ammonium acetate and precipitated with ice cold absolute ethanol.
Following centrifugation, the DNA pellet was washed with 70% ethanol, before
drying under vacuum and resuspension in water. Sequencing was then carried out
using the USB Sequenase kit (Amersham, UK). Sequencing gels were visualized
using autoradiograph film (Kodak, UK).
2.8 Novel Thr-Asn CYP1A1 variant detection PCR
The PCR assay used to genotype the CYP1A1 Ile-Val462 polymorphism could not
differentiate the Thr-Asn variants. A PCR assay was therefore designed to
differentiate the Thr-Asn variants in order to investigate the frequency of this
sequence in the general population. By introducing a base change into the upstream
primer, a Sau96I restriction enzyme site could be engineered into PCR products.
This restriction enzyme recognizes the threonine variant of the CYP1A1 gene, but
will not cut the asparagine variant.
2.8.1 Genotyping of individuals for the novel CYP1A1 polymorphism
Twenty-seven individuals from the Scottish control group previously identified as
heterozygotes for the Ile-Val462 CYP1A1 polymorphism were genotyped for the
novel polymorphism by PCR and Sau96I restriction enzyme analysis (Gibco BRL.
UK). Using the previous Ncol restriction analysis, distinction between the Ile-
Val462 and the Thr-Asn461 polymorphisms was not possible since both mutations
destroy the Ncol site. With the introduction of a base change in the primer, a
restriction enzyme site can be engineered, which is destroyed by the novel CYP1A1
sequence. The assay employed can be seen in schematic form in Figure 2.3. The
primers (Oswell DNA Services, UK) used were:
upstream primer: 5'-AGCGGAAGTGTATCGGTGGG-3'
downstream primer: 5' -GAAGCATGCCTGCTGTGAGC-3'
Following DNA restriction, fragments were electrophoresed on 6% polyacrylamide
gels with DNA molecular weight marker 4>X 174 (Gibco BRL, UK).
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upstream primer
AG CGG AAG TGT ATC GGT GGG
AAG CGG AAG TGT ATC GGT G AGACC ATT GCC CGC TGG GAG GTC TTT CTC






Figure 2.3 Schematic diagram of the PCR assay and restriction enzyme analysis
used to genotype for the novel Thr-Asn461 polymorphism of the CYP1A1 gene. The
base change introduced to the PCR fragment using the upstream primer is indicated
by a *, while the Sau96I restriction site is indicated by a box.
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RESULTS
3.1 Assessment of emphysema in lung samples
In all cases the extent of emphysema was of mild to moderate degree which was
expected since all cases had been obtained from patients deemed fit for surgery, who
had FEV i of at least 1.4 I/s. No difference in gender, age or tumour type was found
between subgroups with different forms of emphysema.
The distribution of emphysema patterns and severity is summarised in Table 3.1.
This study is concerned primarily with centriacinar and panacinar emphysema
patterns. Severity was assessed by eye on the cut surface of the lobe of the lung
which had been removed for the biopsy. Figures 3.1-3.5 show examples of the
varying emphysema patterns and severity encountered in the course of this study.
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Scale bar: 1cm
Figure 3.1 Normal lung with no evidence of emphysema
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Scale bar: 1cm
Figure 3.2 A lung sample with mild panacinar emphysema demonstrating the
uniform distribution of this type of emphysema. Although the airspace size is not
very great, a significant difference can be seen in this sample when compared to the
normal lung (Figure 3.1). It may appear from this photograph that panacinar
emphysema has a tendancy to be peripheral, however this is a consequence of the




Figure 3.3 A lung sample with evidence of mild centriacinar emphysema. The
lung destruction can be seen to occur in focal lesions around the respiratory




Figure 3.4 An example of a lung biopsy with severe panacinar emphysema. The
greatly enlarged airspaces are fairly uniform. In some regions the amount of
destruction has been so great that only blood vessels remain connecting areas of lung
tissue such that they appear as strands crossing the spaces.
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Scale bar: 1 cm
Figure 3.5 A lung sample showing severe centriacinar emphysema. The
destruction of lung tissue has been so great that the focal nature of the lesions, which
is clearly visible in milder disease, has been lost, making the centriacinar pattern
indistinguishable from panacinar emphysema in places.
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3.2.1 Clinical information
No significant differences in age, gender, or tumour type were found within the study
populations. The median FEV i of chronic obstructive airways disease cases was 1.1,
and 2.2 for the biopsy study group. Smoking histories were recorded where possible
in pack years of exposure, and the median pack years for the chronic obstructive
airways disease group was 35, while the biopsy cases had a median of 46 pack years.
3.2.2 Biopsy lung samples
One hundred and fourteen biopsy lung samples contained macroscopic emphysema.
Of these samples, 21 contained only panacinar emphysema, 51 contained centriacinar
emphysema alone, and 42 samples showed evidence of both centriacinar and
panacinar emphysemas. In the lung samples which contained either panacinar or
centriacinar emphysema singly, mild disease contributed the majority of cases, and
the number of cases with moderate or severe emphysema decreased with increasing
severity. In lung biopsies containing both centriacinar and panacinar emphysemas,
the number of samples found which contained mild, moderate or severe disease was
more evenly distributed. However, cases with both centriacinar and panacinar
emphysemas did show a slight trend towards increasing numbers of cases with
increasing disease severity.
Microscopic emphysema was found in 40 of the lung samples measured with the fast
interval processor.
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3.2.3 Autopsy lung samples
Thirty-eight autopsy lung samples were found to contain evidence of macroscopic
emphysema. Panacinar emphysema alone was present in 11 autopsy cases,
centriacinar emphysema was found to be the single pattern present in 3 autopsy
samples, while both centriacinar and panacinar emphysemas were found in 24 lung
autopsy cases. The majority of cases with both centriacinar and panacinar
emphysemas were classed as severe, unlike the biopsy samples. Insufficient numbers
of cases with only one pattern of emphysema were present to identify any trend in
severity.
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Emphysema cases Pattern of Disease Mild Moderate Severe Total
Biopsy cases Panacinar 12 5 4 21 (18%)
Centriacinar 34 12 5 51 (45%)
Both centriacinar
and panacinar
10 14 18 42 (37%)
Total 56 (49%) 31 (27%) 27 (24%) 114
Autopsy cases Panacinar 1 8 2 11 (29%)
Centriacinar 0 1 2 3 (8%)
Both centriacinar
and panacinar
4 3 17 24 (63%)
Total 5 (13%) 12 (32%) 21 (55%) 38
Total cases 61 43 48 152
Table 3.1 Table summarising the pattern and severity of emphysema found in
biopsy and autopsy lung samples.
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3.2 Immunohistochemical detection of glutathione S-transferases in human lung
3.2.1 Glutathione S-transferase Pi
GSTP was present in every lung examined. Bronchial epithelial cells were strongly
positive with reactivity noted in cytoplasm, brush border and most nuclei (Figure
3.6). Muscle, nerve, serous glands and chondrocytes also expressed GSTP. Terminal
bronchioles and both type 1 and type 2 pneumocytes contained GSTP (Figure 3.7),
but no significant reactivity was seen in endothelial cells. Alveolar macrophages
were variably positive. No differences were noted between smokers and non-
smokers.
3.2.2 Glutathione S-transferase Alpha
GSTA was present in the cytoplasm, some nuclei and the brush border of most, but
not all, bronchial epithelial cells. Some chrondrocytes stained but alveolar lining
cells and macrophages were consistently negative (Figure 3.8).
3.2.3 Glutathione S-transferase Mu
GSTM was much more difficult to detect than the other isoenzyme classes, possibly
as a result of lower antibody affinity rather than decreased protein levels. Only two
cases of the 21 studied showed unequivocal positive staining but the majority of
cases showed weak, indeterminate reactivity. However, the pattern of distribution
was the same as for GSTP; that is bronchial epithelium, types 1 and 2 alveolar cells
and macrophages (Figures 3.9 and 3.10).
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Figure 3.6 Immunohistochemical detection of GSTP in human lung. Staining is
localised to bronchial epithelial cells, occasional inflammatory cells and nerves.
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Figure 3.8 Immunohistochemical detection of GSTA in human lung. Staining is
localised to the brush border of the airway epithelia and is heterogeneous in cells.
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Figure 3.9 Weak immunohistochemical staining localised GSTM to the bronchial
epithelium.
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Figure 3.10 Heterogeneous staining of alveolar macrophages for GSTM and weak
staining of alveoli.
Figure 3.11 Negative control for immunohistochemistry showing no significant
reaction product.
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3.2.4 Glutathione S-transferase P in bronchoalveolar lavage (BAL) fluid
All four samples showed reactivity with GSTP antibody, although in two cases
GSTP appeared to be partly degraded (Figure 3.12). The intensity of the bands
varied but the total amount of protein loaded for each case was only approximately
equal. The results should therefore not be regarded as quantitative. The BAL fluids
used were not noticeably bloodstained macroscopically, and contained few red blood






Figure 3.12 Western blot analysis of BAL fluid probed with antibody against
GSTP. In lanes 1 and 2 there are lower molecular weight bands
reaction with the antibody consistent with degradation of protein.
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3.2.5 Comparison of immunohistochemical detection of GSTM with GSTM1
PCR analysis
GSTM1 PCR analysis resulted in specific fragments which were easily interpreted
when visualised on agarose gels as described (Figure 3.14). Of 10 DNA samples
extracted from archival lung tissue, 7 were null at the GSTM1 locus. There was a
poor correlation between GSTM1 genotype and immunophenotype, with 4 cases
scoring positive for immunostaining where GSTM1 was absent by PCR (Table 3.2).
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Table 3.2 Comparison of GSTM1 genotype with immunohistochemical
detection ofGSTM.
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3.2.6 Detection of human GSTM1 by Western blotting
Western blotting using antibodies to mu class GSTs was carried out on proteins
derived from lymphocytes. No expression of GST mu class isoenzymes could be
detected using this technique.
3.2.7 Detection of GSTM1 and GSTM4 in human lung tissue by reverse
transcription
Both GSTM1 and GSTM4 were detected in 3 lung tissue samples by reverse
transcription. GSTM4 was present in all lungs analysed, and GSTM1 expression was










Figure 3.13 Digestion ofRTPCR amplimers by Ncol restriction enzyme. Lane 1
contains a kilobase ladder. Fragments from a lung sample expressing GSTM4 can be
seen in lane 2, while lane 3 shows an Ncol digestion of cDNA from a lung sample
expressing both GSTM1 and GSTM4.
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3.3 Molecular analysis of polymorphic xenobiotic metabolising enzymes in
emphysema, chronic obstructive lung disease and lung cancer
3.3.1 Genotyping of GSTM1 lung biopsy cases with emphysema
Following PCR analysis, the reaction products were electrophoresed in agarose gels
and fragments of 275 base pairs and 202 base pairs, amplified from GSTM1 and
GSTM4 respectively, were visualised. GSTM4 was present in all cases amplified
using the assay (Figure 3.14). The results of the GSTM1 genotyping are summarised
in Table 3.3.
The control group genotyped for GSTM1 numbered 384 samples, 205 (53%) of
which were null for the GSTM1 gene, while 179 (47%) individuals had the intact
gene. The GSTM1 genotype of 110 emphysema cases was determined, and 39
(35%) cases were found to have the GSTM1 gene, while 71 (65%) were identified as
having the GSTM1 gene deletion. Statistical analysis demonstrated a significant
difference between the group of emphysema cases and the control group, with
p=0.038, an odds ratio of 1.59 and 95% confidence limits from 1.02-2.47.
When the total emphysema cases were sub-divided into groups depending on their
pattern of emphysema, 48 cases had centriacinar emphysema alone, panacinar
emphysema alone was found in 20 individuals, and both centriacinar and panacinar
emphysema were found in 42 samples. The group containing only centriacinar
emphysema was found to contain 60% of individuals with deletion of the GSTM1
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gene. Of the cases with panacinar emphysema alone, 65% were null for GSTM1.
The frequency ofGSTM1 deletion in these 2 sub-groups of emphysema did not differ
significantly from the control group (p=0.36, p=0.31 respectively). Both centriacinar
and panacinar emphysemas were found in 43 samples, and 70% of these individuals
were found to have deletion of GSTM1. This proportion of GSTM1 deletion was
significantly different to the frequency of the deletion in the control group, p=0.053,
with an odds ratio of 1.95, and 95% confidence limits from 0.98-3.86.
3.3.2 GSTM1 genotype and association with lung cancer
A further group of cases comprising 46 lung cancer patients with no evidence of
macroscopic emphysema were genotyped for GSTM1. Of these patients, 50% were
found to be null for GSTM1, a similar frequency to the 53% of nulled individuals
found in the control group.
The total number of cases with lung cancer was subdivided according to lung cancer
type and GSTM1 genotypes ascertained for each type of disease. However no
significant differences in the frequency of the GSTM1 polymorphism could be
demonstrated between the control group and any type of lung cancer (Table 3.4).
3.3.3 GSTM1 genotype and association with COPD
Blood collected from patients attending a chronic obstructive pulmonary disease
clinic was genotyped for GSTM1. Of the 80 samples collected, 37 (46%) had the
intact GSTM1 gene, while 43 (54%) were null at the GSTM1 locus. This frequency
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of genotypes was similar to that of the control population where 53% of individuals
lacked the GSTM1 gene.
3.3.4 Genotyping GSTM1 in autopsy lung samples with emphysema
Autopsy samples with evidence of emphysema were collected and genotyped for
GSTM1. Of the 38 autopsy lung samples, 24 (63%) had a GSTM1 gene deletion,
while 14 (37%) samples had an intact GSTM1 gene. The GSTM1 frequency in these
autopsy samples did not differ significantly from the GSTM1 distribution in the
control population.
3.3.5 GSTM1 genotype in microscopic emphysema
Forty samples which had been found to have microscopically assessed emphysema
were genotyped for GSTM1. Of these samples, 15 (37.5%) had an intact GSTM1
gene, while 25 (62.5%) were null at the GSTM1 locus. The frequency of deletion of
GSTM1 in these cases were not significantly different from the controls.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
Figure 3.14 GSTM1 and GSTM4 PCR products amplified from control blood
samples. The 202bp fragment amplified from GSTM4 is present in every sample,
and the 275bp GSTM1 fragment is present in only some cases (lanes 2, 4, 5, 11, 12,
and 13). A negative control reaction containing water and no template was loaded in
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Cases (35%) (65%)






20 1.03 0.310 1.62 0.63-4.15
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Table 3.3 Frequency of GSTM1 deletion polymorphism in lung cancer cases


















22 (40%) 33 (60%) 55 0.85 0.357 1.31 0.74-2.33
Adenocarcinoma 18(41%) 25 (58%) 43 0.35 0.553 1.21 0.64-2.30
Adenosquamous
Carcinoma
0 4(100%) 4 FT* 0.128 7.86 0.42-147.12
Small Cell
Undifferentiated





3 (43%) 4 (57%) 7 FT* 1.00 1.16 0.26-5.27
Other 11 (55%) 9 (45%) 20 0.54 0.464 0.71 0.29-1.75






*Statistics test used was Fishers exact test.
Table 3.4 Table showing the frequency of GSTM1 genotypes in lung cancer
cases
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3.3.6 CYP1A1 genotyping of emphysema samples
Of the 129 lung cancer samples studied, 35 were assessed to have no macroscopic
emphysema, 34 showed centriacinar patterns of damage, 17 samples had panacinar
emphysema, and 35 lung biopsies had both centriacinar and panacinar forms of
emphysema
PCR analysis of control blood samples yielded specific fragments which were easily
visualised on agarose gels (Figure 3.15). DNA extracted from paraffin embedded
lung tissue generally amplified successfully, however there was an increased
tendancy towards smearing and smaller fragments (Figure 3.16). Each CYP1A1
amplimer analysed had a diagnostic Ncol restriction enzyme site which enabled
distinction of the CYP1A1 genotype of the individual, and a second constant control
Ncol site which served to check the efficacy of the enzyme (Figure 3.17).
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Figure 3.15 CYP1A1 PCR products amplified from control DNA samples
(extracted from blood). A product of 322bp is amplified in each case. DNA
molecular weight marker V (Boehringer Mannheim, UK) is loaded in the left hand
lane.
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1 2 3 45 67 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Figure 3.16 CYP1A1 PCR products amplified from DNA extracted from paraffin
embedded lung tissues. The expected 322bp CYP1A1 fragment is present in lanes 2-
17, but with DNA extracted from these samples there was an increased chance of
amplifying smaller fragments and smearing. Lane 1 contains DNA molecular weight
marker V (Boehringer Mannheim, UK). A negative control reaction containing
water and no template has been loaded in lane 21 to act as a negative control.
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Figure 3.17 Results of a Ncol digestion of the CYP1A1 amplimer. The 2 bands
represent the 2 alleles of the gene, the higher molecular weight fragment (250bp)
representing the uncut valine allele of the gene, and the lower molecular weight band
(231 bp) representing the cut isoleucine allele of CYP1A1. Lanes 1,5,6 and 7 therefore
represent heterozygotes for the 2 alleles, while lanes 2,3,4,8,9,10 and 11 contain
digestions from individuals homozygous for the common isoleucine allele. A non¬
specific higher molecular weight band can be seen in lanes 4,6,7,8,9 and 10.
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The control group numbered 281 samples, of which 87% were homozygous for the
lie462 allele, 12% were heterozygous, and 1% were homozygous for the valine allele
of the CYP1A1 gene (Table 3.5). In comparison, the 121 lung resection cases
demonstrated 82% homozygosity at the lie462 allele, heterozygosity in 16% of
individuals, and 2% individuals with Val462 homozygosity. This group was not
significantly different from the control population (Table 3.4).
The CYP1A1 genotype was identified in 35 lung samples which showed evidence of
microscopic emphysema. Of these samples, 24 (68%) were homozygous for the
lie462 allele, 9 (26%) were heterozygotes, and 2 (6%) were Val462 homozygotes. This
distribution of the CYP1A1 polymorphism is significantly different from the control
population frequencies (% =11.15, p=0.001), with an odds ratio of 3.06 and 95%
confidence intervals of 1.54-6.07.
In the clinical group of chronic obstructive pulmonary disease patients, of the 80
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samples, 80 % were homozygous for lie , and 20% were heterozygous for the
polymorphism. No individuals homozygous for the valine allele were found in this
disease group, and no significant difference between this study group and the
controls was seen (Table 3.5).
In order to investigate the CYP1A1 gene polymorphism and susceptibility to
emphysema, the total lung cancer study group was divided according to the pattern of
emphysematous damage in the lung (Table 3.6). When this was done, 35 samples
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were found to show no evidence of emphysema, and of these, 91% were He
homozygotes and 9% were heterozygotes. Centriacinar emphysema only was found
in 34 cases, and of these, 73.5% were homozygous for the valine allele and 26.5%
were Ile/Val. Panacinar emphysema alone was present in 17 samples, 88% of which
462 462
were lie homozygotes, 6% were Ile/Val, and 6% were homozygous for the Val
allele. Both panacinar and centriacinar emphysemas were found in 35 of the lung
cancer samples, and homozygotes for the isoleucine allele accounted for 77% of
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these cases, 20% were heterozygotes, and 3% were Val homozygotes. No
significant differences were found between the control population and the patient
groups with either centriacinar or panacinar emphysema alone and the patients with
both centriacinar and panacinar emphysemas.
3.3.7 Genotyping of CYP1A1 in lung cancer cases
The lung cancer cases were subdivided according to type of lung cancer, and the
frequencies obtained for each type of cancer are shown in Table 3.7. No significant
differences were demonstrated to exist between the frequency of the CYP1A1
polymorphism in the control population and the frequencies obtained for the groups









































































0 80 1.66 0.20 1.49 0.81-2.72
Table 3.5 Table showing CYP1A1 genotypes for the disease groups and control
group for statistical comparison. *Comparison of allele frequencies.
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Ile/Ile Ile/Val Val/Val Total j2 versus P Odds 95%
geno¬ geno¬ geno¬ cases control* value ratio confi¬
type type type dence
limits
Centri- 25 9 0 34 3.42 0.065 2.04 0.94-
acinar (73.5%) (23.5%) 4.42
alone
Pan- 15 1 1 17 pp** 0.725 1.30 0.38-
acinar (88%) (6%) (6%) 4.44
alone
Both 27 7 1 35 3.11 0.08 1.98 0.91-




Table 3.6 Table showing CYP1A1 genotypes of cases with emphysema and
lung cancer divided by pattern of emphysema. *Comparison of allele frequencies.













































































109 1.60 0.21 1.43 0.82-
2.49
Table 3.7 Table showing distribution of CYP1A1 genotypes among lung cancer
cases. ^Comparison of allele frequencies. **Statistical test used was Fishers exact
test.
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3.3.8 Sequence analysis of CYP1A1 gene for polymorphism confirmation
Sequence analysis of the CYP1A1 PCR product confirmed that the PCR assay and
subsequent restriction enzyme analysis identified individuals with the A to G
substitution polymorphism of CYP1A1 (Figure 3.18).
3.3.9 Detection of novel Thr-Asn mutation in CYP1A1 gene
Following sequence analysis of the CYP1A1 PCR product of one individual, it was
discovered that the expected A to G substitution, which results in the replacement of
a valine for an isoleucine amino acid at position 462, was not present, despite this
individual being genotyped as having the mutation by restriction enzyme analysis.
The sequencing data derived from this individual identified a novel CYP1A1
mutation, a C to A substitution, 2 base pairs upstream of the known valine
polymorphism. This mutation would result in the substitution of an asparagine for a
threonine amino acid residue.
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ISOLEUCINE ALLELE VALINE ALLELE
Figure 3.18 Sequence analysis of the CYP1A1 isoleucine to valine polymorphism.
The A to G substitution can be clearly seen when the polymorphic valine allele is
sequenced and compared to the sequence of the more common isoleucine allele.
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C T A G
Figure 3.19 Detection of a novel variant of the CYP1A1 gene by cloning and
sequence analysis. A clear C to A substitution (*A) was identified in one sample
which had been genotyped as homozygous for the polymorphic valine allele using
PCR and Ncol restriction enzyme analysis. The presence of the more common A
(-+A.) as opposed to the polymorphic G base pair is clear, indicating that the false
genotyping obtained for the isoleucine to valine polymorphism resulted from
disruption of the Ncol site by this novel CYP1A1 sequence variation.
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3.3.10 PCR analysis of control population for Thr-Asn polymorphism
Any identification of lie462 using the previous CYP1A1 PCR and Ncol restriction
enzyme assay must be correct, since the enzyme can cut this gene sequence, but
either the Val462 or the Asn461 variants will destroy this restriction enzyme site.
Where destruction of the restriction enzyme site was demonstrated in the previous
assay this was subscribed to the polymorphic valine allele, however this destruction
may be the result of the Thr-Asn461 change, which may be a common variant of the
CYP1A1 gene.
Genotyping was carried out on 26 control samples which had previously been
identified as heterozygotes for the Ile-Val462 polymorphism. The individual who was
demonstrated to have the novel CYP1A1 variant through sequencing had previously
been genotyped as a homozygote for the valine allele. This individual was therefore
also genotyped with the new assay to determine whether this person was
homozygous for the novel mutation, or was a heterozygote with an allele containing
the valine variant of the gene.
With this analsysis, 14 individuals were heterozygous for restriction by Sau96I
enzyme. Since previously these individuals had been demonstrated to have the
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isoleucine variant, their genotype must be isoleucine/asparagine. The CYP1A1
fragments amplified from 12 individuals were found to digest completely with
Sau96I indicating that their original genotyping as heterozygotes for the isoleucine
and valine alleles was correct. The individual who had previously been classified as
a valine homozygote was found to have two copies of the Asn461 allele of the gene.
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M B
Figure 3.20 Photograph of the amplimers obtained using PCR for the novel Thr-
Asn polymorphism ofCYP1A1. The fragment size is 153bp, M refers to DNA
molecular weight Marker V, B refers to the negative control for the PCR (no DNA
added).
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Figure 3.21 Sau96I digestion of the PCR products for the novel Thr-Asn
polymorphism. Lanes 1,2,5 and 9 show individuals heterozygous for the novel Asn
polymorphism, lanes 3,4,7 and 8 show individuals who do not have the Asn allele of
CYP1A1, while the homozygote for the Asn polymorphism is in lane 6. Lane 10
contains DNA molecular weight marker (j)X174.
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DISCUSSION
4.1 Distribution of emphysema in biopsy and autopsy cases
As can be seen in Table 3.1, panacinar and centriacinar emphysemas were not evenly
distributed between the autopsy and biopsy cases. In biopsy cases, more centriacinar
emphysema and both centriacinar and panacinar emphysemas together were present,
with less cases containing panacinar emphysema alone. Moreover, a trend towards
milder disease was also identified, with moderate and severe disease being less
common than mild disease in the biopsy cases.
*
The autopsy cases showed a different distribution in disease pattern and severity to
that seen in biopsy cases. Most autopsy samples contained both centriacinar and
panacinar emphysemas, while panacinar emphysema was more common than
centriacinar emphysema where a single form of the disease was present in the lung.
Indeed, few autopsy cases were found to contain only centriacinar emphysema. In
autopsy cases there seemed to be a tendancy towards increased severity, unlike the
trend identified in biopsy cases. However, since lower numbers of autopsy cases
were assessed, this trend is perhaps less credible than that identified in the biopsy
cases.
The uneven distribution both of emphysema pattern and severity in autopsy and
biopsy cases is not surprising. Since patients undergoing surgery for biopsy need to
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be of a certain level of fitness to survive the operation, these samples would be
expected to contain generally milder disease than might be expected in autopsy
samples. Autopsy samples would generally be expected to contain disease of a more
severe nature since in many of these cases emphysema may have been the cause of
death either directly, or as a contributory factor. Furthermore, while many autopsy
cases may contain emphysema, selection of samples for a study of emphysema would
be more likely to have occurred for interesting cases with more severe emphysema.
Kim and colleagues (1991) demonstrate that the loss of elastic recoil associated with
chronic obstructive pulmonary disease correlates with increased airspace size in the
parenchyma rather than increased airspaces in centrilobular lesions. It might
therefore be hypothesized that panacinar emphysema is more debilitating to lung
function than centriacinar emphysema. With this hypothesis in mind, autopsy cases
might be expected to contain more panacinar emphysema than biopsy samples which
have been obtained from individuals who do not suffer from severe chronic
obstructive pulmonary disease. Individuals with centriacinar emphysema will be less
likely to suffer decreased lung function as a result of their disease and will therefore
be judged capable of surviving biopsy surgery, explaining the increased numbers of
individuals with this type of emphysema in the biopsy group.
If emphysema has contributed significantly to the cause of death, there are several
reasons why it might be expected that the lungs would contain both panacinar and
centriacinar emphysema. Firstly, in more severe disease both forms of emphysema
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are likely to be present, since increased damage reflects increased exposure (and/or
susceptibility) to cigarette smoke. Secondly, both panacinar and centriacinar
emphysema contribute towards decreased lung function, therefore the number of
samples with both types of disease would be expected to be higher in autopsy cases
than in biopsy cases. Indeed, when the proportion of cases with both types of
emphysema in the biopsy and autopsy groups is compared, an increased percentage
of these cases is seen in autopsy samples.
4,2 Immunohistochemical detection of GSTs in human lung tissue
The immunohistochemical findings of previous work carried out in the laboratory
suggested that GST-mediated protection against xenobiotic and oxidative stress in
the lung can be divided into two functional compartments (Cantlay et al, 1994). In
proximal airways all three cytosolic forms GSTP, A and M were present in lining
epithelium, whereas the distal alveolar compartment contained GSTP and GSTM but
no GSTA in both type 1 and 2 pneumocytes as well as macrophages. This is
consistent with biochemical studies which showed that GSTP is the predominant
lung isoenzyme (Ketterer et al, 1992; Carmichael et al, 1993). In a previous study of
GST in human lung development (Cossar et al, 1990), all isoenzymes were
identified, with GSTP the predominant isoenzyme. The levels of GSTP were higher
during fetal development, with strong reactivity in bronchi and protoalveoli, and fell
during late gestation. In another study of only 3 human lungs (Awasthi et al, 1987),
GSTP, GSTA and GSTM were all reportedly present in alveoli. This is inconsistent
with the work of Fryer and colleagues in fetal lungs (1986) and the results obtained
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in our laboratory. The discrepancy may have resulted because an
immunofluorescence assay was used in the study of Awasthi, which is more sensitive
but also produces a higher background.
In previous studies of localisation of GST in mouse and rat lungs (McLellan et al,
1992; Coursin et al, 1992), GST was restricted to bronchial epithelial cells, including
the brush border, with virtually no GST identifiable in alveoli. In addition, GSTP in
rat lung was also identified as an extracellular protein in association with elastin
(Coursin et al, 1992). This was apparent in electron but not light microscopic
preparations. The results obtained in our laboratory provided no
immunohistochemical evidence for extracellular interstitial GST but the presence of
GSTP was demonstrated in BAT fluid. In a previous study both GSTA and GSTP
were found in BAL fluid of tumour bearing lungs (Howie et al, 1990b).
The presence of GSTP in alveolar macrophages and BAL is interesting. GSTP
functions as a homodimer and it can be readily inactivated by oxidation of reduced
sulphydryl groups (Mulder & Tekoppele, 1988). It may therefore function as a
"sacrificial reactive protein" in addition to being a GST dependent enzyme. Indirect
support for this suggestion is provided from a study where cigarette smoke reduced
GSTP activity in alveolar macrophages (Petruzelli et al, 1988), despite the fact that
cigarette smoke contains many chemicals which might increase GSTP expression. In
these cells GSTP activity may have been reduced by oxidative degradation rather
than by reduced expression of the protein.
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Cigarette smoke contains a plethora of chemicals, many of which act as substrates for
GSTP, GSTA and GSTM. Proximal airways contained GSTA which is involved in
selenium-independent glutathione peroxidation reactions, and which may detoxify
DNA and lipid hydroperoxides (Ketterer et al, 1988). Its presence in the brush
border is therefore suggestive of a role for GSTA in the protection of bronchial
epithelium. Most acute damage following cigarette smoke inhalation is seen in small
distal airways and alveoli (Harley, 1988), a site lacking this selenium-independent
peroxidase protection. In individuals null at the GSTM1 locus it therefore follows
that the level of protection in distal airways afforded by GSTs is significantly
reduced. Several reports have suggested that the expression ofGSTM in lung shows
evidence of polymorphism which is consistent with the gene expressed being
GSTM1 rather than GSTM4 (Fryer et al, 1986; Ketterer et al, 1992). However, in
one study of 10 lungs, no evidence of polymorphic expression was seen although the
level of GSTM catalytic activity was markedly variable between cases (Carmichael
et al, 1993). The immunohistochemical expression carried out in our laboratory
could not differentiate specifically the polymorphic enzyme GSTM1 from the non-
polymorphic GSTM4.
Previous studies of polymorphic xenobiotic metabolising enzymes had identified a
role for GSTM1 deletion in influencing susceptibility to lung cancer, and it was
therefore hypothesised that this enzyme deficiency might also influence
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susceptibility to emphysema, another lung disease which has a strong association
with cigarette smoking. If the GSTM1 polymorphism is involved in susceptibility to
lung disease, the expression of this enzyme is of primary interest. GSTM1 is highly
expressed in the liver, therefore a deficiency in metabolism might influence disease
through systemic circulation. However, if GSTM1 expression occurs in lung tissue,
the deficiency in metabolism might be expected to have a direct effect. Any
difference in expression may influence disease susceptibility with regard to the type
of disease and the region of the lung involved. For example in panacinar
emphysema, systemic factors influencing disease may be of particular importance,
since deficiency of al-antiprotease, the major antiprotease which is present in serum
predisposes individuals to develop emphysema of the panacinar type (Guenter et al,
1968).
In order to determine whether expression ofGSTM1 in human lung samples could be
shown by immunohistochemistry, the GSTM1 genotype of lung samples was
compared with immunohistochemistry of the GSTM class enzymes. The GSTM1
genotype was determined by PCR in 10 archival lung samples which had been
included in the previous immunohistochemical analysis. The GSTM1 genotype
showed poor correlation with staining for GSTM class enzymes. This may be
explained by the specificity of the PCR assay for GSTM1 only, while the
immunohistochemistry may identify any of the mu class enzymes, including
GSTM4, which is expressed in lung (Antilla et al, 1993). Since
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immunohistochemical staining of lung tissue for GSTM enzymes could not
specifically demonstrate GSTM1 expression, the GSTM antibodies were used for
Western blotting to see if the antibodies could distinguish polymorphic expression
which might represent GSTM1. However, using the GSTM antibodies, no GSTM
expression could be demonstrated in lymphocytes of individuals genotyped positive
for the GSTM1 gene by PCR.
4.3 Expression ofGSTM1 in lung tissue using RT-PCR
Using reverse transcription PCR, the expression of both GSTM1 and GSTM4
enzymes has been demonstrated in lung tissue. Evidence of enzyme expression in
lung samples does not, however, conclusively prove that lung cells express GSTs,
since inflammatory cells are known to express GSTM1. The inflammatory cell
content of disease-free lung tissue should be minimal, nevertheless, the expression of
GSTM1 as demonstrated by RT-PCR cannot be attributed exclusively to lung cells.
Local expression of GSTM1 in the lung is unlikely to contribute significantly to
disease susceptibility since GSTM1 expression occurs primarily in the liver (Faulder
et al, 1987). GSTM4 was expressed in every lung sample studied. The substrate
specificity of GSTM4 is as yet unknown, however, GSTM1 and GSTM4 are highly
homologous (Zhong et al, 1993b), which suggests that the 2 enzymes may share
similar functions. Recently, Antilla and colleagues (1993) demonstrated expression
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of GSTM3 in lung tissue, which showed interindividual variation and enzyme
induction in the lungs of smokers. It is possible that both GSTM3 and GSTM4 are
important in local lung metabolism of cigarette smoke components. The expression
of other glutathione S-transferases which metabolise cigarette smoke components
and which demonstrate interindividual variation in the lung may explain the
conflicting results obtained in previous studies investigating the role of the GSTM1
polymorphism and susceptibility to lung cancer.
4.4 Analysis of the GSTM1 polymorphism in control and patient populations
4.4.1 Frequency of the GSTM1 polymorphism in the control population
Genotyping of GSTM1 was carried out for 384 anonymous blood samples which
represented the control group for comparison in disease association. Of the 384
control samples, 53% were null at the GSTM1 locus, while 47% of individuals were
found to have the intact gene. There are many reports in the literature of the
frequency of the GSTM1 polymorphism in the general population, some ofwhich are
summarized in Table 4.1. As Table 4.1 shows, the reported frequency of the
polymorphism is highly variable, and ranges from 41 to 65 percent of populations
being null for the GSTM1 gene. Some of this variation can be accounted for by
racial differences in frequency of the polymorphism, a phenomenon known to occur
in polymorphisms of xenobiotic metabolising enzymes (Cosma et al, 1993; Evans,
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1989), however, percentages of null individuals are variable even within the same
population.
In the UK, for example, the percentage of individuals null for GSTM1 ranges from
41 to 61 percent. Most studies in the UK have generated control population values of
approximately 40 percent (Strange et al, 1991), with a single Scottish study finding
61% of the population being null for GSTM1 (Strange et al, 1985). A finding of
53% null individuals in the Scottish control group studied in this thesis is therefore
higher than would be expected from the literature for a UK control group, but is
lower than the frequency of 61% for GSTM1 deletion reported by Strange and
colleagues for a Scottish population (1985). However, Strange and colleagues
genotyped only 52 individuals, hence this study might not fully represent the level of
GSTM1 deletion in the Scottish population. Indeed, the size of control groups used
in most UK studies of GSTM1 deletion have been too small to generate frequencies
representative of the UK population.
While the frequency of GSTM1 deletion in the Scottish population obtained in this
thesis does not correlate with that reported by Zhong and colleagues (1991) which
used a UK control group numbering 225, it is consistent with the control frequencies
reported by Brockmoller and colleagues (1993) and Alexandrie and colleagues
(1994) in their large studies of European populations which number over 300 control
samples. Large studies by Van Poppel and colleagues (1992) and Kihara and
colleagues (1994) are also in disagreement with the data reported here. The Kihara
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study concerned Japanese individuals, therefore the frequency of GSTM1 deletion
may differ from that of the UK population as a result of racial differences in genetic
frequency, as has been reported for other polymorphic xenobiotic metabolising
enzymes (Cosma et al, 1993). However, the European study by Van Poppel was also
inconsistent with this study, but perhaps the use of only males in the control group
has produced an unrepresentative control group.
The frequency ofGSTM1 deletion in the general population is of primary importance
when attempting to ascertain whether the polymorphism is involved in susceptibility
to disease. Several studies of the GSTM1 polymorphism and disease susceptibility
in the British population have generated frequencies of GSTM1 deletion in groups of
patients which have proved significantly different from controls. However, as has
been discussed the control frequencies of GSTM1 deletion used in many of these
studies may have been too low as a result of insufficient sampling of the population.
If control levels of GSTM1 deletion are too low, it is not surprising that significant
differences between disease populations and these control groups can be identified.
If the frequency of GSTM1 deletion for the control group obtained in this thesis was
used for comparison with disease group frequencies in some other UK studies, the
disease association reported would no longer be significant. Fryer and colleagues
(1993a) for example, obtained a frequency of 58% GSTM1 deletion in 195 patients
with pituitary adenoma, which was significantly different to the control group
(n=89), where 44% of individuals were null at the GSTM1 locus. If the frequency of
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GSTM1 deletion in pituitary adenoma patients is compared with the frequency of
53% obtained in this thesis for controls (n=384), the comparison between groups is
no longer significant (x =1.088, p=0.297). Furthermore, Fryer and colleagues
demonstrated a highly significant difference between GSTM1 deletion in 54 patients
with prolactinomas and their control group numbering 89 (x2=6.10, p=<0.05,
increased relative risk with GSTM1 null genotype of 2.56). However, if the
frequency of GSTM1 deletion in patients with prolactinomas is compared to the
control group frequency obtained in this thesis, no significant difference is observed
(X2=3.374, p=0.067).
Fryer and colleagues also used a control group assembled from several published
papers on the frequency of GSTM1 deletion for comparison with their prolactinoma
data. While this brought the overall number of subjects in the control group to over
500, of whom 50% were null at the GSTM1 locus, of the studies which comprised
this combined control group, all genotyped less than one hundred individuals, with
the exception of the study of Kihara and colleagues which investigated the genotype
of 166 Japanese individuals. Using a control group numbering over 500 individuals
would seem to be rigorous in attempting to reduce the error which might be incurred
in selection of a control group, however, if this control group is composed from
smaller studies included together, the degree of error entailed by using small control
groups is still present within the calculation of the large control group frequency.
This large control group used by Fryer and colleagues was also employed by a
second group of investigators who demonstrated a significant difference in the
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frequency of GSTM1 deletion between these controls and a group of patients with
adenocarcinoma of the stomach and colon (Strange et al, 1991).
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Control group Total subjects % population null Type of assay Reference
nationality genotyped for GSTM1 used for
assessment*
Caucasian 40 65 P Board et al, 1981
Chinese 96 58 P Board et al, 1981
Dutch 221 45 P Van Poppel et al, 1992.
French 56 43 P Laisney et al, 1984
German 355 51 G.F.P Brockmoller et al, 1993
Indian 43 35 P Board et al, 1981
Japanese 201 45 G Kihara et al, 1994
Japanese 168 48 P Harada et al, 1987
English 49 41 P Strange et al, 1984
UK 225 42 G,P Zhong et al, 1991
UK 89 44 G,P Fryer et al, 1993a
UK 69 45 G,P Davies et al, 1993
UK 58 47 G Daly et al, 1993
Scottish 52 61 P Strange et al, 1985
Swedish 329 53 G,F Alexandrie et al, 1994
USA 192 42 F Seidegard et al, 1990
USA (Blacks) 180 35 G Bell et al, 1993
USA (Whites) 497 49 G Bell et al, 1993
USA 38 47 G Shields et al, 1993
Table 4.1 Published frequencies of the GSTM1 polymorphism in control
populations. * abbreviations for assay type are G- genetic, F- functional, P- protein.
158
4.4.2 GSTM1 deletion and susceptibility to emphysema and lung cancer in
biopsy and autopsy cases
Deletion of the GSTM1 gene is associated with susceptibility to emphysema
coexistant with lung cancer, but not to cancer with no concomitant emphysema.
Significant differences between the frequency of the polymorphism in the control
group, and all patients with emphysema were obtained. GSTM1 enzyme has a very
broad substrate specificity which includes oxygen derived reactive species, many of
which are present in cigarette smoke (Ketterer et al, 1988). It is therefore perhaps not
surprising that a lack of expression of this enzyme might affect susceptibility to a
disease which results from cigarette smoke exposure. While GSTM1 is
predominantly a liver enzyme, it is known that much cigarette smoke metabolism
and detoxification occurs in the liver and that cigarette smoke related disease states
affect many organs and not just the lungs.
The pathogenesis of centriacinar and panacinar emphysemas is generally thought to
be distinct (Saetta et al, 1994b). Association with GSTM1 deletion might therefore
be expected to occur more strongly with one type of emphysema, hence samples
were analysed according to their pattern of emphysema. No association was found to
occur between GSTM1 deletion and either centriacinar or panacinar emphysema
alone. However, in cases with both patterns of disease, a small association was
demonstrated, indicating that susceptibility to the development of both centriacinar
and panacinar emphysema may result in indviduals with deletion ofGSTM1.
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A link between GSTM1 deletion and susceptibililty to 2 types of emphysema when
present in the same lung sample, but not when present separately, suggests that
GSTM1 deletion has a role in the pathogenesis of both forms of emphysema. Since
all cases studied were ofmild to moderate severity, it may be argued that the level of
damage required to give both centriacinar and panacinar emphysemas together is
greater than that producing moderate or mild centriacinar or panacinar alone.
GSTM1 deletion is likely to have a subtle effect on disease susceptibility, therefore
only with greater amounts of damage would the influence of this polymorphism be
detected.
Since GSTM1 is expressed at high levels in the liver, it was anticipated that the
enzyme polymorphism would have an affect on disease susceptibility in a systemic
manner. Panacinar emphysema is associated with deficiency in the systemic protein
a 1-antiprotease (Guenter et al, 1968), therefore GSTM1 deletion might be expected
to increase susceptibility to this type of emphysema. However, GSTM1 deletion was
not found to be associated with panacinar emphysema alone, but was associated with
the presence of both panacinar and centriacinar emphysemas in the same lung
sample. This implies that GSTM1 is involved in protection against tissue damage at
both the systemic and local level, and therefore that GSTM1 is expressed in both
lung and liver.
The increased relative risk demonstrated for the association between GSTM1
polymorphism and susceptibility to emphysema is relatively small. It is not
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surprising that the increased risk identified is small since GSTM1 is only one of a
cohort of xenobiotic metabolizing enzymes, many of which have overlapping
substrate specificities and may themselves be polymorphic. Although small, the
increased risk demonstrated is likely to account for a significant number of cases of
emphysema, since emphysema is a very common disease.
No association was found between GSTM1 polymorphism and emphysema in
autopsy cases. This result is surprising, particularly since an association was found
between GSTM1 deletion and emphysema in biopsy cases. However, the
emphysema found in autopsy cases is generally more severe than that of biopsy
samples since autopsies are often performed on individuals in whom emphysema has
contributed significantly to cause of death, whereas biopsies are obtained from
individuals fit enough to survive surgery.
GSTM1 is one xenobiotic metabolising enzyme among a cohort of enzymes
affording protection in the lung, therefore the effect of any deficiency is likely to be
marginal, particularly since many other metabolising enzymes have similar substrate
specificities. Furthermore, if the lung tissue is exposed to very great amounts of
xenobiotic insult, the effects of deficiency in a single enzyme are unlikely to be
significant since the xenobiotic metabolising system will be overwhelmed. The
small increased relative risk for moderate to mild emphysema identified in
individuals null for GSTM1 indicates that xenobiotic metabolising enzymes do have
a role in influencing the development of emphysema. Indeed, there are other
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polymorphic xenobiotic metabolising enzymes which are possibly more influential in
increasing susceptibility to emphysema. Recent evidence suggests that the marginal
effect of the GSTM1 polymorphism is not apparent when more serious defects such
as the epoxide hydrolase 'slow' polymorphism are present (Smith CAD, personal
communication). Conceivably, severe emphysema results when several crucial
influencing factors combine to increase susceptibility to injury.
Deletion of the GSTM1 gene was not associated with microscopically assessed
emphysema. However the GSTM1 polymorphism was shown to be associated with
2 different types of macroscopic emphysema where there was concomitant lung
cancer, which suggests that the enzyme may influence disease at an early stage of
damage. Therefore it is perhaps surprising that the GSTM1 polymorphism is not
associated with early emphysema, which is only detectable by microscope. This
contradiction suggests that GSTM1 deletion does not influence very mild disease
since the loss of enzyme function can be compensated for within the protective
system ofmetabolising enzymes. As more damage occurs within the lung, as a result
of increased exposure to toxicity, the loss of this enzyme becomes more influential as
the resources of protective enzymes are stretched. Finally, with very great amounts
of damage, caused by overwhelming levels of toxic insult, deficiency of a single
enzyme has little effect on the disease process. This hypothesis may explain why
GSTM1 deficiency does not influence susceptibility to either very early emphysema,
as assessed microscopically, or to very severe emphysema, such as that seen in
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autopsy cases, but the polymorphism is associated with the mild to moderate
emphysema found in biopsy lung samples.
For this theory to be correct, deficiency of GSTM1 must influence the disease
process in a dose dependant manner. Association between the GSTM1
polymorphism and microscopic emphysema was investigated particlularly because
some cigarette smokers are at an increased risk of developing this type of
emphysema in a manner which is not dependant on their exposure to cigarette smoke
(Gillooly & Lamb, 1993a). If GSTM1 deficiency does influence disease
susceptibility in the dose-dependant manner outlined above it is perhaps not
surprising that this enzyme polymorphism is not associated with microscopic
emphysema.
4.4.3 Lack of association between GSTM1 and lung cancer
Since emphysema is a lung disease which results from exposure to cigarette smoke, it
is often found concomitant with lung cancer. The majority of cases studied
contained both emphysema and lung cancer. There is evidence that GSTM1 deletion
might be involved in increasing susceptibility to lung cancer (Seidegard et al, 1986;
Howie et al, 1990a; Seidegard et al, 1990; Zhong et al, 1991; Hirvonen et al, 1993;
Kihara et al, 1994; Alexandrie et al, 1994). It is therefore possible that an
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association between polymorphism of GSTM1 and emphysema may actually derive
from an underlying association with lung cancer.
However, no significant association could be demonstrated between the GSTM1
polymorphism and susceptibility to lung cancer either in a heterogeneous group of
lung cancer cases, or when the total lung cancer cases genotyped for GSTM1 were
subdivided according to type of disease.
The evidence linking the GSTM1 polymorphism with susceptibility to lung cancer is
confusing. Susceptibility to lung cancer of all types has been reported by several
groups (Seidegard et al, 1986; Howie et al, 1990a;, Seidegard et al, 1990), but other
investigators have failed to demonstrate similar findings (Brockmoller et al, 1993;
Zhong et al, 1991). When GSTM1 deletion has been investigated for conferring
susceptibility to different types of lung cancer the results have again been conflicting.
GSTM1 deletion has been associated with susceptibility to squamous carcinoma of
the lung by several groups (Zhong et al, 1991; Hirvonen et al, 1993; Kihara et al,
1994; Alexandrie et al, 1994). The GSTM1 polymorphism was associated with
susceptibility to adenocarcinoma by Seidegard and colleagues in 1990, but Zhong
and colleagues (1991) found a negative correlation between GSTM1 deletion and
adenocarcinoma. Small cell carcinoma has been linked to the GSTM1
polymorphism by both Kihara and colleagues (1994) and Alexandrie and colleagues
(1994).
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While this evidence does seem to point to a role for GSTM1 deletion in increasing
susceptibility to lung cancer it is not possible with the present information to
understand exactly what role this might be. It is clear that several factors are
involved in moderating the effects of the polymorphism. Differences in racial
expression may explain some of the conflicting results. Polymorphic xenobiotic
metabolising enzyme expression is known to vary between races, and the reports are
derived from different countries although most have investigated Caucasian
populations. Sex differences may also modulate the effects of GSTM1. While the
polymorphism has not been reported to be disproportionately expressed in either
sex, one study demonstrated an association between GSTM1 deletion and squamous
carcinoma in women, but not in men (Alexandrie et al, 1994). Furthermore,
Alexandrie and colleagues found that while there was an association between
GSTM1 polymorphism and small cell carcinoma, this link was significantly related
to the age of the patients studied.
While investigating the GSTM1 polymorphism in a large group of lung cancer
patients was outwith the scope of this thesis, a small group of heterogeneous lung
cancer cases was studied. Forty-six lung cancer samples that contained no evidence
of emphysema were genotyped and analysed in comparison with the control group.
No association was demonstrated to occur between deletion of GSTM1 and lung
cancer. This lack of association with lung cancer suggests that the association
demonstrated for groups of patients with both emphysema and lung cancer may be a
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reflection of effects of the polymorphism on emphysema, and not on concomitant
lung cancer.
An association between the GSTM1 polymorphism and susceptibility to emphysema
has important implications for research into lung cancer susceptibility. Just as it is
possible that an association demonstrated between GSTM1 deletion and emphysema
may reflect an underlying association with lung cancer, the reverse situation is also
possible, where a lack of GSTM1 may be implicated in lung cancer when the
association is merely the result of concomitant emphysema in the samples studied.
This possibility might help explain the disparity in the association of lung cancer and
GSTM1 deletion in the literature.
4.4.4 GSTM1 deletion is not associated with clinically defined COPD
The clinical manifestation of emphysema is chronic obstructive pulmonary disease,
which represents a heterogeneous group of lung diseases that cause obstruction of the
airways and difficulty in breathing. A group of patients attending a chest clinic for
treatment of chronic obstructive pulmonary disease were not found to have any
significant differences in the proportion of GSTM1 deletion when compared to the
control population. This result is perhaps surprising. COPD is a heterogeneous
disease, nevertheless some propensity for developing COPD might be expected to
occur when GSTM1 is absent.
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It is possible that no association between COPD and the GSTM1 polymorphism was
demonstrable because in individuals attending COPD clinics lung tissue destruction
is likely to be extensive, and of much greater severity than that seen in the lungs of
biopsy samples in which an association with GSTM1 has been demonstrated. Biopsy
samples are only obtained from patients who are fit for surgery, therefore the biopsy
cases studied have been selected for a milder level of disease than would generally be
found in a chest clinic. Perhaps in end-stage lung disease so much exposure to toxic
compounds has generated such great amounts of destruction that the singular effects
of one polymorphism cannot be detected.
Another possible explanation for the lack of association between GSTM1 deletion
and COPD is that the relationship between emphysema and COPD as defined by
decreased lung function is not necessarily direct. While increased airspace size in the
parenchyma may reduce elastic recoil thereby affecting lung function, severe
emphysematous lesions are not thought to contribute significantly to the
pressure/volume relationship of the lung nor to a decreased expiration volume of the
lung, because very little change in the volume of severe lesions occurs with lung
deflation (Pare & Hogg, 1995).
The finding of a lack of association between GSTM1 deletion and COPD has also
been demonstrated by Alexandrie and colleagues, who used a group of patients with
chronic obstructive pulmonary disease as a control population (Alexandrie et al,
1994).
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4.4.5 GSTM1 polymorphism and susceptibility to disease
GSTM1 is associated with both emphysema and lung cancer, and to the development
of both centriacinar and panacinar emphysema, which may be two different diseases
with distinct causes (Saetta et al, 1994b). This suggests that an individual lacking
GSTM1 may be more susceptible to lung disease caused by cigarette smoking.
Evidence that GSTM1 is expressed in lung tissue suggests that individuals with the
deletion polymorphism of GSTM1 may have increased susceptibility both at the
local and systemic level, reflecting a lower threshold to any injury involving oxygen
reactive species or GSTM1 substrates, including environmental pollutants, and not
just carcinogenic cigarette smoke components. This is in keeping with the
association between GSTM1 deletion and a wide variety of apparently unrelated
disease states (Strange et al, 1991; Heagerty et al, 1994; Zhong et al, 1991;
Seidegard et al, 1990).
The GSTM1 polymorphism may also affect disease susceptibility by influencing the
expression of other enyzmes in the lung. Recent work by Nakajima and colleagues
(1995) has shown that expression of GSTM1 influences the expression of GSTM3
and possibly GSTM2. Where individuals were found to be null for GSTM1,
significantly lower levels ofGSTM3 were observed compared to levels ofGSTM3 in
individuals with the intact GSTM1 gene. Furthermore, a second GST, which the
investigators ascribed to GSTM2 was only observed in lung samples which
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demonstrated GSTM1 expression. Antilla and colleagues (1995) also showed
reduced expression of GSTM3 in the parenchyma of GSTM1 null individuals who
were current smokers or recent ex-smokers. The expression of GSTM3 was not
affected by GSTM1 genotype in the bronchial epithelium, which suggests that the
genotype and expression of these enyzmes may have further effects on the
differential metabolism of reactive species in the lung. Since GSTM3 has been
shown to have catalytic activity towards electrophiles (Hussey & Hayes, 1993) any
effect on expression of this enzyme as a consequence of the GSTM1 polymorphism
may therefore have a subsequent effect on the levels of reactive species, increasing
susceptibility to disease.
Support for the association of GSTM1 status and disease susceptibility comes from
in vitro studies of leukocytes which demonstrate that cells from GSTMl-null
individuals are more prone to epoxide-induced DNA injury and sister chromatid
exchange (van Poppel et al, 1992; Wiencke et al, 1990). GSTM1 deletion has also
been linked with increased DNA-adduct levels in lung tissue (Shields et al, 1993;
Ketterer et al, 1992; Grinberg-Funes et al, 1994). For this reason the determination
of GSTM1 genotype is important in considering individual susceptibility to
xenobiotic inhalation or cigarette smoke. This is equally relevant to metabolism
occurring in the lung as well as other organs, including the liver where there is high
expression of the enzyme (Faulder et al, 1987).
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4.5 Analysis of the CYP1A1 polymorphism in control and patient populations
4.5.1 Allele frequencies of the CYP1A1 exon 7 polymorphism in the Scottish
population
In the control population the CYP1A1 exon 7 polymorphism was found to be present
in 1% of individuals as homozygotes for the rare valine allele, 12% of controls were
heterozygotes, while 87% of the population were homozygous for the isoleucine
allele ofCYP1A1. These results reflect an allele frequency of 0.93 for the isoleucine
allele and 0.07 for the valine variant ofCYP1A1.
The CYP1A1 allele frequencies in the control population are not significantly
different to those presented by other groups in the literature. While the frequency of
the valine rare allele has been reported in higher numbers in the Japanese (Hayashi et
al, 1992), with a frequency of 0.20, this probably reflects ethnic differences in the
expression of this polymorphism. European studies by Alexandrie and colleagues
(1994) and Hirvonen and colleagues (1992) identified CYP1A1 valine allele
frequencies of 0.03 and 0.05 respectively. A further study investigated the frequency
of the valine variant in Japanese, Hawaiian and Caucasian populations and reported
frequencies of 0.19, 0.07 and 0.00 respectively (Sivaraman et al, 1994). The control
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population numbers studied in the Japanese and European reports were large,
numbering well over 200 individuals in all reports, whereas the study of Sivaraman
and colleagues (1994) used small control groups. The valine allele frequency is
therefore slightly higher in the Scottish population than might have been expected
from other studies of Caucasian populations.
4.5.2 Polymorphism of CYP1A1 and association with emphysema and coexistent
lung cancer
The isoleucine to valine polymorphism of CYP1A1 has been shown to be associated
with macroscopic emphysema. A significant difference was demonstrated to exist
between the control group and patients with emphysema. No association could be
demonstrated between CYP1A1 polymorphism and either centriacinar or panacinar
emphysema alone nor to both patterns of disease together. The group of patients
studied suffered from lung cancer with or without concomitant emphysema.
Association with the CYP1A1 polymorphism did not occur in cases with no evidence
of macroscopic emphysema, nor in the total group of lung cancer patients including
those with and without emphysema. CYP1A1 association only occurred in the
group of cancer cases with concomitant emphysema.
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While no statistically significant association could be demonstrated between a
specific pattern of emphysema and the CYP1A1 polymorphism, a trend towards
increased numbers of heterozygotes for the polymorphism was detected in patients
with centriacinar emphysema singly and in patients with both centriacinar and
panacinar emphysemas together.
The finding that the CYP1A1 polymorphism has an affect on susceptibility to
macroscopic emphysema, with a particular slant towards a propensity for the
development of centriacinar emphysema is not unexpected. McLemore and
colleagues have shown that CYP1A1 is expressed in lung tissue following cigarette
smoke exposure (McLemore et al, 1990). When smoke enters the lungs, it travels
through the airways until it reaches the respiratory bronchioles, where airflow ceases
(Harley, 1988). It is in this region of the lung that most direct damage will occur as a
result of cigarette smoke exposure, since particles contained in the smoke bounce
into the airway walls and are absorbed (Harley, 1988). In this manner, polycyclic
aromatic hydrocarbons contained in cigarette smoke will be absorbed into lung tissue
primarily at the respiratory bronchioles, where they will induce the expression of
CYP1A1. If the CYP1A1 gene induced contains the polymorphic valine allele, the
resulting enzyme will be more efficient at activating polycyclic aromatic
hydrocarbons to reactive intermediates (Hayashi et al, 1991b, quoted in Kawajiri et
al, 1993), which can then contribute to tissue destruction. Thus, the area of the lung
which might be expected to be affected particularly by polymorphism of the
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CYP1A1 gene is the respiratory bronchioles, which is the region of the lung involved
in centriacinar emphysema (Lamb, 1995).
A lack of association between the CYP1A1 polymorpism and panacinar emphysema
alone is also not a surprising result. Panacinar emphysema has been shown to result
in individuals suffering from al-antiprotease deficiency (Laurell & Eriksson, 1963),
indicating that the damage which results in this disease derives from a primarily
systemic source. Since CYP1A1 is expressed locally in lung tissue, and is an
extrahepatic enzyme, cigarette smoke metabolism by the enzyme will occur locally
and would therefore not be likely to have an effect on systemic disease.
The association between CYP1A1 polymorphism and macroscopic emphysema was
obtained only in cases of emphysema with concurrent lung cancer. This finding
implies that any increased susceptibility to lung disease conferred by the CYP1A1
polymorphism is an early event, occurring at a stage before the injury response pathway
leading to cell death and inflammation has diverged from that leading to mutagenesis
and eventual tumour progression. This is in keeping with the likely position of CYP1A1
in the pathway of cigarette smoke metabolism that is, it is proximate to the insult by
nature of its expression in lung parenchyma and its role in phase 1 metabolism.
While polymorphism of CYP1A1 is associated with emphysema and lung cancer the
increased relative risk found is rather small, and is only significant when both diseases
are present. However, emphysema and lung cancer are extremely prevalent diseases
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hence even a slight increase in disease susceptibility conferred by this polymorphism
may account for a large proportion of cases.
The isoleucine to valine polymorphism of CYP1A1 was also found to be associated with
microscopic emphysema, which represents early disease, with a relatively high odds
ratio and confidence intervals. This finding correlates well with both the early role of
CYP1A1 in Phase I metabolism, and the induction of enzyme expression in lung tissue
by cigarette smoke components, and provides good evidence that CYP1A1
polymorphism is involved in the development of early disease resulting from exposure
to cigarette smoke and other toxic xenobiotics. Furthermore, studies by Gillooly &
Lamb (1993c) have shown that there is a population of smokers who have increased
susceptibility to microscopic emphysema which is not dependant on their level of
exposure to cigarette smoke. Conceivably the CYP1A1 polymorphism may account for
this susceptibility since the association between the polymorphism and microscopic
emphysema is very strong (p=0.001).
4.5.3 Polymorphism of CYP1A1 is not associated with lung cancer
Genotyping of CYP1A1 was carried out on a heterogeneous lung cancer patient
group in whom the presence of emphysema had been excluded. This enabled
investigation into whether or not the association found in emphysema cases was due
to a real relationship with emphysema, or was the result of an association with
concomitant lung cancer, which was present in a high proportion of the cases studied.
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No association could be demonstrated between the CYP1A1 polymorphism and
susceptibility to lung cancer.
Previous studies investigating CYP1A1 and lung cancer have provided conflicting
data. Whereas in Japanese populations CYP1A1 conferred a 3-fold risk of lung
cancer (Nakachi et al, 1991; Kawajiri et al, 1993), similar studies of Scandinavian
populations have failed to find any association (Tefre et al, 1991; Hirvonen et al,
1992; Alexandrie et al, 1994).
Confounding factors have recently been shown to be of importance in studies of
association between CYP1A1 polymorphism and lung cancer. Histological type of
tumour has been shown to be significant, with certain types of tumour more likely to
be influenced by CYP1A1 genotype. For example, Nakachi and colleagues (1995)
have shown that in addition to the association between CYP1A1 polymorphism and
lung squamous cell carcinomas which they had previously identified (Nakachi et al,
1991; Nakachi et al, 1993), there is also an association between this enzyme
polymorphism and adenocarcinoma of the lung, but this association is related to
grade of tumour differentiation. Level of cigarette smoke exposure has also been
shown to affect the association between CYP1A1 genotype and lung cancer. Okada
and colleagues (1994), have demonstrated that squamous cell carcinoma is
significantly associated with genotype C of the CYP1A1 Mspl polymorphism,
especially in light smokers (pO.OOl). Lymph node or distant metastasis was also
found to be more frequent in individuals with squamous carcinomas, especially
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among light smokers, with genotype C (p<0.05). Association linked to cigarette
smoke exposure was also demonstrated by Sugimura and colleagues (1995), who
demonstrated that the Ile-Val polymorphism of CYP1A1 was associated with
squamous carcinoma, particularly in light smokers.
Perhaps in using a small, heterogeneous group of lung cancer cases, association may
not have been detected through not analysing confounding factors such as tumour
types, cigarette smoke exposure, age, sex and metastatic frequency in the tumours
studied. However, no study to date has considered the possibility that CYP1A1 may
confer susceptibility not just to lung cancer but also to other forms of lung disease,
such as emphysema, and that association with other diseases might influence or even
explain the conflicting associations seen between CYP1A1 polymorphism and lung
cancer.
4.5.4 Lack of association between CYP1A1 polymorphism and COPD
No association was found to exist between polymorphism of the CYP1A1 gene and
susceptibility to chronic obstructive pulmonary disease. This result is perhaps
surprising since COPD is the clinical manifestation of emphysema, which has been
shown to be associated with CYP1A1 polymorphism. One other study has
investigated the CYP1A1 polymorphism in a group of chronic obstructive pulmonary
disease patients (Alexandrie et al, 1994). No difference in the distribution of
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CYP1A1 alleles was found between COPD patients and healthy controls in this
study.
It is likely that the explanation for a lack of association with COPD, even though an
association has been demonstrated with emphysema, is a consequence primarily of
the increased severity of emphysema in COPD and perhaps also of the heterogeneous
nature of COPD. Clinical cases of chronic obstructive airways disease do not represent
only emphysema, but also include chronic obstructive airways disease secondary to
chronic bronchitis. The cases with both lung cancer and emphysema which were derived
from biopsy samples had mild or moderate emphysema relative to the clinical group
with chronic obstructive airways disease which represented very severe disease.
Perhaps, the CYP1A1 polymorphism contributes little towards susceptibility to severe,
non-neoplastic lung injury. Conceivably, in severe emphysema such great amounts of
exposure to toxins has generated so much damage that the lung defense represented by
xenobiotic metabolising enyzmes is overwhelmed, and polymorphic expression of these
enzymes is of negligible effect.
4.5.5 CYP1A1 polymorphism and susceptibility to disease
The CYP1A1 polymorphism was associated with emphysema and concomitant lung
cancer. Thus polymorphism of CYP1A1 is involved in the mechanisms which result
in both tumorigenesis and the tissue destruction seen in emphysema. This implies
that the polymorphism has a general role in the protection or damage of tissues
against disease.
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A further speculation can be made following the demonstration that the CYP1A1
polymorphism is associated with microscopic emphysema which represents very
early disease, and with mild to moderate emphysema only in the presence of
concomitant lung cancer. This finding suggests that the effect of the polymorphism
manifests at a very early stage of disease progression in the lung following cigarette
smoke exposure. This is perhaps not surprising since CYP1A1 is involved in Phase I
metabolism and therefore represents an early defense mechanism preventing tissue
destruction (Gibson & Skett, 1986). The lack of association between the CYP1A1
polymorphism and COPD, an end-stage lung disease, corroborates this theory.
4.6 Lung cancer and polymorphisms ofGSTM1 and CYP1A1
Previous studies investigating polymorphisms of GSTM1 and CYP1A1 have not
produced consistent evidence to support their involvement in conferring
susceptibility to lung cancer. In the case of GSTM1 deletion, both adenocarcinoma,
squamous cell carcinoma and small cell carcinoma have been implicated as
associated diseases in separate studies (Seidegard et al, 1990; Zhong et al, 1991;
Hirvonen et al, 1993; Alexandrie et al, 1994). Polymorphism of the CYP1A1 gene
has been shown to be associated with susceptibility to lung cancer in Japanese
populations (Nakachi et al, 1991; Kawajiri et al, 1993), however studies on
Caucasians have been unable to verify these findings (Tefre et al, 1991; Hirvonen et
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al, 1992; Alexandrie et al, 1994). Ethnic differences may account for some of the
inconsistencies in the literature, however, they cannot explain the disparity in all
cases. In particular, GSTM1 deletion has been shown to be associated with lung
cancer generally, and specifically with squamous cell carcinoma, adenocarcinoma
and small cell carcinoma but a consistent pattern of disease susceptibility has not yet
been detected. It seems unlikely that ethnic differences are the reason for these
contrasting reports. This study demonstrates that polymorphisms of GSTM1 and
CYP1A1 are involved in susceptibility to emphysema. From the results obtained in
this study, it might be speculated that susceptibility to emphysema conferred by
polymorphic GSTM1 or CYP1A1 has influenced studies of these polymorphisms in
lung cancer. Indeed, there are other polymorphic xenobiotic metabolising enzymes
which may also be regarded as candidates for influencing susceptibility to both lung
cancer and emphysema.
4.7 Polymorphic xenobiotic metabolising enzymes and susceptibility to disease
Association of the GSTM1 and CYP1A1 polymorphisms with different types of
emphysema and cancer suggests that these enzyme polymorphisms have a general
role in influencing disease susceptibility. Furthermore, the association between the
polymorphisms with different types of emphysema and with different diseases
implies that the enzymes have their protective effects at an early stage in the pathway
to tissue damage, scarring and tumorigenesis. The finding that neither the GSTM1
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nor the CYP1A1 polymorphisms were associated with chronic obstructive
pulmonary disease, an end-stage lung disease, provides evidence to substantiate this
hypothesis.
Recently, evidence has been presented which indicates that the polymorphisms of
GSTM1 and CYP1A1 can increase susceptibility to lung cancer in a synergistic
manner (Hayashi et al, 1992). The mechanism behind this synergistic increase in
susceptibility is presumably that with a more highly inducibile CYP1A1 increased
amounts of reactive species will be generated. Where there is a concurrent deletion
in GSTM1, the defence against reactive species provided by Phase II metabolism is
compromised, leading to increased amounts of damage.
If this phenomenon of synergistic effects on disease susceptibility can occur for
polymorphisms of GSTM1 and CYP1A1, it may also result with other
polymorphisms in the system of xenobiotic metabolising enzymes. There is
considerable evidence to support a general role for these enzymes in influencing
susceptibility to cancer, and there have been several reports of xenobiotic
metabolising enzymes being involved in the development of non-neoplastic disease
including pituitary adenoma (Fryer et al, 1993), Parkinson's disease (Smith et al,
1992), and chronic liver hepatitis (Harada et al, 1987).
Furthermore, in the context of emphysema and lung cancer, there are many other
xenobiotic metabolising enzymes which are likely to influence susceptibility to these
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diseases by virtue of their expression in the lung and their substrate specifities.
Polymorphisms of the xenobiotic metabolising system are likely to influence disease
susceptibility through a number of detrimental and beneficial effects mediated by the
interacting network of enzymes.
GSTM1 deletion and the Ile-Val462 and Mspl polymorphisms of CYP1A1 have also
been associated with increased risk for mutation in the tumour suppressor gene p53
(Ryberg et al, 1994; Kawajiri et al, 1996). Thus polymorphisms of xenobiotic
metabolising enzymes influence disease susceptibility not only through the network
of metabolising enzymes but may affect disease processes through their effects on
other genes.
The effect of xenobiotic metabolising enzyme polymorphisms on disease
susceptibility will be influenced by other mechanisms of disease development. These
other mechanisms may be more important than xenobiotic metabolising enzyme
polymorphisms in determining the likelihood of cigarette smoke injury resulting in
predominantly genotoxic or cytotoxic injury. Thus certain protective mechanisms such
as other enzymes of the glutathione dependant system, epoxide hydrolase, and
differences in proteolytic enzymes or antiproteases may reduce the likelihood of cell
damage caused by lipid or protein peroxidation leading to emphysema. Conversely,
differences in DNA repair and other genes involved in recognising and eliminating
DNA damage may be very important in determining whether or not tumorigenesis can
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occur. These mechanisms are likely to differ between individuals and consistent with
this is the presence of known polymorphisms/ mutations, for example in the p53 gene
and in the DNA mismatch repair system (Service, 1994; Papadopoulos et al, 1994;
Marx, 1993). These polymorphisms or mutations may contribute to interindividual
differences in the capacity to eliminate DNA damage and therefore prevent mutations
leading to tumourigenesis.
Only in cases with no bias towards, or away from, non-neoplastic or neoplastic lung
disease would polymorphism of GSTM1 or CYP1A1 be expected to have a detectable
effect on the susceptibility to disease rather than simply a more subtle underlying
modification of mechanisms and responses to injury.
4.8 Genetic susceptbility to Emphysema
This is the first time that investigation into susceptibility to emphysema has focused
on a genetic basis for the disease, other than the well-characterised susceptibility
which is governed by deficiency in al-antiprotease. Polymorphism in both the
GSTM1 and CYP1A1 genes have been shown to be associated with emphysema, and
this evidence opens up the way for further research into whether other polymorphic
xenobiotic metabolising enzymes might have a similar role in increasing the risk of
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an individual to develop emphysema. Within the system of xenobiotic metabolising
enzymes, there are many known polymorphisms, some of which have been
characterized at the genetic level, and some of which have been identified through
pharmacogenetic variance (Gibson & Skett, 1986). Since many of these polymorphic
enzymes will have substrate specificities which include components of cigarette
smoke, this field of study represents an ideal opportunity for further research.
Of particular interest might be the enzyme epoxide hydrolase, which is known to be
involved in benzo[a]pyrene metabolism (Gibson & Skett, 1986), and is polymorphic
(Hassett et al, 1994). The cytochromes P450 2F1, 2D6, and 3A4 might conceivably
have roles in increasing susceptibility to emphysema. CYP2F1 is thought to be
polymorphic, it is expressed in lung tissue, and it metabolises cigarette smoke
components (Nhambuto et al, 1989). CYP3A4 is expressed in lung and liver tissue,
and expression in the liver has been shown to be highly variable (McManus et al,
1990; Shimada et al, 1989). Furthermore, CYP3A4 substrates include compounds
present in cigarette smoke. CYP2D6 is polymorphic, and the polymorphism has
been associated with increased susceptibility to breast, bladder, and lung cancer,
leukaemia and Parkinson's disease. However, the association between CYP2D6 and
susceptibility to breast, lung, and bladder cancer has not been categorically proven
since genotype studies do not affirm the original association identified with
phenotyping assays (Smith, 1994).
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4.9 Identification of a novel CYP1A1 variant
While sequencing a sample which had previously been identified as homozygous for
the valine allele of the CYP1A1 gene, it was discovered that the sample did not in
fact have the valine allele but had an isoleucine at amino acid residue 462, and was
subject to a different polymorphism. This novel CYP1A1 sequence contains an
asparagine residue instead of a threonine at amino acid position 461 of the CYP1A1
gene. Hayashi and colleagues demonstrated that the isoleucine to valine substitution
had an affect on the ability of the enzyme to activate polycyclic aromatic
hydrocarbons in yeast (1991b, quoted in Kawajiri et al, 1993). From this finding,
Kawajiri and colleagues speculated that the effect of the mutation might result from
disruption of a haem-binding thiolate ligand, a cysteine residue present 5 residues
upstream of the site of the mutation. Since the novel threonine to asparagine
substitution identified in this study is even closer to the crucial cysteine residue
which is required for haem-binding of CYP1A1, it is possible that this
polymorphism also affects enzyme function, and may even be more disruptive of
function than the previously described isoleucine to valine substitution.
Previous studies concerning the CYP1A1 polymorphism have utilised 2 PCR
strategies to detect the polymorphism. Most investigators have used the allele
specific PCR described by Hayashi and colleagues (1991a). This method employs
PCR primers specific for either of the 2 possible alleles resulting from the
isoleucine/valine polymorphism along with an upstream primer which will amplify
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either of the polymorphic variants. Genotype is determined by 2 separate PCRs
using each of the specific primers with the common upstream primer. The PCR
strategy employed by Hayashi and colleagues, and other researchers who
subsequently used this method, would not have detected the novel polymorphism of
CYP1A1 described here. The allele specific primers designed by Hayashi and
colleagues do not cover the site of the threonine to asparagine substitution, hence
either of these alleles would be amplified using this technique.
The other strategy used to detect the CYP1A1 Ile/Val polymorphism is similar to the
method described in this thesis, which has also coincidentally been used by Shields
and and colleagues (1993). This strategy engineers a downstream primer to create
an Ncol restriction enzyme site in the lie462 variant of the gene, which is destroyed in
the Val462 variant. While this strategy does detect the threonine to asparagine
polymorphism, since this base change also results in destruction of the Ncol site, this
polymorphism can only be distinguished from the substitution causing the Ile/Val
polymorphism by cloning and sequencing the PCR products.
The study by Shields and colleagues (1993) using a similar PCR strategy to identify
the Ile-Val polymorphism was only used to genotype 38 individuals. Of these 38, 32
were homozygous for the lie462 allele, 2 were heterozygotes, and 4 had only the
Val462 allele of CYP1A1. While the number of individuals found to be homozyous
for the valine allele does seem higher than might be expected for a Caucasian
population, the number of individuals genotyped is perhaps too small to allow
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specultation that the higher frequencies obtained by Shields and colleagues can be
ascribed to the novel Thr-Asn polymorphism.
Only sequencing cloned DNA from an individual with the asparagine variant of the
CYP1A1 gene would detect this novel polymorphism. Hayashi and colleagues did
sequence genomic DNA from individuals of each genotype for the lle/Val
polymorphism (1991a), but none of the investigators who have subsequently studied
this polymorphism present sequencing evidence to validate their PCR results. In the
original publication of the CYP1A1 cDNA gene sequence, sequencing of each gene
fragment was carried out for both strands at least once, and commonly the fragments
were sequenced between 5 and 20 times (Jaiswal et al, 1985). Therefore, it is
possible that the CYP1A1 polymorphism identified in this thesis has not been
previously detected because the gene has only been sequenced in this region a limited
number of times.
To provide some preliminary information on the frequency of this novel variant of
the CYP1A1 gene in the population, the genotype of 27 indidviduals was ascertained
by using a novel PCR and restriction enzyme assay which allowed detection of the
asparagine variant. Of these 27, 26 had previously been genotyped as heterozygotes,
and of these, 14 were found to have the asparagine polymorphism while 12 were
found to be heterozygotes for the isoleucine/valine polymorphism. The other
individual genotyped had previously been shown to be a homozygote for the Val462
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variant, however, restriction enzyme analysis indicated that this person was actually
homozygous for the asparagine polymorphism of CYP1A1.
This data is preliminary, but it does imply that the threonine to asparagine
polymorphism of CYP1A1 is common in the Scottish population, and may even be
more common than the Val462 variant of CYP1A1 previously characterised.
However since only 27 individuals have been genotyped, the frequency of the
polymorphism requires confirmation. The high frequency of the novel
polymorphism in this subset of the control group has implications for the disease
association demonstrated in this thesis, however it is difficult with the limited
information available to predict whether or not this polymorphism will effect enzyme
function and disease susceptibility. Certainly the increased level of exon7
polymorphism in the general population demonstrated in this thesis as compared to
other studies is likely to be a reflection of detection of the novel polymorphism as
well as the lie-Val462 polymorphism. Whether or not the increased frequency of exon
7 polymorphism in individuals with emphysema and concomitant lung cancer is the
result of disproportionately high Ile-Val462 or Thr-Asn461 variants remains to be
shown.
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4.10 Opportunities for further research
As well as demonstrating a role for xenobiotic metabolising enzymes in modifying
susceptibility to emphysema, the work presented in this thesis has identified several
other aspects of emphysema and xenobiotic metabolising enzymes which merit
further study.
4.10.1 The novel CYP1A1 polymorphism
A novel variant of the CYP1A1 gene has been identified. This polymorphism results
in amino acid replacement close to the cysteine residue which is critical for haem-
binding of the CYP1A1 protein, and may therefore influence the function of the
protein. The previously characterised isoleucine to valine substitution in the same
region of the CYP1A1 gene has been shown to result in increased activity of the
protein (Hayashi et al, 1991b, quoted in Kawajiri, et al, 1993), therefore this novel
variant may have a similar effect on protein activity.
Detection of a novel polymorphism of the CYP1A1 gene creates a number of
exciting avenues for future research. A PCR assay has been developed which can
detect the C to A polymorphism which causes the threonine to asparagine
substitution. With this assay, 15/27 individuals from the control group were found to
have the Thr-Asn461 variant of CYP1A1. Fourteen of these individuals were
heterozygous, and had an isoleucine allele at amino acid position 462, and one
individual was found to be homozygous for Thr-Asn461. Confirmation of the
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frequency of this novel sequence in the general population must be carried out.
Conceivably this polymorphism may be race specific in a similar manner to the
polymorphism of CYP1A1 found in African-Americans (Crofts et al, 1993). If the
novel sequence is found to be present in the general population at a significant level,
the effect of this polymorphism on disease susceptibility could then be investigated.
Furthermore, the effect of the novel sequence on the activity of the enzyme could be
studied in a similar manner to that employed by Hayashi and colleagues (1991b).
4.10.2 GSTM1 and CYP1A1 polymorphisms and disease susceptibility
While polymorphisms of GSTM1 and CYP1A1 have been shown to influence
susceptibility to emphysema, these results require verification. Furthermore, the
results obtained have identified associations and trends between the gene
polymorphisms and susceptibility to specific patterns of emphysema, namely
panacinar and centriacinar emphysema. The aetiology of these 2 patterns of
emphysema is thought to be distinct (Saetta et al, 1994b), but the mechanism by
which the aetiology might differ is unknown. This study therefore presents
important evidence which may help elucidate the different mechanisms involved in
the development of the patterns of emphysema. Association between the GSTM1
polymorphism and lung cancer was not identified in this study. Similarly, the
CYP1A1 polymorphism was not associated with lung cancer alone, but was found to
increase susceptibility to emphysema in the presence of lung cancer. Previous
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reports of the association between both the CYP1A1 and GSTM1 gene
polymorphisms and increased risk for lung cancer have been contradictory. Further
research into the role of these enzymes in the development of lung cancer, and in
particular, to the specific types of cancer, is required.
In summary, further work on the GSTM1 and CYP1A1 polymorphisms, and on other
xenobiotic metabolising enzymes may provide important information which can be
used to elucidate the role of the xenobiotic metabolising system of enzymes in
influencing the aetiology of disease.
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Background - Glutathione S-transferases
(GSTs) are involved in the detoxification
of xenobiotics by conjugation with glu¬
tathione. One of the mu class genes of
this superfamily of enzymes, GSTM1, is
polymorphic because of a partial gene de¬
letion. This results in a failure to express
GSTM1 in approximately 50% of in¬
dividuals. Several studies have linked
GSTM1 null status to an increased risk of
lung carcinoma. This study investigated
the expression and distribution of GST
isoenzymes in human lung, and developed
a polymerase chain reaction (PCR) assay
which would allow genotyping of archival,
paraffin embedded lung tissue.
Methods - Distribution was examined
using a panel of polyclonal anti-GST
antibodies for immunohistochemistry in
normal tissue of 21 tumour-bearing lungs.
DNA for PCR was extracted from paraffin
blocks and a control group of 350 blood
lysates. As a positive control each assay
amplified part ofGSTM4, a mu class gene
which is not polymorphic but which shows
strong sequence homology to GSTM1. The
presence ofGST in bronchoalveolar lavage
fluid was sought by Western analysis.
Results - Proximal airways contained pi
class GST, alpha class GST, and mu class
GST with expression concentrated in the
brush border. In distal airspaces no alpha
GST was expressed but pi GST and mu
GST were present in alveolar cells and also
alveolar macrophages. Pi class GST was
present in bronchoalveolar lavage fluid.
The PCR assay enabled genotypic de¬
termination using DNA extracted from
archival material. Of the control group
56% were null at the GSTM1 locus.
Conclusions - The distribution ofGST iso¬
enzymes in the lung is heterogeneous with
an apparent decrease in GST in distal lung.
Since GSTM1 status has already been as¬
sociated with susceptibility to disease, the
PCR assay developed will allow further
studies of the relation between genotype
and structural disorders in the lung using
archival pathological material.
(Thorax 1994;49:1010-1014)
Glutathione S-transferases (GSTs) are a
superfamily of enzymes involved in the
conjugation of a wide range of electrophilic
substrates with glutathione, thereby facilitating
detoxification and further metabolism and ex¬
cretion. Regulation of GST expression is com¬
plex: it has tissue specificity in terms of dis¬
tribution and it may be induced by xenobiotics,
including carcinogens such as aromatic hy¬
drocarbons and benzo(a)pyrene, which are
present in cigarette smoke.1 At least five differ¬
ent families exist, four cytosolic (GST P, A,
M, and T) and at least one microsomal GST.2
GSTP and M are both involved in the de¬
toxification of 7,8-dihydroxy-9,10-oxy-7,8,9,
10-tetrahydrobenzo(a)pyrene, an active cyto¬
chrome P450-derived metabolite of benzo-
(a)pyrene.3 Although GST catalytic activity
is much higher in liver, lung GST is probably
of importance in the primary metabolism of
many inhaled xenobiotics present in cigarette
smoke or the atmosphere. Furthermore, GSTs
can be induced in mouse lung by phenolic
antioxidants such as butylated hydroxyanisole.4
GSTM contains at least five distinct genes.5
Owing to a polymorphism of human GSTM1,
which comprises a deletion of part of exons 4
and 5 of the gene, about half of the population
fail to express this isoenzyme.6 Several studies
have shown that individuals who fail to express
GSTM1 are more susceptible to pituitary
adenoma and to developing adenocarcinoma
of colon and lung.7"12 This indicates that
individuals with a GSTM1 nulled genotype/
phenotype have less protection against chem¬
ical stress.
In addition to xenobiotic metabolism, some
human GSTs have significant selenium-
independent glutathione peroxidase activity,1
and they are also implicated in non-substrate
covalent binding of some carcinogens." The
conjugation of leukotriene A4 with glutathione
to produce the cysteinyl leukotrienes C4, D4,
and E4 is a GST-dependent reaction.14 Since
leukotrienes are intimately involved in lung
injury and inflammation, variation of GST ex¬
pression between individuals may have sig¬
nificant effects on the extent of lung injury.
Several studies of GST distribution in rats"
or mice4 have been published but there are few
reports on the distribution of GST isoenzymes
in adult human lung.16 18 In this paper we
describe the distribution of GST isoenzymes in
human lung tissue and bronchoalveolar lavage
fluid, and describe a polymerase chain reaction
assay for determining the GSTM1 genotype
using DNA derived from formalin fixed
archival biopsy and autopsy material.
Methods
LUNG TISSUE
Twenty one lungs or lobes of lungs obtained
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at pneumonectomy were studied. These lungs
had been removed because of small peripheral
tumours which proved to be lung carcinomas.
For histological preparation lungs were fixed
inflated with buffered formalin for 24 hours
before selection of blocks from macroscopically
normal lung. All but two of the patients from
whom tissue was taken were known cigarette
smokers. These blocks were then processed to
paraffin wax and sectioned at 2 pm for immuno-
histochemical study.
IMMUNOHISTOCHEMISTRY
Polyclonal rabbit antisera to human GST were
donated by Dr J D Hayes and have been de¬
scribed elsewhere.19 Anti-GSTP was raised
against purified human lung GSTP and the
other antisera were raised against human liver
preparations. This antibody reacted only with
GSTP in liver and lung Western blots, and
cross reacted with no other GST isoenzyme.
Anti-GSTM was raised against liver GSTM
which is the product of the GSTM1 gene.
However, since GSTM4 has greater than 90%
sequence homologywithGSTM 1,15 it is possible
that the polyclonal antibody could react with
the product of both genes. The immuno-
staining protocol was as described previously19
using avidin-peroxidase and 3,3-diamino-
benzidine detection. The only addition was
preincubation of sections with 50% pooled
normal human serum in Tris-buffered saline
(TBS). This preincubation resulted in sig¬
nificant reduction of background staining in
controls using normal rabbit serum instead of
polyclonal antibody. Antisera were used at a
dilution of 1:200 in TBS containing 5% normal
swine serum. Sections were assessed by two
independent observers who then discussed the
results at a twin headed microscope.
WESTERN BLOT ANALYSIS OF BRONCHOALVEOLAR
LAVAGE FLUID
Four bronchoalveolar lavage fluid samples were
obtained from healthy volunteers. These were
not obviously blood stained. Following cen-
trifugation to remove cellular debris, 10 ml
aliquots were taken and placed in separate
lengths of 14 mm Viskose dialysis tubing (Medi-
cell International Ltd, London, UK). Protein
was concentrated by dialysis against glycol
methacrylate (BDH Chemicals, Poole, Dorset,
UK) overnight at 4°C to give a final sample
volume of 200 pi. An aliquot of this con¬
centrate was tested for the presence of haem¬
oglobin using proprietary Dipstix to ensure
that GST detected was not simply the result
of leakage from red blood cells. The protein
extract was mixed with an equal volume of
sample buffer (3-6 ml distilled water, 1 ml0-5M
Tns-HCl pH 6-8, 10% w/v SDS, 0 8 ml 1M
dithiothreitol, 0 8 ml glycerol, and 0 05 ml
0 05% w/v bromophenol blue) and boiled for
five minutes before loading on a 7-5% poly-
acrylamide gel. Purified GSTP (Sigma, UK)
and liver cytosol were included as controls
for antibody specificity. Protein was trans¬
ferred to nitrocellulose and probed with GSTP
antibody. Detection was by enhanced chemi-
luminescence (Amersham, UK).
POLYMERASE CHAIN REACTION (PCR)
Preparation of DNA
DNA was extracted from paraffin blocks,
mounted tissue sections and peripheral blood
using a modification of published tech¬
niques.2021 Sections were cut at 10 pm from
blocks or scraped from slides and placed in an
Eppendorf tube. To this was added 400 pi
buffer A (50 mM KC1, 2-5 mM MgCl,, 20 mM
Tns-HCl (pH 8 0), 0-45% Nonidet P-40,
0-45% Tween-20) containing 200 mg/ml pro¬
teinase K. The sections were then incubated
for two hours at 55°C before boiling for 20
minutes and storing at 4°C. In PCR reactions
15 pi of this crude solution was used as tem¬
plate DNA. Control blood samples were col¬
lected from a randomly selected, anonymous
white population (n = 350) at a routine blood
donor clinic.
PCR assay
The PCR buffer was a standard mix of nuc¬
leotides and contained 3% DMSO. The
amplification was achieved by adding five units
of Taq polymerase (Promega, UK) in a hot
start, and undergoing 35 amplifications of 59°C
for 30 seconds, 72°C for 90 seconds, and 94°C
for 30 seconds. Amplified DNA was elec-
trophoresed in 3% agarose gels. DNA was
visualised by ethidium bromide staining and
examined under ultraviolet irradiation.
Primers
The primer strategy used a modification of that
used by Zhong et aP and Shea et al22 (fig 1).
This method allowed the amplification of both
GSTM1 and GSTM4 and hence provided a
positive control for each reaction since
GSTM4, which is not polymorphic,5 was al¬
ways amplified. This was particularly important
as DNA extracted from archival paraffin blocks
may be of poor yield. A loss of GSTM1 iden¬
tified in this way could therefore be dis¬
tinguished from a failed PCR reaction.
The following oligonucleotide primers were












Primers: 22y 23y 24y
Figure 1 Schematic structure of the GSTM I gene. The
upstream primer (22y) is situated in exon 4, tuhereas both
downstream primers (23y and 24y) are located in exon 5.
Both 22y and 23y anneal to GSTM4 in addition to
GSTM 1 and thus serve as a positive control for the PGR
assay. Primer 24y is specific to GSTM I.
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Figure 2 (a) GSTP in bronchial epithelial cells (big arrozohead), serous cells (small arrowhead), and chondrocytes
(bottom right side of photomicrograph). (b) Alveolar macrophages in the lumen and lining cells, particularly type II
alveolar cells (arrowheads), stained strongly for GSTP. (c) GSTA presence limited to airway epithelium (arrowhead);
alveoli and macrophages not stained, (d) GSTM present in bronchial epithelium (arroivhead) including the brush border,
(e) Heterogeneous staining of alveolar macrophages for GSTM (small arrowhead) and weak staining of alveoli (big
arrowhead) which was more intense than a negative control sample. (J) Negative control showing no significant reaction
product. All that is visible is nuclei counterstained with haematoxylin. There is no immunoreactivity.
The primers 22y and 23y, when used together
in a PCR reaction, amplify a DNA fragment
of 202 bp in length, while the use of 22y and
24y together results in the amplification of a
fragment 275 bp long.
Results
LOCALISATION OF GST ISOENZYMES IN LUNG
TISSUE
There was complete agreement between the
two observers on the pattern of distribution of
GSTs in the lung samples. No formal attempt
was made to quantify the amount of GST
present, but cases were scored as positive when
the staining intensity was greater than a control
slide for which non-immune rabbit serum was
substituted for primary antiserum (fig 2f).
GSTP
GSTP was present in every lung examined.
Bronchial epithelial cells were strongly positive
with reactivity noted in cytoplasm, brush bor¬
der, and most nuclei. Muscle, nerve, serous
glands, and chondrocytes were also positive
(fig 2a). Terminal bronchioles and both type
1 and type 2 pneumocytes contained GSPP.
Endothelial cells were not stained. Alveolar
macrophages were variably positive (fig 2b).
No differences were noted between smokers
and the two tissue samples from non-smokers.
GSTA
There was GSTA present in the cytoplasm,
some nuclei, and brush border of most, but
not all, bronchial epithelial cells. Some chon¬
drocytes stained but alveolar lining cells
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and macrophages were consistently negative
(fig 2c).
samples extracted from blood samples showed





The staining intensity for GSTM was less than
for other isoenzymes. Only two cases of the 21
studied showed strong staining for GSTM,
seven were weakly stained, and the remainder
were negative. The pattern of distribution was
the same as for GSTP, however - that is,
bronchial epithelium, types 1 and 2 alveolar
cells, and macrophages (figs 2d and 2e).
LOCALISATION OF GST ISOENZYMES IN
BRONCHOALVEOLAR LAVAGE FLUID
All four samples showed reactivity with GSTP
antibody, although in two cases GSTP ap¬
peared to be partly degraded (fig 3). In three
cases no evidence was found to indicate that
haem was present. In one sample there was
trace positivity by testing with Dipstix.
POLYMERASE CHAIN REACTION ANALYSIS
PCR analysis resulted in specific fragments
which were easily interpreted when visualised
on agarose gels as described (fig 4). Of 16
DNA samples extracted from archival lung
tissue nine were null at the GSTM1 locus.
There was no correlation demonstrable be¬
tween GSTM1 genotype and immuno-
phenotype. Analysis of 350 random DNA
30 kD
21 kD
re 3 Western blot analysis of bronchoalveolar lavage fluid probed with antibody
nst GSTP. In lanes 1 and 2 lower molecular weight bands reacting with antibody can
en, consistent with degradation of protein. This pattern is not seen with the positive
vl sample of purified GSTP.
275 bp
202 bp
e 4 Examination of DNA amplified by polymerase chain reaction from blood
s and paraffin embedded tissue clearly identified the null GSTM I homozygous
epe (lanes 2 and 5) as opposed to the presence of the intact wild type allele (lanes I,
ind 6). In each lane the constant lower molecular weight fragment represents control
fication of GSTM4.
Discussion
Our findings suggest that GST mediated pro¬
tection against xenobiotic and oxidative stress
in the lung can be divided into two functional
compartments. In proximal airways all three
cytosolic forms (GST P, A, and M) were pre¬
sent in lining epithelium, whereas the distal
alveolar compartment contained GSTP and
GSTM but no GSTA in both type 1 and 2
pneumocytes as well as macrophages. This is
consistent with biochemical studies which
showed that GSTP is the predominant lung
isoenzyme.2324 In a previous study of GST in
human lung development all isoenzymes were
identified, with GSTP being the predominant
isoenzyme. The levels of GSTP were higher
during fetal development, with strong reactivity
in bronchi and protoalveoli, and fell during
late gestation.25 In another study of only three
human lungs16 GSTP, GSTA, and GSTM were
all reportedly present in alveoli. This is in¬
consistent with the work of Fryer and col¬
leagues in fetal lung1' and with our own study.
The discrepancy may be because an im¬
munofluorescence assay was used in the study
of Awasthi et aV6 which is more sensitive but
also produces higher backgrounds. When we
omitted the preincubation of sections with a
blocking buffer containing 50% human serum
we also obtained diffuse alveolar staining with
all antibodies. Our findings are in broad agree¬
ment with the distribution of GST enzymes
reported by Antilla and colleagues.18
In previous studies of localisation of GST
in mouse and rat lungs415 cellular GST was
restricted to bronchial epithelial cells, including
the brush border, with virtually no GST iden¬
tifiable in alveoli. In addition, GSTP in rat lung
was also identified as an extracellular protein in
association with elastin." This was apparent in
electron but not light microscopic preparations.
We found no evidence for extracellular, in¬
terstitial GST but we have suggested that
GSTP is present in bronchoalveolar lavage
fluid. Another possibility for the presence of
GSTP in bronchoalveolar lavage fluid is by
leakage from red blood cells. However, three
of the samples were negative for haem when
tested and the fourth showed a trace of haem.
This may indicate the presence of blood con¬
tamination, but another possibility is that haem
present in cytochromes P450 was detected.
Cytochromes P450 are thought to be a normal
constituent of the epithelial lining fluid in the
lung (R Richards, personal communication).
Furthermore, our findings are consistent with
a previous study in which both GSTA and
GSTP were found in bronchoalveolar lavage
fluid of tumour-bearing lungs.26
Cigarette smoke contains a plethora of chem¬
icals, many ofwhich are electrophilic or become
electrophiles after metabolism principally by
cytochrome P450 enzymes. These compounds
serve as substrates for GSTP, GSTA, and
GSTM. Proximal airways contained GSTA
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which is involved in selenium-independent glu¬
tathione peroxidation reactions, and which may
detoxify DNA and lipid hydroperoxides.' Its
presence in the brush border is therefore sug¬
gestive of a role for GSTA in the protection
of bronchial epithelium. Most acute damage
following cigarette smoke inhalation is seen in
small distal airways and alveoli,2' a site lacking
this selenium-independent peroxidase pro¬
tection. In individuals null at the GSTM1 locus
it therefore follows that the level ofprotection in
distal airways afforded by GSTs is significantly
reduced. Several reports have suggested that
the expression of GSTM in lung shows evid¬
ence of polymorphism which is consistent with
the gene expressed being GSTM1 rather than
GSTM4.1723 In one study of 10 lungs, however,
no evidence of polymorphic expression was
seen although the level of GSTM catalytic
activity was markedly variable between
cases.24 In this present study we cannot con¬
firm that the immunohistochemical expression
seen was specifically the polymorphic enzyme
GSTM1 rather than the non-polymorphic
GSTM4. Further studies are in progress to
address this problem by analysis of mRNA.
Support for the association ofGSTM1 status
and disease susceptibility comes from in vitro
studies of leucocytes which showed that cells
from GSTM 1 null individuals were more prone
to epoxide-induced DNA injury and sister
chromatid exchange.28 For this reason the
determination of GSTM1 genotype is im¬
portant in considering individual susceptibility
to xenobiotics by inhalation of cigarette smoke.
This is equally relevant to metabolism oc¬
curring in the lung, as well as other organs
including the liver where there is high ex¬
pression of the enzyme.29
The presence of GSTP in alveolar macro¬
phages and bronchoalveolar lavage fluid is in¬
teresting. GSTP functions as a homodimer and
it can be readily inactivated by oxidation of
reduced sulphydryl groups.13 It may therefore
function as a "sacrificial reactive protein" in
addition to being a GST-dependent enzyme.
Indirect support for this suggestion is provided
from a study where cigarette smoke reduced
GSTP activity in alveolar macrophages,29 des¬
pite the fact that cigarette smoke contains many
chemicals which might increase GSTP ex¬
pression. In these cells GSTP activity may have
been reduced by oxidative degradation rather
than by reduced expression of the protein.
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Association between the CYP1A1 gene
polymorphism and susceptibility to emphysema
and lung cancer
A M Cantlay, D Lamb, M Gillooly, J Norrman, D Morrison, CAD Smith,
D J Harrison
Abstract
Aim—To investigate cytochrome P4501A1
(CYP1A1) polymorphism and suscept¬
ibility to emphysema and lung cancer.
Methods—A novel polymerase chain re¬
action (PCR) for genotyping the CYP1A1
polymorphism, corresponding to putative
low or high enzyme activity, was developed
to genotype lung cancer resection samples
which had been assessed macroscopically
for the presence of centriacinar and pan-
acinar emphysema. Samples were col¬
lected and genotyped from a group of
patients with chronic obstructive airways
disease. A control group of anonymous
blood donations was genotyped to de¬
termine the basal levels of the poly¬
morphism in the Scottish population.
Results—The high activity allele of the
CYP1A1 gene is associated with sus¬
ceptibility to centriacinar emphysema
and lung cancer but not panacinar em¬
physema. CYP1A1 polymorphism is not
linked to lung cancer in the absence of
emphysema, nor to chronic obstructive
airways disease which is the clinical mani¬
festation of emphysema, particularly of
the panacinar type.
Conclusions—Susceptibility to emphy¬
sema and lung cancer is associated with
polymorphism of the P4501A1 gene. A
trend towards damage ofcentriacinar pat¬
tern has been detected, which supports
the theory that centriacinar emphysema
results from local, direct damage to the
respiratory bronchioles from exposure to
cigarette smoke.
(J Clin Pathol: Mol Pathol 1995;48:M210-M214)
Keywords: CYP1A1 polymorphism, emphysema, lung
cancer, cigarette smoke.
A single inhalation of cigarette smoke contains
approximately 1016 reactive species,1 which are
both cytotoxic and genotoxic. Lung tissue dam¬
age occurs through reactive species' destruction
of cell membranes and structural components.1
Procarcinogens and oxidants cause DNA mut¬
ations,3 which may lead to cancer initiation.4
Cigarette smoke can stimulate macrophages
to release chemotactic factors which recruit
inflammatory cells36 and nicotine has been
shown to be chemotactic.' These cells release
proteases, particularly elastase, during their in¬
flammatory response.3 In rats emphysema has
been induced by administration of elastase to
the lungs.' Antiproteases protect the structure
of the lung from destruction by proteases such
as elastase and collagenase.8 Oxidants present
in cigarette smoke inhibit the action of anti¬
proteases, further reducing the protective cap¬
acity of the lungs.10 Cigarette smoke causes at
least two diseases ofmajor clinical importance,
lung cancer and emphysema.
The lungs are protected from the toxic
effects of cigarette smoke by antiproteases,
antioxidants and xenobiotic metabolising en¬
zymes.1 In the lung both cancer and em¬
physema induced by cigarette smoke may result
from variation in the protective capacity of
lung tissue. Xenobiotic metabolising enzymes
metabolise exogenous compounds, which may
be toxic, to forms which are more easily ex¬
creted in the urine or bile.11 This metabolism
may be an important primary defense against
lung injury resulting from exposure to cigarette
smoke. Variation in interindiviaual expression
of metabolising enzymes may result in the
differential ability of tissues to protect against
disease.
Several of the major xenobiotic metabolising
enzymes are polymorphic at the genetic level.
These include cytochrome P4502D6,12 gluta¬
thione S-transferase Ml13 and N-acetyl trans¬
ferase.14 Association between some of these
enzyme polymorphisms and cancer suscept¬
ibility has been demonstrated1'—for example,
both cytochrome P4502D6 and glutathione
S-transferase Ml polymorphisms have been
associated with susceptibility to lung cancer,
and the N-acetyl transferase 2 gene poly¬
morphism has been implicated in bladder and
colon cancers.
Cytochrome P4501A1 is a phase I meta¬
bolising enzyme which may activate pro-
carcinogens and xenobiotics to their full
carcinogenic and electrophilic forms.16 Ex¬
pression of this enzyme is primarily extra-
hepatic17 and is widespread in the lung.
CYP1A1 expression is inducible by polycyclic
aromatic hydrocarbons such as benzo[a]pyrene
and 3-methylcholanthrene,1920 which form a
major component of cigarette smoke.21 A point
mutation in exon 7 of the CYP1A1 gene results
in an amino acid substitution from an isoleucine
to a valine.22 This mutation occurs in the region
of the gene which encodes the heme binding
motif of the protein, and studies of benzo-
[ajpyrene metabolism have shown that the
valine protein demonstrates almost twice the
enzyme activity of the isoleucine protein.16 This
polymorphism is linked to a Mspl restriction
enzyme fragment length polymorphism in the
V region of the gene,22 which is associated
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GT ATC GGT GAG AI2C ATT GKC CGC TGG GAG GTC TTT 3'
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Downstream primer 3' AC CGG GCG ACC CTC CAG AAA 5'
hematic diagram of the CYP1A1 gene. Sequences of the two alleles of the
le are shown, along with the downstream primer, which introduces a base
i amplimer. Following PCR, the base mismatch introduced into the amplimer
oI site (box) in the Isoleucine allele only, the site is absent in the Valine
with susceptibility to lung cancer in studies
of Japanese populations.2324 Studies of white
populations have been unable to demonstrate
similar associations, which may be a reflection
of the lower prevalence of these polymorphisms
in whites.2526 Much larger study groups are
required to investigate the polymorphism in
the latter to generate sufficient numbers of rare
alleles to permit statistical analysis of disease
association.
To investigate involvement of the cyto¬
chrome P4501A1 gene polymorphism in sus¬
ceptibility to lung disease, we collected lung
samples which were resected for carcinoma.
We also obtained blood samples from patients
with chronic obstructive airways disease.
Chronic obstructive airways disease is believed
to be the clinical manifestation of emphy¬
sema27 28; however, this clinical manifestation is
more commonly seen in panacinar rather than
centriacinar emphysema.29 Previous strategies
for analysis of the exon 7 CYP1A1 poly¬
morphism have made use of specific differential
polymerase chain reaction (PCR) priming of
the allelic variants of the gene, and have relied
on high specificity of priming.30 We developed
a novel PCR assay to genotype paraffin wax
embedded lung tissues for the exon 7 poly¬
morphism of the CYP1A1 gene, as use of
high specificity primers relies on very stringent
conditions which may reduce the yield of PCR
amplimers.
Methods
Lung resection specimens (n = 129) from
smokers with lung cancer were collected. The
presence, type and extent of emphysema was
assessed macroscopically in non-involved lobes
and this assessment was confirmed by morpho-
metric microscopic analysis of alveolar wall
surface area per unit volume (AWUV).31 All
emphysema cases were of mild or moderate
disease severity, with a forced expiratory vol¬
ume in one second (FEVt) of at least 1-4, as
patients must be sufficiently fit to recover from
surgery.
Blood samples collected from a blood donor
clinic served as an anonymous control popu-
DNA EXTRACTION AND PCR ANALYSIS
DNA extraction from paraffin wax embedded
lung samples with no evidence of carcinoma
and blood samples was carried out as described
previously.32 Genotyping was carried out by
PCR analysis using buffer and 1-5 mM MgCl2
(Promega, Southampton, UK), 150 mM de-
oxynucleotides (Pharmacia, Milton Keynes,
UK), 5% DMSO (Sigma, St Louis, Missouri,
USA), 25 pmoles primer (Oswell DNA Ser¬
vices, Edinburgh, UK), and 2-5 units of Taq
polymerase (Promega, UK). The primers
used were: upstream, 5'-AAAGGCTGGG-
TCCACCCTCT-3'; and downstream, 5'-
AAAGACCTCCCAGCGGGCCA-3' (fig 1).
The downstream primer incorporated a mis¬
matched base to engineer a Ncol restriction
enzyme site in the PCR products derived from
the He462 allele of the gene. This restriction site
is lost in the Val462 allele of the gene. The
primers amplify both alleles and the genotypes
are distinguished by Ncol digestion of the prod¬
ucts. A Ncol restriction enzyme site located
upstream of the mutation in either genotype
serves as a positive control for PCR product
digestion. PCR products were electrophoresed
in 3% NuSeive and SeaKem agarose (FMC
Bioproducts, Rockland, Maine, USA), and re¬
striction enzyme digestion fragments were elec¬
trophoresed in 3% Metaphor agarose (FMC
Bioproducts).
STATISTICAL ANALYSES
Odds ratios and confidence intervals were used
to analyse the frequencies of the CYP1A1 geno¬
types, significance testing was by x2 analysis.33
Results
DISEASE INFORMATION
No significant differences in age, sex, or tumour
type were found within the study populations.
The median FEV! of chronic obstructive air¬
ways disease cases was 1-1, and 2-2 for the
biopsy study group. Smoking histories were
recorded where possible in pack years of ex¬
posure, and the median pack years for the
chronic obstructive airways disease group was
35, while the biopsy cases had a median of 46
pack years.
Of the 129 lung cancer samples studied, 42
had no macroscopic emphysema, 34 showed
centriacinar patterns of damage, 17 samples
had panacinar emphysema, and 36 lung biopsy
specimens had both centriacinar and panacinar
forms of emphysema.
GENOTYPING OF CYP1A1 GENE
POLYMORPHISM
Each amplimer analysed had a diagnostic Ncol
restriction enzyme site and a second constant
control Ncol site, which enabled distinction of
the CYP1A1 genotype of the individual. PCR
analysis and subsequent enzyme restriction
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analysis yielded specific fragments which were
easily visualised on agarose gels (fig 2).
The control group numbered 281 samples,
of which 87% (244/281) were homozygous for
the lie462 allele, 12% (34/281) were hetero¬
zygous and 1% (three of281) were homozygous
for the valine allele of the CYP1A1 gene (table
1). In comparison, of the 129 lung resection
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Figure 2 (A) Results of a PCR of the CYP1A1 gene.
DNA molecular marker V is shown in the lefthand lane,
with PCR amplimers in the remaining lanes. The
amplimer (322 base pairs) lies between fragments of 434
and 267 base pairs of the marker. (B) Results of a Ncol
digestion of the CYP1A1 amplimer. The two bands
represent the two alleles of the gene, the higher molecular
weight fragment (250 base pairs) representing the uncut
valine allele of the gene, and the lower molecular weight
band (231 base pairs) representing the cut isoleucine allele
of CYPIA1. Lanes 1, 5 and 6 therefore represent
heterozygotes for the two alleles, while lanes 2, 3 and 4
contain digestions from individuals homozygous for the
common Isoleucine allele.
at the lie462 allele, 16% (21/129) were het¬
erozygous for lie462 while 2% (three of 129)
exhibited Val462 homozygosity. This group was
not significantly different from the control
population.
In the group of patients with chronic ob¬
structive airways disease, of the 51 samples,
82% (42/51) were homozygous for lie162 and
18% (nine of 51) were heterozygous for the
polymorphism. No individuals homozygous for
the valine allele were found in this disease
group, and no significant difference between
this study group and the controls was seen.
To investigate the CYP1A1 gene poly¬
morphism and susceptibility to emphysema,
the total lung cancer study group was divided
according to the pattern of emphysematous
damage in the lung (table 2). When this was
done, 42 samples showed no evidence of em¬
physema and of these, 93% (39/42) were lie'62
homozygotes; 7% (three of 42) were het¬
erozygotes. Centriacinar emphysema only was
found in 34 cases and of these, 73-5% (25/
34) were homozygous for the valine allele and
26-5% (nine of 34) were Ile/Val. Panacinar
emphysema alone was present in 17 samples
and 88% (15/17) were lie462 homozygotes, 6%
(one of 17) were Ile/Val, and 6% (one of 17)
were homozygous for the Val462 allele. Both
panacinar and centriacinar emphysemas were
found in 36 of the lung cancer samples and
homozygotes for the isoleucine allele accounted
for 75% (27/36) of these cases, 22% (eight of
36) were heterozygotes and 3% (one of 36)
were Val462 homozygotes.
Of these disease groups, only those patients
with centriacinar emphysema alone and both
centriacinar and panacinar emphysema differed
significantly from the controls. Odds ratios
were 2-45 (95% confidence limits 1 06—5-67)
and 2-25 (95% confidence limits 0-98-5-17),
respectively.
Discussion
We have found a statistically significant as¬
sociation of the rare, putative high activity allele
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of CYP1A1 in cases with both lung cancer and
emphysema (odds ratios of 2-45 and 2-25) but
not in cases with chronic obstructive airways
disease or cancer alone. Clinical cases of
chronic obstructive airways disease do not rep¬
resent just emphysema but also include chronic
abstructive airways disease secondary to
chronic bronchitis. This may explain why a
lack of CYP1A1 association is seen for this
condition, but association with the poly¬
morphism is seen with pathological emphy¬
sema. Previous studies investigating CYP1A1
and lung cancer have provided conflicting data.
Whereas in Japanese populations CYP1A1
conferred a threefold increased risk of lung
cancer, similar studies of Scandinavian popu¬
lations have failed to find any association.2526
No study to date has considered the possibility
that CYP1A1 may confer susceptibility not just
to lung cancer but also to other forms of lung
disease, such as emphysema. What do the res¬
ults we have obtained suggest?
Firstly, although our data indicate that
CYP1A1 is associated with lung cancer and
emphysema, the increased relative risk we have
found is rather small and is only significant
when both diseases are present. However, em¬
physema and lung cancer are extremely pre¬
valent diseases, hence even a slight increase in
disease susceptibility conferred by this poly¬
morphism may account for a large proportion
of cases.
Secondly, the increased susceptibility to lung
disease conferred by the CYP1A1 poly¬
morphism appears to be an early event, oc¬
curring at a stage before the injury response
pathway leading to cell death and inflammation
has diverged from that leading to mutagenesis
and eventual tumour progression. This is in
keeping with the likely position of CYP1A1 in
the pathway of cigarette smoke metabolism—
that is, it is proximate to the insult by nature
of its expression in lung parenchyma and role
in phase I metabolism.
Thirdly, the effect of CYP1A1 genotype and
phenotype on disease susceptibility will be in¬
fluenced by other mechanisms of disease de¬
velopment. These may be more important than
CYP1A1 in determining the likelihood of
cigarette smoke injury to result in pre¬
dominantly genotoxic or cytotoxic injury. Thus,
certain protective mechanisms such as the glu¬
tathione dependant system, epoxide hydrolase,
differences in proteolytic enzymes, or anti-
proteases may reduce the likelihood of cell
damage caused by lipid or protein peroxidation
leading to emphysema. It is perhaps significant
that the cases with both lung cancer and em¬
physema had mild or moderate emphysema
whereas the clinical group with chronic ob¬
structive airways disease had severe disease—
that is, CYP1A1 polymorphism contributes
little towards susceptibility to severe, non-neo-
plastic lung injury.
Conversely, differences in DNA repair and
other genes involved in recognising and elim¬
inating DNA damage may be very important
in determining whether or not tumorigenesis
can occur. These mechanisms are likely to differ
between individuals and consistent with this is
the presence of known polymorphisms/mut¬
ations—for example, in the p53 gene and in
the DNA mismatch repair system.34-36 These
polymorphisms or mutations may contribute
to interindividual differences in the capacity to
eliminate DNA damage and therefore prevent
mutations leading to tumorigenesis.
Only in cases with no bias towards, or away
from, non-neoplastic or neoplastic lung disease
would CYP1A1 be expected to have a de¬
tectable effect on the susceptibility to disease
rather than simply a more subtle underlying
modification of mechanisms and responses to
injury.
The results that we have obtained in this
study show that a genetically determined
difference in xenobiotic metabolism, in this
case components of cigarette smoke, may alter
the response of cells or tissue to injury and
thus susceptibility to disease.
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